<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77408</article-id><article-id pub-id-type="doi">10.7554/eLife.77408</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Nr2f1a maintains atrial <italic>nkx2.5</italic> expression to repress pacemaker identity within venous atrial cardiomyocytes of zebrafish</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-271261"><name><surname>Martin</surname><given-names>Kendall E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-271262"><name><surname>Ravisankar</surname><given-names>Padmapriyadarshini</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-264441"><name><surname>Beerens</surname><given-names>Manu</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-33942"><name><surname>MacRae</surname><given-names>Calum A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-61423"><name><surname>Waxman</surname><given-names>Joshua S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8132-487X</contrib-id><email>joshua.waxman@cchmc.org</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e3m7079</institution-id><institution>Molecular Genetics, Biochemistry, and Microbiology Graduate Program, University of Cincinnati College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01hcyya48</institution-id><institution>Molecular Cardiovascular Biology Division and Heart Institute, Cincinnati Children’s Hospital Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6nzv94</institution-id><institution>Divisions of Cardiovascular Medicine, Genetics and Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e3m7079</institution-id><institution>Department of Pediatrics, University of Cincinnati College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Meilhac</surname><given-names>Sigolène M</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Imagine-Institut Pasteur</institution></institution-wrap><country>France</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0165r2y73</institution-id><institution>Max Planck Institute for Heart and Lung Research</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>15</day><month>05</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e77408</elocation-id><history><date date-type="received" iso-8601-date="2022-01-27"><day>27</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-28"><day>28</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-02-24"><day>24</day><month>02</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.02.24.481762"/></event></pub-history><permissions><copyright-statement>© 2023, Martin et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Martin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77408-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-77408-figures-v1.pdf"/><abstract><p>Maintenance of cardiomyocyte identity is vital for normal heart development and function. However, our understanding of cardiomyocyte plasticity remains incomplete. Here, we show that sustained expression of the zebrafish transcription factor Nr2f1a prevents the progressive acquisition of ventricular cardiomyocyte (VC) and pacemaker cardiomyocyte (PC) identities within distinct regions of the atrium. Transcriptomic analysis of flow-sorted atrial cardiomyocytes (ACs) from <italic>nr2f1a</italic> mutant zebrafish embryos showed increased VC marker gene expression and altered expression of core PC regulatory genes, including decreased expression of <italic>nkx2.5</italic>, a critical repressor of PC differentiation. At the arterial (outflow) pole of the atrium in <italic>nr2f1a</italic> mutants, cardiomyocytes resolve to VC identity within the expanded atrioventricular canal. However, at the venous (inflow) pole of the atrium, there is a progressive wave of AC transdifferentiation into PCs across the atrium toward the arterial pole. Restoring Nkx2.5 is sufficient to repress PC marker identity in <italic>nr2f1a</italic> mutant atria and analysis of chromatin accessibility identified an Nr2f1a-dependent <italic>nkx2.5</italic> enhancer expressed in the atrial myocardium directly adjacent to PCs. CRISPR/Cas9-mediated deletion of the putative <italic>nkx2.5</italic> enhancer leads to a loss of Nkx2.5-expressing ACs and expansion of a PC reporter, supporting that Nr2f1a limits PC differentiation within venous ACs via maintaining <italic>nkx2.5</italic> expression. The Nr2f-dependent maintenance of AC identity within discrete atrial compartments may provide insights into the molecular etiology of concurrent structural congenital heart defects and associated arrhythmias.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>heart development</kwd><kwd>atrial cardiomyocytes</kwd><kwd>cellular plasticity</kwd><kwd>Nr2f transcription factor</kwd><kwd>pacemaker cardiomyocyte</kwd><kwd>Nkx2.5 transcription factor</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01 HL137766</award-id><principal-award-recipient><name><surname>Waxman</surname><given-names>Joshua S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01 HL141186</award-id><principal-award-recipient><name><surname>Waxman</surname><given-names>Joshua S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>R01 HL154522</award-id><principal-award-recipient><name><surname>Waxman</surname><given-names>Joshua S</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>F31 HL152600</award-id><principal-award-recipient><name><surname>Martin</surname><given-names>Kendall E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>R24 OD017870</award-id><principal-award-recipient><name><surname>MacRae</surname><given-names>Calum A</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Leducq Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>MacRae</surname><given-names>Calum A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The transcription factor Nr2f1a represses ventricular and pacemaker cardiomyocyte identities within distinct regions of the zebrafish atrium.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The vertebrate heart relies on the coordination of multiple specialized cardiomyocyte populations. Cardiomyocytes of the atrium, ventricle, atrioventricular canal (AVC), and pacemaker are each characterized by distinct mechanical, morphological, and electrophysiological properties (<xref ref-type="bibr" rid="bib12">Bootman et al., 2006</xref>; <xref ref-type="bibr" rid="bib13">Brandenburg et al., 2016</xref>; <xref ref-type="bibr" rid="bib22">Christoffels et al., 2010</xref>; <xref ref-type="bibr" rid="bib48">Keith and Flack, 1907</xref>; <xref ref-type="bibr" rid="bib73">Ng et al., 2010</xref>; <xref ref-type="bibr" rid="bib88">Smyrnias et al., 2010</xref>). Pacemaker cardiomyocytes (PCs) of the sinoatrial node (SAN), which is located at the venous pole of the single atrial chamber in zebrafish and the base of the right atrial chamber in mammals, initiate the synchronized wave of contraction that passes through the working atrial cardiomyocytes (ACs), slows at the AVC, and then rapidly activates ventricular cardiomyocytes (VCs) (<xref ref-type="bibr" rid="bib3">Arrenberg et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Burkhard et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Christoffels et al., 2010</xref>; <xref ref-type="bibr" rid="bib69">Moorman and Christoffels, 2003</xref>). Specific gene regulatory programs confer the differentiation and maintenance of these different cardiomyocyte populations within the heart during development (<xref ref-type="bibr" rid="bib5">Barth et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Ng et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Pradhan et al., 2017</xref>; <xref ref-type="bibr" rid="bib92">Tabibiazar et al., 2003</xref>; <xref ref-type="bibr" rid="bib93">Targoff et al., 2013</xref>; <xref ref-type="bibr" rid="bib97">van Weerd and Christoffels, 2016</xref>; <xref ref-type="bibr" rid="bib110">Xin et al., 2007</xref>). Importantly, mutations in genes associated with promoting cardiomyocyte differentiation as well as the maintenance of identity, such as the transcription factors (TFs) <italic>NKX2.5</italic>, <italic>TBX5</italic>, and <italic>NR2F2</italic>, are associated with human congenital heart defects (CHDs), the most common type of congenital malformations found in newborn children (<xref ref-type="bibr" rid="bib1">Al Turki et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Benjamin et al., 2018</xref>; <xref ref-type="bibr" rid="bib8">Benson et al., 1999</xref>; <xref ref-type="bibr" rid="bib21">Cheng et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">Hoffman and Kaplan, 2002</xref>; <xref ref-type="bibr" rid="bib60">Loffredo, 2000</xref>; <xref ref-type="bibr" rid="bib71">Nakamura et al., 2011</xref>; <xref ref-type="bibr" rid="bib86">Schott et al., 1998</xref>; <xref ref-type="bibr" rid="bib96">van der Linde et al., 2011</xref>). Moreover, structural CHDs are often accompanied by arrhythmias that cause additional complications, morbidity, and death (<xref ref-type="bibr" rid="bib15">Bruneau et al., 1999</xref>; <xref ref-type="bibr" rid="bib31">Ellesøe et al., 2016</xref>; <xref ref-type="bibr" rid="bib106">Williams and Perry, 2018</xref>). In adults, variants in <italic>NKX2.5</italic> and <italic>TBX5</italic> are also associated with isolated arrhythmias, such as atrial fibrillation, and improper cardiomyocyte gene expression (<xref ref-type="bibr" rid="bib8">Benson et al., 1999</xref>; <xref ref-type="bibr" rid="bib15">Bruneau et al., 1999</xref>; <xref ref-type="bibr" rid="bib36">Guo et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Jhaveri et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Ma et al., 2016</xref>; <xref ref-type="bibr" rid="bib72">Nakashima et al., 2014</xref>; <xref ref-type="bibr" rid="bib112">Yu et al., 2014</xref>). Thus, the acquisition and maintenance of an appropriate number and identity of each cardiomyocyte population within the developing heart is vital for its normal function throughout life.</p><p>The Nr2f (Coup-tf) family of nuclear hormone receptor TFs are conserved regulators of atrial development. In humans, mutations in <italic>NR2F2</italic> have been associated with multiple types of CHDs, most commonly atrioventricular septal defects (AVSDs) (<xref ref-type="bibr" rid="bib1">Al Turki et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Nakamura et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Qiao et al., 2018</xref>; <xref ref-type="bibr" rid="bib95">Upadia et al., 2018</xref>). Consistent with a role in AC differentiation, NR2F1 and NR2F2 are expressed in ACs of the developing hearts of mice and humans (<xref ref-type="bibr" rid="bib1">Al Turki et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Li et al., 2016</xref>). In vitro studies have shown that both NR2F1 and NR2F2 promote AC differentiation in human embryonic stem cell (ESC)-derived cardiomyocytes (<xref ref-type="bibr" rid="bib23">Churko et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Devalla et al., 2015</xref>). Global <italic>Nr2f2</italic> knockout (KO) mice are embryonic lethal with prominent heart defects, including severely hypomorphic atria that lack septa, which is associated with reduced AC differentiation (<xref ref-type="bibr" rid="bib75">Pereira et al., 1999</xref>). However, at subsequent stages, Nr2f2 appears to maintain atrial identity by directly repressing TFs including <italic>Irx4</italic> and <italic>Hey2,</italic> which promote and maintain the differentiation of VCs. Hence, cardiac-specific conditional KO of <italic>Nr2f2</italic> in mice results in ventricularized atria, while its ectopic expression in VCs is sufficient to promote AC identity (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>). Although Nr2f2 appears to be the primary regulator of AC differentiation and identity in vivo in mammals, we have found that zebrafish Nr2f1a is the functional homolog of mammalian Nr2f2 with respect to heart development (<xref ref-type="bibr" rid="bib29">Dohn et al., 2019</xref>; <xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>). <italic>Nr2f1a</italic> mutant zebrafish develop smaller atria due to reduced AC differentiation at the venous pole and fail to restrict the size of the AVC, which results in an expansion of AVC markers into the atrium (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>). Despite the established requirements for Nr2f TFs in promoting and maintaining atrial differentiation, the mechanisms by which Nr2f TFs function within vertebrate ACs are still not well understood.</p><p>Interactions between different regulatory programs determine the number and proportions of cardiomyocytes within the ventricle, AVC, atrium, and pacemaker that initially differentiate and are continuously required to reinforce their identity, which maintains compartmental boundaries within the heart that allow it to function properly. At the venous pole of the heart, a conserved regulatory network of TFs including Isl1, Shox/Shox2, and Tbx3 drives PC differentiation and concurrently represses AC identity. Loss of these TFs results in ectopic expression of working AC markers within the SAN and, in turn, a hypoplastic SAN; conversely, ectopic Tbx3 in working murine cardiomyocytes is sufficient to confer PC identity, and overexpression of Shox2 in murine ESCs during differentiation leads to an upregulation of PC genes (<xref ref-type="bibr" rid="bib33">Espinoza-Lewis et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Espinoza-Lewis et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Hoogaars et al., 2007</xref>; <xref ref-type="bibr" rid="bib45">Ionta et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Liang et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib94">Tessadori et al., 2012</xref>; <xref ref-type="bibr" rid="bib97">van Weerd and Christoffels, 2016</xref>). Nkx2.5 performs multiple functions within cardiomyocytes during heart development, consistent with pleiotropic structural and conduction defects found in patients with <italic>NKX2.5</italic> mutations (<xref ref-type="bibr" rid="bib8">Benson et al., 1999</xref>; <xref ref-type="bibr" rid="bib31">Ellesøe et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Elliott et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Jhaveri et al., 2018</xref>; <xref ref-type="bibr" rid="bib66">McElhinney et al., 2003</xref>; <xref ref-type="bibr" rid="bib86">Schott et al., 1998</xref>; <xref ref-type="bibr" rid="bib109">Xie et al., 2013</xref>; <xref ref-type="bibr" rid="bib112">Yu et al., 2014</xref>). At the venous pole of the heart, it is a critical repressor of the PC differentiation regulatory network within working ACs, as loss of Nkx2.5 results in an expansion of PC marker identity within the atrium of mice and zebrafish (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Espinoza-Lewis et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Nakashima et al., 2014</xref>). Within VCs at the arterial pole of the heart, Nkx2.5, as well as the TFs Irx4 and Hey2, maintain ventricular identity and repress the atrial gene program. Loss of these genes in mice and zebrafish results in ectopic expression of AC markers within the ventricle (<xref ref-type="bibr" rid="bib4">Bao et al., 1999</xref>; <xref ref-type="bibr" rid="bib16">Bruneau et al., 2000</xref>; <xref ref-type="bibr" rid="bib50">Koibuchi and Chin, 2007</xref>; <xref ref-type="bibr" rid="bib78">Pradhan et al., 2017</xref>; <xref ref-type="bibr" rid="bib93">Targoff et al., 2013</xref>). Moreover, in embryonic zebrafish hearts, AC identity is repressed in VCs by FGF signaling, which functions upstream of Nkx2.5 and by inhibition of BMP (<xref ref-type="bibr" rid="bib26">de Pater et al., 2012</xref>; <xref ref-type="bibr" rid="bib78">Pradhan et al., 2017</xref>). However, in mice, FGF signaling is also necessary for proper ventricular conduction through regulation of connexin 43 (<xref ref-type="bibr" rid="bib83">Sakurai et al., 2013</xref>). While the repression of AC identity is central to normal development of the ventricle and SAN, we still lack an understanding of mechanisms that maintain AC identity and plasticity within the embryonic vertebrate heart.</p><p>Here, we demonstrate that Nr2f1a is required to inhibit the progressive acquisition of VC and PC identity within different regions of the embryonic zebrafish atrium. At the arterial (outflow) pole of the atrium, Nr2f1a represses VC identity, similar to what has been shown in conditional <italic>Nr2f2</italic> KO mice. However, we find it is only sensitized cardiomyocytes within the expanded AVC of <italic>nr2f1a</italic> mutants, which co-express AC and VC differentiation markers, that progressively resolve to express only VC markers. Importantly, at the venous (inflow) pole of the atrium, we identify a requirement for Nr2f1a in repressing PC identity. While the initial PC population differentiates normally in <italic>nr2f1a</italic> mutants despite reduced AC differentiation, there is a subsequent expansion of PC markers and complementary loss of Nkx2.5 from the venous pole into the atrium. Electrophysiological studies demonstrate that the transdifferentiated ACs in <italic>nr2f1a</italic> mutants are adopting central conduction system identity. Genetic epistasis using a heat-shock inducible <italic>nkx2.5</italic> transgene showed that overexpressing Nkx2.5 is sufficient to inhibit the transdifferentiation of ACs that occurs in <italic>nr2f1a</italic> mutant hearts, indicating that within ACs Nr2f1a functions upstream of Nkx2.5 in the conserved genetic hierarchy that limits PC differentiation. Chromatin accessibility integrated with our transcriptomic analysis of sorted ACs identified a putative Nr2f1a-dependent <italic>nkx2.5</italic> enhancer that is expressed in a specific subset of venous ACs bordering the SAN. Deletion of this enhancer results in a loss of Nkx2.5 expression and an expansion of a PC reporter within ACs at the venous pole of the atrium. Overall, our results demonstrate that maintenance of Nr2f expression is critical for normal vertebrate heart development through sustaining atrial identity in different AC subpopulations, which may provide insights into the etiology of concomitant congenital structural cardiac and conduction defects found in humans.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Cardiomyocytes within the AVC progressively resolve to VC identity in <italic>nr2f1a</italic> mutants</title><p>Although previous studies have indicated that Nr2f TFs are required to promote atrial differentiation (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>; <xref ref-type="bibr" rid="bib75">Pereira et al., 1999</xref>; <xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>), we still do not fully understand the effects of Nr2f loss on AC identity. To investigate the consequences of Nr2f loss within the atrium, we performed RNA-seq on flow-sorted cardiomyocytes expressing the AC differentiation marker <italic>atrial myosin heavy chain</italic> (<italic>amhc</italic>; also called <italic>myh6</italic>) from wild-type (WT) and <italic>nr2f1a</italic> mutant embryos. Embryos carrying the <italic>Tg(amhc:EGFP</italic>) transgene (<xref ref-type="bibr" rid="bib114">Zhang et al., 2013</xref>) were dissociated at 48 hr post-fertilization (hpf) and fluorescence-activated cell sorting (FACS) was performed to isolate <italic>amhc:</italic>EGFP<sup>+</sup> cardiomyocytes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The resulting RNA-seq dataset revealed 2077 upregulated and 1297 downregulated genes with &gt;2-fold change in the <italic>nr2f1a</italic> mutant <italic>amhc:</italic>EGFP<sup>+</sup> cardiomyocytes relative to WT (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Genes associated with AC differentiation, such as <italic>amhc</italic> itself, were decreased in the <italic>amhc:</italic>EGFP<sup>+</sup> cardiomyocytes captured from <italic>nr2f1a</italic> mutant embryos relative to the WT embryos, confirming the success of this approach (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). However, we also observed two additional trends in the <italic>nr2f1a</italic> mutant <italic>amhc:</italic>EGFP<sup>+</sup> cardiomyocytes: an increase in the expression of genes associated with VC and outflow tract identity of the heart, such as the <italic>irx4</italic> and <italic>isl2</italic> paralogs (<xref ref-type="bibr" rid="bib16">Bruneau et al., 2000</xref>; <xref ref-type="bibr" rid="bib17">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib93">Targoff et al., 2013</xref>; <xref ref-type="bibr" rid="bib107">Witzel et al., 2017</xref>; <xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>); and misexpression of core genes associated with PC differentiation, with genes shown to promote PC differentiation, such as <italic>tbx3a</italic> and <italic>shox,</italic> being increased (<xref ref-type="bibr" rid="bib42">Hoogaars et al., 2007</xref>; <xref ref-type="bibr" rid="bib49">Kenyon et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib81">Ribeiro et al., 2007</xref>; <xref ref-type="bibr" rid="bib85">Sawada et al., 2015</xref>), while <italic>nkx2.5</italic>, a critical repressor of PC differentiation, was decreased (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Espinoza-Lewis et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Nakashima et al., 2014</xref>; <xref ref-type="fig" rid="fig1">Figure 1B</xref>). Thus, transcriptional analysis implies that <italic>nr2f1a</italic> mutant atria have increased expression of genes associated with promoting both VC and PC differentiation.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The atrioventricular canal (AVC) resolves to Vmhc-expressing cardiomyocytes in <italic>nr2f1a</italic> mutant hearts.</title><p>(<bold>A</bold>) Schematic for isolation of atrial cardiomyocytes (ACs) using <italic>Tg(amhc:EGFP</italic>) transgene for RNA-seq and assay for transpose-accessible chromatin sequencing (ATAC-seq) at 48 hr post-fertilization (hpf). (<bold>B</bold>) Differential expression of genes associated with ventricular cardiomyocyte (VC)/arterial pole, AC, and pacemaker cardiomyocyte (PC) differentiation in <italic>nr2f1a</italic> mutants compared to wild-type (WT). (<bold>C–H</bold>) IHC for Amhc (blue) and Vmhc (red) in <italic>nr2f1a</italic> and WT hearts at 48, 72, and 96 hpf. White arrows indicate region of overlapping Amhc<sup>+</sup> and Vmhc<sup>+</sup> cardiomyocytes in the AVC. Blue arrows indicate overt arterial position of the AVC of <italic>nr2f1a</italic> mutant atria. Number of embryos examined - 48 hpf: WT (n=3), <italic>nr2f1a<sup>-/-</sup></italic> (n=4); 72 hpf: WT (n=4), <italic>nr2f1a<sup>-/-</sup></italic> (n=6); 96 hpf: WT (n=7), <italic>nr2f1a<sup>-/-</sup></italic> (n=10). (<bold>I</bold>) Schematic for cell quantification: Amhc<sup>+</sup>/Vmhc<sup>-</sup> (blue) cardiomyocytes (CMs) mark the atria; Amhc<sup>+</sup>/Vmhc<sup>+</sup> (green/blue) cardiomyocytes mark the AVC; Amhc<sup>-</sup>/Vmhc<sup>+</sup> (green) cardiomyocytes mark the ventricles; DsRed2-NLS (pan-cardiac) marks the cardiomyocyte nuclei. (<bold>J–L</bold>) Quantification of Amhc<sup>+</sup>/Vmhc<sup>-</sup> cardiomyocytes, Amhc<sup>+</sup>/Vmhc<sup>+</sup> (AVC) cardiomyocytes, and Amhc<sup>-</sup>/Vmhc<sup>+</sup> cardiomyocytes. Error bars indicate s.e.m. 48 hpf: WT (n=4), <italic>nr2f1a<sup>-/-</sup></italic> (n=5); 72 hpf: WT (n=5), <italic>nr2f1a<sup>-/-</sup></italic> (n=8); 96 hpf: WT (n=5), <italic>nr2f1a<sup>-/-</sup></italic> (n=12). Scale bar indicates 50 μm. Differences between WT and <italic>nr2f1a<sup>-/-</sup></italic> were analyzed using ANOVA with multiple comparisons. *p=0.05–0.001, **p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Individual channels showing the resolution of atrioventricular canal (AVC) cardiomyocytes to ventricular cardiomyocyte (VC) identity in <italic>nr2f1a</italic> mutants.</title><p>(<bold>A–H’’</bold>) IHC for Amhc (blue) and Vmhc (red) at 30, 48, 72, and 96 hr post-fertilization (hpf) in wild-type (WT) and <italic>nr2f1a</italic> mutant embryos. Forty-eight to 96 hpf images (<bold>B–D</bold>) and (<bold>F–H</bold>) are the same as presented in <xref ref-type="fig" rid="fig1">Figure 1C–H</xref>. White arrows indicate region of Amhc/Vmhc overlap within the hearts. Blue arrow indicates overt arterial position of AVC in <italic>nr2f1a</italic> mutant atria. Number of 30 hpf embryos examined: WT (n=20), <italic>nr2f1a<sup>-/-</sup></italic> (n=12). Scale bars indicate 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Quantification of cardiomyocytes in <italic>nr2f1a</italic> mutants.</title><p>(<bold>A</bold>) Quantification of only Amhc<sup>+</sup>/Vmhc<sup>-</sup> cardiomyocytes (CMs) within the wild-type (WT) and <italic>nr2f1a</italic> mutant hearts. (<bold>B</bold>) Quantification of only Amhc<sup>+</sup>/Vmhc<sup>+</sup> (AVC) cardiomyocytes within the WT and <italic>nr2f1a</italic> mutant hearts. (<bold>C</bold>) Quantification of only Amhc<sup>-</sup>/Vmhc<sup>+</sup> cardiomyocytes within the WT and <italic>nr2f1a</italic> mutant hearts. (<bold>D</bold>) Proportions of Amhc<sup>+</sup>/Vmhc<sup>+</sup> and Amhc<sup>-</sup>/Vmhc<sup>+</sup> cardiomyocytes in WT and <italic>nr2f1a</italic> mutant hearts; 48 hpf: WT (n=4), <italic>nr2f1a<sup>-/-</sup></italic> (n=5); 72 hpf: WT (n=5), <italic>nr2f1a<sup>-/-</sup></italic> (n=8); 96 hpf: WT (n=5), <italic>nr2f1a<sup>-/-</sup></italic> (n=12). Graphs are the same data presented in <xref ref-type="fig" rid="fig1">Figure 1J, K and L</xref>. Differences between WT and <italic>nr2f1a<sup>-/-</sup></italic> in A–C were analyzed using ANOVA with multiple comparisons. *p=0.05–0.001, **p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title><italic>Nr2f1a</italic> mutant hearts do not have increased cardiomyocyte death.</title><p>(<bold>A–D</bold>) z-Slices of IHC for cleaved Caspase 3 (green) and Mhc (red) in wild-type (WT) and <italic>nr2f1a</italic> mutant embryos. The cleaved Caspase 3<sup>+</sup> cells shown in the heart were not cardiomyocytes. Number of embryos examined - 72 hr post-fertilization (hpf): WT (n=7), <italic>nr2f1a<sup>-/-</sup></italic> (n=8). 96 hpf: WT (n=9), <italic>nr2f1a<sup>-/-</sup></italic> (n=6). Scale bar indicates 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Cardiomyocytes within the <italic>nr2f1a</italic> mutant atria do not have increased proliferation.</title><p>(<bold>A–F</bold>) z-Slices of IHC for phosphohistone H3 (pHH3) (green), Mhc (pan-cardiac; purple), and <italic>myl7:</italic>DsRed2-NLS (pan-cardiac; red) in wild-type (WT) and <italic>nr2f1a</italic> mutant hearts from 48 to 96 hr post-fertilization (hpf). The pHH3<sup>+</sup> cells shown in the hearts were not cardiomyocytes. Number of embryos examined - 48 hpf: WT (n=9), <italic>nr2f1a<sup>-/-</sup></italic> (n=7); 72 hpf: WT (n=8), <italic>nr2f1a<sup>-/-</sup></italic> (n=8); 96 hpf: WT (n=9), <italic>nr2f1a<sup>-/-</sup></italic> (n=7). (<bold>G</bold>) Schematic of the two Edu pulse-chase experiments. (<bold>H–K</bold>) Representative z-slices of Edu (green) with IHC for <italic>myl7:</italic>DsRed2-NLS (red) and Amhc (blue). White arrows indicate representative Edu<sup>+</sup>/<italic>myl7</italic>:DsRed2-NLS<sup>+</sup>/Amhc<sup>+</sup> and Edu<sup>+</sup>/<italic>myl7</italic>:DsRed2-NLS<sup>+</sup>/Amhc<sup>-</sup> cardiomyocytes that were proliferating within the hearts. (<bold>L,M</bold>) Proliferation indices of Amhc<sup>+</sup> and Amhc<sup>-</sup> cardiomyocytes (CMs) in the hearts of WT and <italic>nr2f1a</italic> mutant embryos; 72 hpf: WT (n=8), <italic>nr2f1a<sup>-/-</sup></italic> (n=7); 96 hpf: WT (n=11), <italic>nr2f1a<sup>-/-</sup></italic> (n=8). Differences between conditions were analyzed using Student’s t-test. *p=0.05–0.001, **p&lt;0.001. Scale bars indicate 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig1-figsupp4-v1.tif"/></fig></fig-group><p>Conditional KO of <italic>Nr2f2</italic> in murine ACs results in their acquisition of VC identity (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>). Furthermore, while our transcriptomic analysis here and previous analysis of the ventricular differentiation marker <italic>ventricular myosin heavy chain</italic> (<italic>vmhc</italic>; also called <italic>myh7</italic>) (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>) also suggests there may be an expansion of VC/arterial pole identity into the atrium of <italic>nr2f1a</italic> mutants, it was still not clear if a fate switch of ACs to VCs occurred within <italic>nr2f1a</italic> mutant atria at 48 hpf comparable to what was reported in the conditional <italic>Nr2f2</italic> KO mice (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>). To examine cardiomyocyte identities more closely within <italic>nr2f1a</italic> mutant hearts, we performed immunohistochemistry (IHC) for the cardiomyocyte differentiation markers Amhc and Vmhc (<xref ref-type="fig" rid="fig1">Figure 1C–H</xref>) and quantified cardiomyocyte number by using the pan-cardiac <italic>Tg(myl7:DsRed2-NLS</italic>) transgene (<xref ref-type="fig" rid="fig1">Figure 1l</xref>; <xref ref-type="bibr" rid="bib63">Mably et al., 2003</xref>). Although we found a significant overlap of Amhc and Vmhc in the heart tubes at 30 hpf, which was indistinguishable between WT and <italic>nr2f1a</italic> mutant hearts (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–A”, E–E”</xref>), the number of Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes, which we classify as cardiomyocytes of the AVC, becomes significantly restricted by 48 hpf in the hearts of WT embryos (<xref ref-type="fig" rid="fig1">Figure 1C and J–L</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–B”</xref>). Subsequently, from 48 to 96 hpf there remained a relatively constant and small number of Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes in the hearts of WT embryos (<xref ref-type="fig" rid="fig1">Figure 1C, E, G and J–L</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–D”</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). However, by 48 hpf in <italic>nr2f1a</italic> mutant hearts, there were still a significant number of cardiomyocytes co-expressing Amhc and Vmhc (<xref ref-type="fig" rid="fig1">Figure 1D and J–L</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F–F</xref>’’; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>), consistent with their expanded AVC that we reported previously (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>). Interestingly, the number of Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes within this region of <italic>nr2f1a</italic> mutant hearts was progressively reduced through 96 hpf (<xref ref-type="fig" rid="fig1">Figure 1F, H and J–L</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G–G”, H-H”</xref>; <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>). While Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes remained constant over these stages, there was a modest increase of Amhc<sup>+</sup>/Vmhc<sup>-</sup> cardiomyocytes in the atria of WT hearts. However, total Amhc<sup>+</sup> cardiomyocytes (Amhc<sup>+</sup>/Vmhc<sup>-</sup> and Amhc<sup>+</sup>/Vmhc<sup>+</sup>) were found to diminish from 48 to 96 hpf in the <italic>nr2f1a</italic> mutant hearts, which was primarily due to the decrease in Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes as the number of Amhc<sup>+</sup>/Vmhc<sup>-</sup> cardiomyocytes, while dramatically reduced compared to WT hearts, did not change significantly over these stages (<xref ref-type="fig" rid="fig1">Figure 1J</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F–H”</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>). Conversely, there were more total Vmhc<sup>+</sup> (Amhc<sup>-</sup>/Vmhc<sup>+</sup> and Amhc<sup>+</sup>/Vmhc<sup>+</sup>) cardiomyocytes in <italic>nr2f1a</italic> mutant hearts compared to WT hearts across all timepoints, which primarily reflects the expansion of Vmhc expression within the enlarged AVC of the <italic>nr2f1a</italic> mutant hearts (<xref ref-type="fig" rid="fig1">Figure 1K</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F–H”</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B and C</xref>). Furthermore, the number of Vmhc<sup>+</sup>-only (Amhc<sup>-</sup>/Vmhc<sup>+</sup>) cardiomyocytes progressively increased from 48 to 96 hpf in <italic>nr2f1a</italic> mutant hearts, complementing the loss of Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes within the AVC (<xref ref-type="fig" rid="fig1">Figure 1K</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F–H”</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C and D</xref>). Interestingly, the total number of cardiomyocytes in <italic>nr2f1a</italic> mutant hearts remained constant from 48 to 96 hpf, stages that showed a progressive increase in the total number of cardiomyocytes in WT hearts (<xref ref-type="fig" rid="fig1">Figure 1L</xref>), implying that Nr2f1a loss within the atrium affects overall heart growth. Cell death, as assayed with IHC for active Caspase 3, and proliferation, as assayed with IHC for phosphohistone H3 (pHH3), were not affected at these stages in <italic>nr2f1a</italic> mutant hearts (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A–D</xref>; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A–F</xref>). Similarly, EdU pulses at 48 or 72 hpf showed that Amhc<sup>+</sup> cardiomyocytes in <italic>nr2f1a</italic> mutants hearts also do not have reduced proliferation (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4G–M</xref>). However, Amhc<sup>-</sup> cardiomyocytes, which are predominantly VCs, did show reduced proliferation (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4G–M</xref>), suggesting the lack of increase in heart size in <italic>nr2f1a</italic> mutants primarily reflects a lack of ventricular growth. Thus, our data indicate that changes in the different cardiomyocyte populations of <italic>nr2f1a</italic> mutants hearts are not due to increased cell death or proliferation. However, the lack of observed heart growth is potentially due to Nr2f1a loss cell non-autonomously affecting proliferation of VCs, which will be investigated in the future. Collectively, these results show that the expansion and acquisition of VC identity within <italic>nr2f1a</italic> mutant hearts is regionally restricted, with cardiomyocytes comprising the expanded AVC that initially expresses both AC and VC differentiation markers resolving to VC identity.</p></sec><sec id="s2-2"><title>PC identity progressively expands throughout <italic>nr2f1a</italic> mutant atria</title><p>Our results show that in the absence of Nr2f TFs not all Amhc<sup>+</sup> cardiomyocytes within the atrium acquire VC identity. Moreover, our transcriptomic data indicated there was also misexpression of core regulatory genes that control PC differentiation in the <italic>nr2f1a</italic> mutant Amhc<sup>+</sup> cardiomyocytes (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). Orthologs of genes associated with promoting PC differentiation and function, including <italic>tbx3a</italic>, <italic>shox</italic>, and <italic>fgf13a</italic> (<xref ref-type="bibr" rid="bib20">Burkhard and Bakkers, 2018</xref>; <xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Espinoza-Lewis et al., 2009</xref>; <xref ref-type="bibr" rid="bib42">Hoogaars et al., 2007</xref>; <xref ref-type="bibr" rid="bib49">Kenyon et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Poon et al., 2016</xref>; <xref ref-type="bibr" rid="bib81">Ribeiro et al., 2007</xref>; <xref ref-type="bibr" rid="bib85">Sawada et al., 2015</xref>; <xref ref-type="bibr" rid="bib98">Wang et al., 2011</xref>; <xref ref-type="bibr" rid="bib99">Wang et al., 2017</xref>; <xref ref-type="bibr" rid="bib111">Yang et al., 2016</xref>), were predominantly increased, while <italic>nkx2.5</italic>, a critical repressor of PC identity in mice and zebrafish (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Hoogaars et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Nakashima et al., 2014</xref>), was decreased. To determine if there are effects on the PCs in <italic>nr2f1a</italic> mutants, we used the <italic>SqET33-mi59B</italic> enhancer trap line, which for clarity we refer to as <italic>Et(fgf13a:EGFP</italic>), as it reports <italic>fgf13a</italic> expression and is expressed in PCs (<xref ref-type="bibr" rid="bib76">Poon et al., 2016</xref>). At 48 hpf, we found no overt difference in <italic>Et(fgf13a:EGFP</italic>) expression between the WT and <italic>nr2f1a</italic> mutant embryos (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–A’’’, D–D’’’</xref>), despite the smaller atria in the <italic>nr2f1a</italic> mutants. However, while <italic>Et(fgf13a:EGFP</italic>) expression is normally restricted to the venous pole in WT hearts, we found a progressive expansion of <italic>Et(fgf13a:EGFP</italic>) expression from the venous pole throughout the Amhc<sup>+</sup> cardiomyocytes in the atrium of the <italic>nr2f1a</italic> mutant hearts through 96 hpf (<xref ref-type="fig" rid="fig2">Figure 2C–F</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–C’’’, E–F’’’</xref>). Quantification of Amhc<sup>+</sup> cardiomyocytes co-expressing the <italic>Et(fgf13a:EGFP</italic>) transgene via incorporation of the <italic>Tg(myl7:DsRed2-NLS</italic>) transgene confirmed the concurrent increase in <italic>fgf13a</italic>:EGFP<sup>+</sup>/Amhc<sup>+</sup> cardiomyocytes and decrease in <italic>fgf13a:</italic>EGFP<sup>-</sup>/Amhc<sup>+</sup> cardiomyocytes within the <italic>nr2f1a</italic> mutant atria (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>), even as the total number of Amhc<sup>+</sup> cardiomyocytes decreases (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). Equivalent results were found with IHC for the SAN marker Isl1 (<xref ref-type="bibr" rid="bib57">Liang et al., 2015</xref>; <xref ref-type="bibr" rid="bib91">Sun et al., 2007</xref>; <xref ref-type="bibr" rid="bib94">Tessadori et al., 2012</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Additionally, real-time quantitative PCR (RT-qPCR) on flow-sorted cardiomyocytes from 96 hpf embryos using the pan-cardiac <italic>Tg(myl7:EGFP</italic>) transgene (<xref ref-type="bibr" rid="bib44">Huang et al., 2003</xref>) showed an increase in PC differentiation marker expression, as well as <italic>vmhc</italic> expression, and decrease in <italic>amhc</italic> at these stages in <italic>nr2f1a</italic> mutant hearts (<xref ref-type="fig" rid="fig2">Figure 2J and K</xref>), reflecting the progressive expansion observed with expression of <italic>Et(fgf13a:EGFP</italic>) and Isl1 with IHC analysis.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Pacemaker cardiomyocyte (PC) identity expands from the venous pole across the atrium in <italic>nr2f1a</italic> mutant hearts.</title><p>(<bold>A–F</bold>) IHC for Amhc (blue), Vmhc (red), and <italic>fgf13a</italic>:EGFP (green). White arrows indicate boundaries of <italic>Et(fgf13a:EGFP</italic>) expression within the atrium. Number of embryos examined - 48 hr post-fertilization (hpf): wild-type (WT) (n=10), <italic>nr2f1a<sup>-/-</sup></italic> (n=12); 72 hpf: WT (n=10), <italic>nr2f1a<sup>-/-</sup></italic> (n=10); 96 hpf: WT (n=7), <italic>nr2f1a<sup>-/-</sup></italic> (n=10). (<bold>G–I</bold>) Quantification of Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>-</sup>, Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>+</sup>, and total Amhc<sup>+</sup> cardiomyocytes (CMs) using the <italic>Tg(myl7:DsRed2-NLS</italic>) transgene within the hearts of WT and <italic>nr2f1a</italic> mutants. Error bars indicate s.e.m.; 48 hpf: WT (n=16), <italic>nr2f1a<sup>-/-</sup></italic> (n=11); 72 hpf: WT (n=14), <italic>nr2f1a<sup>-/-</sup></italic> (n=11); 96 hpf: WT (n=15), <italic>nr2f1a<sup>-/-</sup></italic> (n=12). (<bold>J</bold>) Schematic for the isolation of cardiomyocytes at 96 hpf using the <italic>Tg(myl7:EGFP</italic>) transgene. (<bold>K</bold>) Fold change of marker genes relative to <italic>β-actin</italic> from real-time quantitative PCR (RT-qPCR) on isolated cardiomyocytes of WT and <italic>nr2f1a</italic> mutants at 96 hpf. Scale bar indicates 50 μm. Differences between WT and <italic>nr2f1a<sup>-/-</sup></italic> were analyzed using ANOVA with multiple comparisons. *p=0.05–0.001, **p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Individual channels showing that pacemaker cardiomyocyte (PC) identity expands from the venous pole across the atrium in <italic>nr2f1a</italic> mutant hearts.</title><p>(<bold>A–F’’’</bold>) IHC for Vmhc (red), Amhc (blue), and <italic>fgf13a</italic>:EGFP (green) at 48, 72, and 96 hr post-fertilization (hpf). White arrows indicate boundaries of <italic>fgf13a</italic>:EGFP expression within the atrium. Images (<bold>A–F</bold>) are the same as presented in <xref ref-type="fig" rid="fig2">Figure 2A–F</xref>. Scale bar indicates 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Isl1 expression expands throughout the atrium in <italic>nr2f1a</italic> mutant embryos.</title><p>(<bold>A–F</bold>) Isl1 (green), Amhc (purple), and Mhc (red) expression in wild-type (WT) and <italic>nr2f1a</italic> mutant embryos at 48, 72, and 96 hr post-fertilization (hpf). White arrows mark boundaries of Isl1 expression at the venous pole. Number of embryos examined - 48 hpf: WT (n=5), <italic>nr2f1a<sup>-/-</sup></italic> (n=5); 72 hpf: WT (n=5), <italic>nr2f1a<sup>-/-</sup></italic> (n=5); 96 hpf: WT (n=6), <italic>nr2f1a<sup>-/-</sup></italic> (n=10). Scale bar indicates 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Newly differentiating cardiomyocytes are not added to the atrium in <italic>nr2f1a</italic> mutant hearts.</title><p>(<bold>A</bold>) Schematic depicting strategy for assessing newly differentiating cardiomyocytes using the <italic>Tg(myl7:NLS-KikGR</italic>) and <italic>Tg(fgf13a:EGFP</italic>) transgenes. (<bold>B–E”</bold>) Wild-type (WT) and <italic>nr2f1a</italic> mutant embryos photoconverted at 72 hr post-fertilization (hpf) and imaged at 96 hpf. Number of embryos examined - WT (n=6), <italic>nr2f1a<sup>-/-</sup></italic> (n=6). Blue arrows mark boundaries of <italic>fgf13a</italic>:EGFP expression. White arrows indicate photoconverted (red) cells also expressing <italic>fgf13a</italic>:EGFP. Scale bar indicates 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig2-figsupp3-v1.tif"/></fig></fig-group><p>Because the total number of cardiomyocytes in the hearts of the <italic>nr2f1a</italic> mutants does not change over the stages examined (<xref ref-type="fig" rid="fig1">Figure 1L</xref>), the aforementioned analysis of cardiomyocyte death and proliferation (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref> and <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>) would suggest that the arterial-directed expansion of <italic>Et(fgf13a:EGFP</italic>) expression in Amhc<sup>+</sup> cardiomyocytes reflects an acquisition of PC identity in these cardiomyocytes and is not due to the incorporation of newly differentiating cardiomyocytes at the venous pole of the heart. We sought to further test this hypothesis via lineage tracing of cardiomyocytes using a temporal differentiation assay with the transgene <italic>Tg(myl7:NLS-KikGR</italic>), which expresses the photoconvertible NLS-KikGR in all cardiomyocytes (<xref ref-type="bibr" rid="bib54">Lazic and Scott, 2011</xref>). The cardiomyocyte-specific NLS-KikGR was photoconverted from green to red in the hearts of embryos also carrying the <italic>Et(fgf13a:EGFP</italic>) transgene at 72 hpf. The hearts were then analyzed at 96 hpf for the presence of red and green <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). Importantly, the green, nuclear KikGR was visible within the cardiomyocytes even with expression of the cytosolic <italic>fgf13a:</italic>EGFP. We found that in both WT and <italic>nr2f1a</italic> mutant hearts all <italic>fgf13a</italic>:EGFP<sup>+</sup> cardiomyocytes within the atria co-expressed both photoconverted (red) NLS-KikGR and newly expressed (green) NLS-KikGR, including those in the expanded <italic>fgf13a</italic>:EGFP<sup>+</sup> expression domain and venous pole of <italic>nr2f1a</italic> mutant hearts (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B–E”</xref>). The absence of green-only, newly differentiated NLS-KikGR<sup>+</sup> cardiomyocytes in the <italic>nr2f1a</italic> mutant atria at 96 hpf indicates that all of the <italic>fgf13a</italic>:EGFP<sup>+</sup> cardiomyocytes were present in the atrium at 72 hpf. Thus, our data support that venous Amhc<sup>+</sup> ACs are progressively transdifferentiating into PCs in the absence of Nr2f1a.</p><p>Next, we wanted to determine if the ACs that are acquiring PC marker gene expression in the <italic>nr2f1a</italic> mutants are functionally adopting PC characteristics. PCs have different electrophysiological properties than working cardiomyocytes, including slower depolarization and the ability to spontaneously generate action potentials (<xref ref-type="bibr" rid="bib22">Christoffels et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Lakatta et al., 2010</xref>; <xref ref-type="bibr" rid="bib67">Mesirca et al., 2015</xref>; <xref ref-type="bibr" rid="bib87">Schram et al., 2002</xref>). Moreover, given that the intrinsic automaticity of coupled cells is a function of their total electrical capacitance (<xref ref-type="bibr" rid="bib41">Honjo et al., 1996</xref>; <xref ref-type="bibr" rid="bib47">Joyner and van Capelle, 1986</xref>; <xref ref-type="bibr" rid="bib64">Mangoni and Nargeot, 2008</xref>; <xref ref-type="bibr" rid="bib100">Watanabe et al., 1995</xref>), one might predict that if there are more ACs adopting PC or central conduction system-like characteristics then the heart rates of <italic>nr2f1a</italic> mutants may be slower than WT embryos. We assessed heart rate using high-speed time lapse imaging (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>; <xref ref-type="video" rid="fig3video1 fig3video2 fig3video3 fig3video4 fig3video5 fig3video6">Figure 3—videos 1–6</xref>). At 48 hpf, there was no difference in heart rate between WT and <italic>nr2f1a</italic> mutant hearts (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). However, as the heart rate of WT embryos increased through 96 hpf, the heart rate of <italic>nr2f1a</italic> mutant hearts failed to increase (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). To examine the electrophysiological properties of the ACs that are acquiring PC marker expression in <italic>nr2f1a</italic> mutant hearts, we analyzed myocardial electrophysiology using optical voltage mapping (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Mosimann et al., 2015</xref>; <xref ref-type="bibr" rid="bib74">Panáková et al., 2010</xref>). The intrinsic bradycardia we observed appeared to be related to effects on the duration and extent of repolarization with evidence of modest hyperpolarization in both heterozygous and homozygous <italic>nr2f1a</italic> mutant hearts, as well as substantial prolongation of repolarization in the homozygous <italic>nr2f1a</italic> mutant hearts, as conservatively assessed based on the action potential duration at 20% repolarization (APD20) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Measuring the APD20 within the center of the atria (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), which acquires PC marker expression in the <italic>nr2f1a</italic> mutants based on the IHC analysis, showed that even at 48 hpf the ACs in <italic>nr2f1a</italic> mutant hearts depolarize more slowly compared to WT and heterozygous <italic>nr2f1a</italic> atria (<xref ref-type="fig" rid="fig3">Figure 3E</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). These effects were not associated with any changes in Phase 4 depolarization (data not shown). There was evidence of significantly slower conduction across the <italic>nr2f1a</italic> mutant atria by 96 hpf (<xref ref-type="fig" rid="fig3">Figure 3F–L</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>), but with no effect on Vmax (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>), consistent with less chamber-like and more central conduction system-like intercellular coupling characteristics. Remarkably, there was no evidence of the emergence of the AVC slow conduction zone in the <italic>nr2f1a</italic> mutant hearts that is characteristic of the AV junction and the resultant sequential chamber contraction that is the hallmark of the vertebrate heart (<xref ref-type="fig" rid="fig3">Figure 3G–L</xref>), supporting that the cardiomyocytes in the AVC of <italic>nr2f1a</italic> mutants also have acquired intermediate physiological properties with the VCs. Collectively, our data support that more venous ACs in <italic>nr2f1a</italic> mutant hearts are adopting a functional identity that exhibits delayed repolarization and reduced intercellular coupling, closer to the physiology of the cardiomyocytes of the central conduction system and paralleling the PC-associated gene expression changes we observe within the <italic>nr2f1a</italic> mutant atria.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Atrial cardiomyocytes (ACs) in <italic>nr2f1a</italic> mutants function as pacemaker cardiomyocytes (PCs).</title><p>(<bold>A</bold>) Schematic of point placements to measure heart rate (cyan) and action potential duration at 20% repolarization (APD20) (magenta) in a 48 hr post-fertilization (hpf) heart. (<bold>B</bold>) Representative kymograph used to analyze heart rate in wild-type (WT) and <italic>nr2f1a</italic> mutant embryos. (<bold>C</bold>) Quantification of heart rate in WT and <italic>nr2f1a</italic> mutant embryos; 48 hpf: WT (n=6), <italic>nr2f1a<sup>-/-</sup></italic> (n=6); 72 hpf: WT (n=6), <italic>nr2f1a<sup>-/-</sup></italic> (n=6); 96 hpf: WT (n=6), <italic>nr2f1a<sup>-/-</sup></italic> (n=6). (<bold>D</bold>) Representative atrial action potentials of WT, <italic>nr2f1a<sup>+/-</sup></italic>, and <italic>nr2f1a<sup>-/-</sup></italic> embryos at 96 hpf. (<bold>E</bold>) APD20 in WT and <italic>nr2f1a<sup>-/-</sup></italic> hearts; 48hpf: WT (n=21), <italic>nr2f1a<sup>-/-</sup></italic> (n=4); 72 hpf: WT (n=13), <italic>nr2f1a<sup>-/-</sup></italic> (n=9); 96 hpf: WT (n=9), <italic>nr2f1a<sup>-/-</sup></italic> (n=14). (<bold>F</bold>) Atrial velocity in WT and <italic>nr2f1a<sup>-/-</sup></italic> hearts; 72 hpf: WT (n=13), <italic>nr2f1a<sup>-/-</sup></italic> (n=9); 96 hpf: WT (n=9), <italic>nr2f1a<sup>-/-</sup></italic> (n=14). (<bold>G–L</bold>) Representative isochronal maps illustrating the positions of the depolarizing wave front in 5 ms intervals for WT and <italic>nr2f1a<sup>-/-</sup></italic> embryos at 48, 72, and 96 hpf; 48 hpf: WT (n=20), <italic>nr2f1a<sup>-/-</sup></italic> (n=6) 72 hpf: WT (n=12), <italic>nr2f1a<sup>-/-</sup></italic> (n=7) 96 hpf: WT (n=11), <italic>nr2f1a<sup>-/-</sup></italic> (n=14). Differences between WT and <italic>nr2f1a<sup>-/-</sup></italic> analyzed using ANOVA with multiple comparisons. Error bars in all graphs indicate s.e.m. *p=0.05–0.001, **p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Prolonged repolarization and decreased atrial conduction velocity in <italic>nr2f1a</italic> mutants compared to wild-type (WT) and heterozygous <italic>nr2f1a</italic> atria.</title><p>(<bold>A</bold>) Action potential duration at 20% repolarization (APD20) of WT, <italic>nr2f1a<sup>+/-</sup></italic>, and <italic>nr2f1a<sup>-/-</sup></italic> hearts. (<bold>B</bold>) Atrial velocity of WT, <italic>nr2f1a<sup>+/-</sup></italic>, and <italic>nr2f1a<sup>-/-</sup></italic> hearts. (<bold>C</bold>) Vmax of WT, <italic>nr2f1a<sup>+/-</sup></italic>, and <italic>nr2f1a<sup>-/-</sup></italic> hearts. Error bars indicate s.e.m.; 48 hr post-fertilization (hpf): WT (n=7), <italic>nr2f1a<sup>+/-</sup></italic> (n=14), <italic>nr2f1a<sup>-/-</sup></italic> (n=4); 72 hpf: WT (n=2), <italic>nr2f1a<sup>+/-</sup></italic> (n=11), <italic>nr2f1a<sup>-/-</sup></italic> (n=9); 96 hpf: WT (n=3), <italic>nr2f1a<sup>+/-</sup></italic> (n=6), <italic>nr2f1a<sup>-/-</sup></italic> (n=14). (<bold>A and B</bold>) are the same data presented in <xref ref-type="fig" rid="fig3">Figure 3E and F</xref>. Differences between WT, <italic>nr2f1a<sup>+/-</sup>,</italic> and <italic>nr2f1a<sup>-/-</sup></italic> were analyzed using ANOVA with multiple comparisons. *p=0.05–0.001, **p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig3-figsupp1-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-77408-fig3-video1.mp4" id="fig3video1"><label>Figure 3—video 1.</label><caption><title>Heart from 48 hr post-fertilization (hpf) wild-type (WT) embryo.</title></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-77408-fig3-video2.mp4" id="fig3video2"><label>Figure 3—video 2.</label><caption><title>Heart from 48 hr post-fertilization (hpf) <italic>nr2f1a</italic> mutant embryo.</title></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-77408-fig3-video3.mp4" id="fig3video3"><label>Figure 3—video 3.</label><caption><title>Heart from 72 hr post-fertilization (hpf) wild-type (WT) embryo.</title></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-77408-fig3-video4.mp4" id="fig3video4"><label>Figure 3—video 4.</label><caption><title>Heart from 72 hr post-fertilization (hpf) <italic>nr2f1a</italic> mutant embryo.</title></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-77408-fig3-video5.mp4" id="fig3video5"><label>Figure 3—video 5.</label><caption><title>Heart from 96 hr post-fertilization (hpf) wild-type (WT) embryo.</title></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-77408-fig3-video6.mp4" id="fig3video6"><label>Figure 3—video 6.</label><caption><title>Heart from 96 hr post-fertilization (hpf) <italic>nr2f1a</italic> mutant embryo.</title></caption></media></fig-group></sec><sec id="s2-3"><title>Nr2f1a represses SAN identity upstream of Nkx2.5</title><p>We next wanted to understand how Nr2f1a may be regulating the PC gene regulatory network within the atrium. We prioritized examining Nkx2.5 in <italic>nr2f1a</italic> mutant hearts, as Nkx2.5 loss in mice and zebrafish results in an expansion of PCs within the atrium (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Espinoza-Lewis et al., 2011</xref>; <xref ref-type="bibr" rid="bib72">Nakashima et al., 2014</xref>) and its expression was reduced in the bulk RNA-seq data of <italic>nr2f1a</italic> mutant <italic>amhc</italic>:EGFP<sup>+</sup> cardiomyocytes (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). IHC for Nkx2.5 and either the <italic>Et(fgf13a:EGFP</italic>) reporter or Isl1 both showed that in WT hearts at 48 through 96 hpf Nkx2.5 is expressed throughout the atrial myocardium but is predominantly excluded from the PCs at the venous pole (<xref ref-type="fig" rid="fig4">Figure 4A–C”</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), consistent with what has been reported in zebrafish and mice (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Mommersteeg et al., 2007</xref>). At 48 hpf in <italic>nr2f1a</italic> mutants, Nkx2.5 shows a similar complementary pattern with the <italic>Et(fgf13a:EGFP</italic>) reporter despite the smaller atria (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). As the <italic>Et(fgf13a:EGFP</italic>) reporter expands toward the AVC into the Amhc<sup>+</sup> ACs through 96 hpf in <italic>nr2f1a</italic> mutants, Nkx2.5 expression recedes from the venous pole and predominantly maintains the complementary expression pattern (<xref ref-type="fig" rid="fig4">Figure 4E–F”</xref>). Equivalent results were obtained using the <italic>TgBAC(–36Nkx2.5:ZsYellow</italic>) transgene (<xref ref-type="bibr" rid="bib115">Zhou et al., 2011</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Thus, a progressive loss of Nkx2.5 within ACs correlates with and abuts the expansion of PC identity in <italic>nr2f1a</italic> mutant atria.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Nkx2.5 expression recedes from venous pole in <italic>nr2f1a</italic> mutant atria.</title><p>(<bold>A–F’’’</bold>) IHC for Nkx2.5 (purple), Amhc (blue), and <italic>fgf13a:</italic>EGFP (SAN - green) in wild-type (WT) and <italic>nr2f1a</italic> mutant embryos from 48 to 96 hr post-fertilization (hpf). White arrows indicate border of Nkx2.5<sup>+</sup> and <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes. Number of embryos examined - 48 hpf: WT (n=7), <italic>nr2f1a<sup>-/-</sup></italic> (n=6); 72 hpf: WT (n=7), <italic>nr2f1a<sup>-/-</sup></italic> (n=10); 96 hpf: WT (n=14), <italic>nr2f1a<sup>-/-</sup></italic> (n=23). Scale bar indicates 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Nkx2.5 is predominantly excluded from pacemaker cardiomyocytes (PCs) at the venous pole of the atrium.</title><p>(<bold>A–A”</bold>) IHC for Nkx2.5 (green), Isl1 (red), and Amhc (blue) in wild-type (WT) hearts at 72 hr post-fertilization (hpf) (n=4). White arrows indicate cardiomyocytes expressing both Nkx2.5 and Isl1. Blue arrows mark cardiomyocytes expressing Isl1 only. Scale bar indicates 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title><italic>Nkx2.5:</italic>ZsYellow expression recedes toward the arterial pole of the atrium in <italic>nr2f1a</italic> mutants.</title><p>(<bold>A–D’’’</bold>) IHC for <italic>nkx2.5:</italic>ZsYellow (<italic>nkx</italic>:ZY - purple), Amhc (blue), and <italic>fgf13a:</italic>EGFP (green) in the atria of wild-type (WT) and <italic>nr2f1a</italic> mutant embryos. White arrows indicate border of <italic>nkx2.5:</italic>ZsYellow<sup>+</sup> and <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes within the atria. Number of embryos examined - 48 hr post-fertilization (hpf): WT (n=8), <italic>nr2f1a<sup>-/-</sup></italic> (n=10); 96 hpf: WT (n=9), <italic>nr2f1a<sup>-/-</sup></italic> (n=12). Scale bar indicates 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig4-figsupp2-v1.tif"/></fig></fig-group><p>To determine if restoring Nkx2.5 in <italic>nr2f1a</italic> mutants can repress the transdifferentiation of ACs to PCs, we used the <italic>Tg(hsp70l:nkx2.5-EGFP</italic>) transgene (<xref ref-type="bibr" rid="bib35">George et al., 2015</xref>). <italic>Nr2f1a<sup>+/-</sup></italic> fish that carry the <italic>Tg(myl7:DsRed2-NLS) and Et(fgf13a:EGFP</italic>) transgenes were crossed to <italic>nr2f1a<sup>+/-</sup></italic> fish carrying the <italic>Tg(hsp70l:nkx2.5-EGFP</italic>) transgene (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The resulting embryos were sorted for the <italic>Et(fgf13a:EGFP</italic>) transgene and then heat-shocked at 20 hpf, as a single heat-shock at ~20 hpf using the <italic>Tg(hsp70l:nkx2.5-EGFP</italic>) transgene is sufficient to rescue <italic>nkx2.5</italic> mutants to adulthood (<xref ref-type="bibr" rid="bib35">George et al., 2015</xref>). Following heat-shock, the embryos were sorted based on the presence of Nkx2.5-EGFP expression and allowed to develop until 48 and 96 hpf, at which point the Nkx2.5-EGFP is no longer visible, and the number of <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes was quantified (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). At 48 hpf, there was a modest decrease in the number of <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes in Nkx2.5-EGFP<sup>+</sup> WT hearts compared to the Nkx2.5-EGFP<sup>-</sup> WT siblings (<xref ref-type="fig" rid="fig5">Figure 5B, C, J and K</xref>). However, Nkx2.5-EGFP<sup>+</sup> <italic>nr2f1a</italic> mutants had a complete absence of <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes at the venous pole (<xref ref-type="fig" rid="fig5">Figure 5F, G, J and K</xref>), suggesting that Nkx2.5 is sufficient to repress PC differentiation in <italic>nr2f1a</italic> mutant hearts and, further, that <italic>nr2f1a</italic> mutant ACs may be sensitized to increased Nkx2.5 expression. At 96 hpf, both Nkx2.5-EGFP<sup>+</sup> WT and <italic>nr2f1a</italic> mutant hearts had an increased number of <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes compared to those at 48 hpf, yet Nkx2.5-EGFP<sup>+</sup> <italic>nr2f1a</italic> mutants still had significantly fewer <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes than mutants lacking the transgene (<xref ref-type="fig" rid="fig5">Figure 5D, E and H–K</xref>). While we see a repression of the <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocyte expansion at 48 hpf, we found that the overexpression of Nkx2.5 did not rescue the heart rate of <italic>nr2f1a</italic> mutants at 96 hpf when we observe the resumption of the PC reporter (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), suggesting that despite the inhibition of the reporter expansion, additional Nkx2.5-independent mechanisms downstream of Nr2f1a also contribute to the inhibition of PC identity. We found that heat-shock induction of Nkx2.5-EGFP at 40 hpf could also repress the expansion of <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes in <italic>nr2f1a</italic> mutant atria (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A–C, F, G, J and K</xref>). However, the repression of <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes within the mutant atria was not as effective or prolonged as the heat-shock induction of Nkx2.5-EGFP at 20 hpf (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2D, E and H–K</xref>). Overall, these data suggest that Nr2f1a prevents the expansion of PC identity within the venous pole of the atrium at least in part through promoting or maintaining Nkx2.5 in ACs.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Nkx2.5 induction at 20 hr post-fertilization (hpf) represses pacemaker cardiomyocyte (PC) marker expansion in <italic>nr2f1a</italic> mutant atria.</title><p>(<bold>A</bold>) Schematic of timeline for heat-shock experiments. (<bold>B–I</bold>) IHC of representative hearts for Amhc (blue), <italic>fgf13a:</italic>EGFP (green), and <italic>myl7:</italic>DsRed2-NLS (red) used to quantify Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes (CMs) marking PCs from wild-type (WT) and <italic>nr2f1a</italic> mutant embryos with and without Nkx2.5-EGFP. White arrows indicate boundaries of <italic>Tg(fgf13a:EGFP</italic>) expression. Scale bar indicates 50 μm. (<bold>J–K</bold>) Quantification of Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>+</sup>/<italic>myl7:</italic>DsRed2-NLS<sup>+</sup> (PCs) and Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>-</sup>/<italic>myl7:</italic>DsRed2-NLS<sup>+</sup> cardiomyocytes in the atria with and without Nkx2.5-EGFP induction; 48 hpf WT: Nkx2.5-EGFP<sup>-</sup> (n=6), Nkx2.5-EGFP<sup>+</sup> (n=4); 48 hpf <italic>nr2f1a<sup>-/-</sup></italic>: Nkx2.5-EGFP<sup>-</sup> (n=7), Nkx2.5-EGFP<sup>+</sup> (n=5); 96 hpf WT: Nkx2.5-EGFP<sup>-</sup> (n=4), Nkx2.5-EGFP<sup>+</sup> (n=4); 96 hpf <italic>nr2f1a<sup>-/-</sup></italic>: Nkx2.5-EGFP<sup>-</sup> (n=7), Nkx2.5-EGFP<sup>+</sup> (n=4). Differences between WT and <italic>nr2f1a<sup>-/-</sup></italic> at the different time points were analyzed using Student’s t-test. Error bars indicate s.e.m. *p=0.05–0.001, **p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Induction of Nkx2.5 at 20 hr post-fertilization (hpf) does not rescue heart rate.</title><p>Quantification of heart rate in wild-type (WT) and <italic>nr2f1a</italic> mutant embryos at 96 hpf following induction of Nkx2.5 at the 20 somite stage; 96 hpf WT: Nkx2.5-EGFP<sup>-</sup> (n=7), Nkx2.5-EGFP<sup>+</sup> (n=8); 96 hpf <italic>nr2f1a<sup>-/-</sup></italic>: Nkx2.5-EGFP<sup>-</sup> (n=8), Nkx2.5-EGFP<sup>+</sup> (n=7). Analyzed using Student’s t-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Nkx2.5-EGFP induction at 40 hr post-fertilization (hpf) partially represses the expansion of pacemaker cardiomyocyte (PC) identity.</title><p>(<bold>A</bold>) Schematic of heat-shock experiments. (<bold>B–I</bold>) IHC for Amhc (blue), <italic>fgf13a:</italic>EGFP (green), and <italic>myl7:</italic>DsRed2-NLS (red) of representative hearts from wild-type (WT) and <italic>nr2f1a</italic> mutant embryos with and without Nkx2.5-EGFP. White arrows indicate boundaries of <italic>fgf13a:</italic>EGFP expression. Scale bar indicates 50 μm. (<bold>J–K</bold>) Quantification of Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes (CMs) and Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>-</sup> cardiomyocytes using the <italic>myl7:</italic>DsRed2-NLS transgene with and without Nkx2.5-EGFP induction at 72 and 120 hpf; 72 hpf WT: Nkx2.5-EGFP<sup>-</sup> (n=3), Nkx2.5-EGFP<sup>+</sup> (n=6); 72 hpf <italic>nr2f1a<sup>-/-</sup></italic>: Nkx2.5-EGFP<sup>-</sup> (n=7), Nkx2.5-EGFP<sup>+</sup> (n=6); 120 hpf WT: Nkx2.5-EGFP<sup>-</sup> (n=2), Nkx2.5-EGFP<sup>+</sup> (n=4); 120 hpf <italic>nr2f1a<sup>-/-</sup></italic>: Nkx2.5-EGFP<sup>-</sup> (n=3), Nkx2.5-EGFP<sup>+</sup> (n=4). Differences between WT and <italic>nr2f1a<sup>-/-</sup></italic> were analyzed using Student’s t-test. Error bars indicate s.e.m. *p=0.05–0.001, **p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig5-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>A putative <italic>nkx2.5</italic> enhancer is expressed within the venous pole of the atrium</title><p>To identify cis-regulatory elements that may control <italic>nkx2.5</italic> expression and be affected by Nr2f1a loss, we assayed chromatin accessibility by performing assay for transpose-accessible chromatin sequencing (ATAC-seq) on flow-sorted <italic>amhc</italic>:EGFP<sup>+</sup> cardiomyocytes from 48 hpf embryos, similar to what is described above (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Changes in called peaks of WT and <italic>nr2f1a</italic> mutant <italic>amhc</italic>:EGFP<sup>+</sup> cardiomyocytes were scored relative to the nearest differentially expressed genes (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). HOMER was used to determine enrichment for canonical Nr2f TF binding sites on the putative enhancer elements. One of the peaks that was revealed to close in <italic>nr2f1a</italic> mutant atria and contain an Nr2f binding site was ~55 kb upstream of the <italic>nkx2.5</italic> transcriptional start site (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Although this region did not show significant sequence conservation, enhancer conservation can vary between tissue types, with enhancers that drive expression in the heart often being weakly conserved (<xref ref-type="bibr" rid="bib11">Blow et al., 2010</xref>). This putative enhancer region was placed into a reporter vector upstream of the basal <italic>E1b</italic> promoter to drive GFP expression (<xref ref-type="fig" rid="fig6">Figure 6B</xref>; <xref ref-type="bibr" rid="bib9">Birnbaum et al., 2012</xref>), and transgenic lines were generated using Tol2 (<xref ref-type="bibr" rid="bib52">Kwan et al., 2007</xref>). Remarkably, stable transgenic lines showed that this putative enhancer is expressed in a group of cardiomyocytes at the venous pole of the atrium (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), which are directly adjacent to Isl1<sup>+</sup> PCs (<xref ref-type="fig" rid="fig6">Figure 6D and D’</xref>). The <italic>Tg(–55nkx2.5:EGFP</italic>) transgene was then crossed into <italic>nr2f1a</italic> mutant allele carriers to determine if the expression of this putative <italic>nkx2.5</italic> enhancer is affected in <italic>nr2f1a</italic> mutants. We found the number of atria with <italic>Tg(–55nkx2.5:EGFP</italic>) expression was significantly decreased in <italic>nr2f1a</italic> mutants compared to WT, suggesting that Nr2f1a is required for enhancer expression or for those cardiomyocytes to develop (<xref ref-type="fig" rid="fig6">Figure 6C, E and F</xref>). Together, these data suggest that a putative Nr2f1a-dependent <italic>nkx2.5</italic> enhancer promotes expression in ACs adjacent to PCs.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>A putative <italic>nkx2.5</italic> enhancer is expressed in atrial cardiomyocytes (ACs) adjacent to the sinoatrial node (SAN).</title><p>(<bold>A</bold>) Comparison of assay for transpose-accessible chromatin sequencing (ATAC-seq) peaks from wild-type (WT) and <italic>nr2f1a</italic> mutant <italic>amhc</italic>:EGFP<sup>+</sup> cardiomyocytes at 48 hr post-fertilization (hpf), ~55 kb upstream of <italic>nkx2.5</italic>. Asterisk denotes canonical Nr2f binding site. (<bold>B</bold>) Schematic of –55 kb <italic>nkx2.5</italic> enhancer reporter construct. (<bold>C</bold>) IHC for <italic>Tg(–55nkx2.5:EGFP</italic>) enhancer (green), Amhc (blue), and Vmhc (red) in hearts at 72 hpf. White arrow indicates –<italic>55nkx2.5</italic>:EGFP expression. (<bold>D–D’</bold>) IHC for <italic>–55nkx2.5:</italic>EGFP (green), Isl1 (purple), Amhc (blue), and sarcomeric myosin heavy chain (Mhc: pan-cardiac - red). The transgenic enhancer reporter is expressed in the ACs directly adjacent to the Isl1<sup>+</sup> pacemaker cardiomyocytes (PCs). (<bold>E</bold>) IHC for <italic>Tg(–55nkx2.5:EGFP</italic>) enhancer (green), Amhc (blue), and Vmhc (red) in an <italic>nr2f1a</italic> mutant heart at 72 hpf. Expression of transgenic enhancer reporter is lost in <italic>nr2f1a</italic> mutants. Yellow arrow indicates venous pole devoid of <italic>–55nkx2.5:</italic>EGFP expression. (<bold>F</bold>) Comparison of percentage of WT and <italic>nr2f1a</italic> mutant embryos with <italic>–55nkx2.5:</italic>EGFP expression in the heart at 72 hpf WT (n=16); <italic>nr2f1a<sup>-/-</sup></italic> (n=16), using Fisher’s exact test. (<bold>G,H</bold>) IHC for Nkx2.5 (green), Amhc (purple), and Mhc (red) in uninjected control and <italic>–55nkx2.5</italic> crispant embryo hearts at 96 hpf. White arrow in (<bold>G</bold>) indicates the border of Nkx2.5<sup>+</sup> cardiomyocytes extends close to the venous pole. Yellow arrow in (<bold>H</bold>) indicates that the Nkx2.5<sup>+</sup> cardiomyocyte border is located farther from the venous pole of the atrium in crispant embryos. (<bold>I</bold>) Quantification of Nkx2.5<sup>+</sup>/Amhc<sup>+</sup> cardiomyocytes in uninjected control (n=11) and <italic>–55nkx2.5</italic> crispant (n=11) embryos at 96 hpf. (<bold>J,K</bold>) IHC for <italic>fgf13a</italic>:EGFP (green), Amhc (blue), and <italic>myl7</italic>:DsRed2-NLS (red) in uninjected control and <italic>–55nkx2.5</italic> crispant <italic>Tg(fgf13a:EGFP)<sup>+</sup></italic> embryo hearts at 96 hpf. White arrows in (<bold>J</bold>) indicate the region of <italic>fgf13a</italic>:EGFP<sup>+</sup> cardiomyocytes at the venous pole. Yellow arrows in (<bold>K</bold>) indicates that the region of <italic>fgf13a</italic>:EGFP<sup>+</sup> cardiomyocytes is expanded from the venous pole in the atrium of crispant embryos. (<bold>L</bold>) Quantification of <italic>fgf13a</italic>:EGFP<sup>+</sup>/Amhc<sup>+</sup> cardiomyocytes in uninjected control (n=10) and <italic>–55nkx2.5</italic> crispant (n=11) embryo hearts at 96 hpf. Differences between uninjected control and <italic>–55nkx2.5</italic> crispants were analyzed using Student’s t-test. Error bars indicate s.e.m. *p=0.05–0.001, **p&lt;0.001. Scale bars in all images indicate 50 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Peaks showing open chromatin surrounding representative loci from the assay for transpose-accessible chromatin sequencing (ATAC-seq) data.</title><p>(<bold>A–C</bold>) Regions of open chromatin using images from the UCSC genome browser were found at the promoters and adjacent to <italic>nr2f1a</italic>, <italic>tbx3a</italic>, and <italic>isl1</italic> in the sorted <italic>amhc</italic>:EGFP<sup>+</sup> cardiomyocytes from wild-type (WT) and <italic>nr2f1a</italic> mutant embryos.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Deletion of the putative <italic>nkx2.5</italic> enhancer in crispants.</title><p>(<bold>A,B</bold>) Transgenic <italic>Tg(–55nkx2.5:EGFP</italic>) control and crispant embryos at 96 hr post-fertilization (hpf). Images are lateral views with anterior to the left and dorsal up. White arrows in (<bold>A</bold>) indicate expression in dorso-lateral jaw and fin. Yellow arrowheads in (<bold>B</bold>) indicate reduced expression in the dorso-lateral jaw and loss of expression in the fin in <italic>Tg(–55nkx2.5:EGFP</italic>) crispants. Scale bar is 500 µm. (<bold>C</bold>) Comparison of the percentage of <italic>Tg(–55nkx2.5:EGFP</italic>) uninjected control and crispant embryos with EGFP expression at 72 hpf. Number of Tg(<italic>–55nkx2.5:EGFP</italic>) embryos examined - uninjected control (n=184); <italic>–55nkx2.5</italic> crispant (n=78). *p&lt;0.001 using Fisher’s exact test. Experiments were performed by outcrossing hemizygous <italic>Tg(–55nkx2.5</italic>:EGFP) to wild-type (WT) embryos. Hence, 50% of the control embryos did not carry the transgene. (<bold>D</bold>) PCR for the <italic>–55nkx2.5:EGFP</italic> transgenic locus in individual –<italic>55nkx2.5:</italic>EGFP uninjected control and crispant embryos. The expected product size for the transgenic –<italic>55nkx2.5</italic> enhancer is 512 bp (blue box in controls). The –<italic>55nkx2.5</italic> transgenic element is almost completely eliminated (blue box in crispants). Green box indicates deletions. (<bold>E</bold>) PCR for the endogenous –<italic>55nkx2.5</italic> locus in individual uninjected control and crispant embryos. The expected product for the endogenous –<italic>55nkx2.5</italic> enhancer from uninjected control (WT) embryos is 246 bp (blue box in controls). The endogenous locus is significantly affected in crispants (blue box in crispants). Green box indicates products showing deletion of the locus. Red arrowheads in D and E indicated location of dgRNA pairs. Black arrows indicate location of the primers. Schema are not drawn to scale.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Uncropped gel pictures of PCR analysis for efficacy of the dgRNA pairs in generating deletions of the transgenic and endogenous <italic>–55nkx2.5</italic> loci.</title><p>Numbers in the labeled gels indicate individual control uninjected and CRISPR/Cas9-injected embryos. Control uninjected embryos 6–8 and CRISPR/Cas9-injected embryos 1–3 are shown in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77408-fig6-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Nr2f1a is expressed throughout cardiomyocytes in the atrium.</title><p>(<bold>A–A”</bold>) IHC for Nr2f1a (purple), <italic>fgf13a</italic>:EGFP (green), Amhc (blue), and Mhc (red) in wild-type (WT) hearts at 72 hr post-fertilization (hpf) (n=7). White arrows indicate Nr2f1a<sup>+</sup> and <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes. (<bold>B–B”</bold>) IHC for Nr2f1a (green), Isl1 (red), and Amhc (blue) in WT hearts at 72 hpf (n=4). White arrows mark Nr2f1a<sup>+</sup> and Isl1<sup>+</sup>. Scale bars indicate 50 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig6-figsupp3-v1.tif"/></fig></fig-group><p>To determine if the putative <italic>nkx2.5</italic> enhancer is required to promote Nkx2.5 expression and restrict PC identity within the venous pole of the atrium, we employed an established, highly efficient CRISPR/Cas9 system to remove the enhancer in embryos with guide RNAs (gRNAs) that flank the <italic>nkx2.5</italic> enhancer sequence (<xref ref-type="bibr" rid="bib43">Hoshijima et al., 2019</xref>). We found that <italic>Tg(–55nkx2.5:EGFP</italic>) crispant (CRISPR/Cas9-injected) embryos completely lacked or had significantly reduced EGFP expression within their hearts and other tissues where the enhancer is expressed (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–C</xref>). PCR for the transgenic locus in individual <italic>Tg(–55nkx2.5:EGFP</italic>) embryos and the endogenous locus in individual WT embryos showed the gRNA pair used significantly abrogated both the transgenic and WT enhancer loci, respectively (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2D and E</xref>). IHC for Nkx2.5 in <italic>–55nkx2.5</italic> crispants showed that Nkx2.5 did not extend as far toward to the venous pole of their atria and that they had a significant reduction in the number of Nkx2.5<sup>+</sup>/Amhc<sup>+</sup> cardiomyocytes within the atria compared to control embryos (<xref ref-type="fig" rid="fig6">Figure 6G–I</xref>). Conversely, <italic>–55nkx2.5</italic> crispant embryos concurrently carrying the <italic>Et(fgf13a:EGFP</italic>) and <italic>Tg(myl7:DsRed2-NLS</italic>) transgenes showed an arterial-directed expansion of <italic>Et(fgf13a:EGFP</italic>) expression within their atria and an increase in the number of <italic>fgf13a</italic>:EGFP<sup>+</sup> cardiomyocytes at the venous pole compared to control embryos (<xref ref-type="fig" rid="fig6">Figure 6J–L</xref>). Altogether, these data support that this putative <italic>nkx2.5</italic> enhancer is required to promote or maintain Nkx2.5 expression within a subpopulation of ACs that in turn may limit the extent of PCs within the venous pole of the atrium.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Vertebrate embryonic cardiomyocytes maintain a high degree of plasticity, with their identity being continually reinforced even after they have overtly differentiated (<xref ref-type="bibr" rid="bib5">Barth et al., 2005</xref>; <xref ref-type="bibr" rid="bib73">Ng et al., 2010</xref>; <xref ref-type="bibr" rid="bib78">Pradhan et al., 2017</xref>; <xref ref-type="bibr" rid="bib92">Tabibiazar et al., 2003</xref>; <xref ref-type="bibr" rid="bib93">Targoff et al., 2013</xref>; <xref ref-type="bibr" rid="bib97">van Weerd and Christoffels, 2016</xref>; <xref ref-type="bibr" rid="bib110">Xin et al., 2007</xref>). Here, our data have advanced our understanding of the requirements of Nr2f TFs within the vertebrate heart and show that they are required to maintain AC identity while concurrently repressing both VC and PC identity in different regions of the atrium (<xref ref-type="fig" rid="fig7">Figure 7</xref>). In mice, Nr2f2 maintains AC identity by repressing the expression of TFs that promote a ventricular identity program, including <italic>Irx4</italic> and <italic>Hey2</italic> (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>). Moreover, murine Nr2f2 appears to be required over a relatively long developmental period after ACs express differentiation markers to prevent the acquisition of VC identity within the atrium. Specifically, loss of Nr2f2 by e9.5 using the <italic>Myh6-Cre</italic> or by e12.5 using the inducible <italic>Myh6-MerCreMer</italic> both result in the ectopic expression of VC differentiation genes within ACs (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>). Conversely, ectopic Nr2f2 expression in VCs is sufficient to induce AC gene expression (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>). Although our previous work had shown that zebrafish Nr2f1a promotes atrial differentiation (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>), it was still unclear if ACs in zebrafish <italic>nr2f1a</italic> mutants acquired VC identity, similar to what was shown for <italic>Nr2f2</italic> loss in mice. We now show that there is acquisition of VC identity within the <italic>nr2f1a</italic> mutant atria. However, with the murine conditional <italic>Nr2f2</italic> KO approaches, the two atria were formed, but enlarged and appeared to express VC markers throughout the atria (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>). In contrast to what was shown in the conditional KO mice, the acquisition of VC identity in zebrafish <italic>nr2f1a</italic> mutants was limited to the population of less-differentiated cardiomyocytes that comprise the expanded AVC, which extends into the smaller single atria. Moreover, our data show that initially within the early zebrafish heart tube there is significant overlap of Vmhc and Amhc expression. Normally, the population of cardiomyocytes expressing both Vmhc and Amhc becomes significantly refined to the AVC. However, this population of cardiomyocytes that comprise the AVC is not restricted within the <italic>nr2f1a</italic> mutants and they then progressively resolve to VC identity in an arterial-to-venous direction via losing expression of AC differentiation markers. We presently cannot rule out that these overt differences in effects on the ACs are due to slightly different species-specific requirements of Nr2f TFs within mice and zebrafish or technical differences from the global zebrafish <italic>nr2f1a</italic> mutants vs the conditional <italic>Nr2f2</italic> approaches. Nevertheless, taken together, the trends reinforce that there are conserved requirements for vertebrate Nr2f TFs in repressing VC identity within ACs. However, our results with global loss of Nr2f1a support that not all ACs have the potential to transdifferentiate into VCs and that this transformation occurs in a sensitized AC population.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Model summarizing the consequences of Nr2f1a loss on atrial development.</title><p>Following its initial requirement promoting atrial cardiomyocyte (AC) differentiation (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>), Nr2f1a is required to maintain AC identity within the arterial (outflow) and venous (inflow) regions of the zebrafish atrium. In the absence of Nr2f1a, cardiomyocytes within the enlarged atrioventricular canal (AVC), where there is expression of both AC and ventricular cardiomyocyte (VC) differentiation markers, progressively lose expression of AC differentiation markers and only express VC differentiation markers. Concurrently, more venous ACs progressively gain PC differentiation marker expression.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77408-fig7-v1.tif"/></fig><p>Our data also support a new paradigm whereby Nr2f TFs are required to limit the acquisition of PC identity within more venous ACs. Work predominantly in mice has revealed a transcriptional regulatory network that promotes the differentiation of PCs within the SAN at the venous pole of the right atrium (<xref ref-type="bibr" rid="bib19">Burkhard et al., 2017</xref>; <xref ref-type="bibr" rid="bib22">Christoffels et al., 2010</xref>; <xref ref-type="bibr" rid="bib97">van Weerd and Christoffels, 2016</xref>). Tbx3, Isl1, and Shox/Shox2 TFs are part of a core regulatory network that promotes PC differentiation within venous ACs, while Nkx2.5 represses PC identity in working ACs (<xref ref-type="bibr" rid="bib10">Blaschke et al., 2007</xref>; <xref ref-type="bibr" rid="bib33">Espinoza-Lewis et al., 2009</xref>; <xref ref-type="bibr" rid="bib34">Espinoza-Lewis et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Hoogaars et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Liang et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib68">Mommersteeg et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Nakashima et al., 2014</xref>; <xref ref-type="bibr" rid="bib91">Sun et al., 2007</xref>; <xref ref-type="bibr" rid="bib102">Weinberger et al., 2012</xref>; <xref ref-type="bibr" rid="bib105">Wiese et al., 2009</xref>). Although the characterization of PC differentiation has been less extensive in zebrafish, functional analysis of Isl1, Shox/Shox2, and Nkx2.5 support that this regulatory network is fundamentally conserved (<xref ref-type="bibr" rid="bib10">Blaschke et al., 2007</xref>; <xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">de Pater et al., 2009</xref>; <xref ref-type="bibr" rid="bib39">Hoffmann et al., 2013</xref>; <xref ref-type="bibr" rid="bib94">Tessadori et al., 2012</xref>). Our data show that in <italic>nr2f1a</italic> mutants there is a progressive expansion of central conduction system identity from the venous pole toward the arterial pole of the atrium, supporting a role for Nr2f TFs in regulating this conserved network within ACs. The progressive expansion, where the number of PCs is initially unchanged in <italic>nr2f1a</italic> mutant atria despite being smaller, contrasts some with <italic>Nkx2.5</italic> mutant mice and zebrafish (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Mommersteeg et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Nakashima et al., 2014</xref>), which show an initial expansion of PC markers and ectopic differentiation at earlier stages. Although the studies of <italic>Nr2f2</italic> conditional KO mice did not examine PC and SAN differentiation, manual interrogation of their data, which was from whole hearts, does show they have increased expression of <italic>Tbx3</italic> and <italic>Fgf13</italic> (<xref ref-type="bibr" rid="bib108">Wu et al., 2013</xref>), implying that this requirement in repressing PC identity may also be conserved within the vertebrate atrium. However, determining if murine Nr2f2 possesses similar requirements in repressing PC identity at the venous pole of the right atrium in mammals will require additional analysis.</p><p>Our data support that one mechanism by which Nr2f1a intersects with the PC regulatory network and represses the progressive acquisition of PC identity within ACs is through maintaining Nkx2.5 expression at the venous pole of the atrium. Interestingly, Nkx2.5 induction at early stages of heart development can initially completely repress PC reporter expression in the <italic>nr2f1a</italic> mutant atria at later stages. Thus, these results imply that the transcriptional complexes reflecting the complementary changes in Nkx2.5 and PC gene expression observed at later stages must actually be established much earlier during heart development and that Nr2f1a loss actually sensitizes these ACs to Nkx2.5. Furthermore, early Nkx2.5 induction does not produce a permanent repression of PC reporter expansion, as the PC reporter expands by 96 hpf, though less than in <italic>nr2f1a</italic> mutant atria. While one interpretation could be that Nkx2.5 expression needs to be maintained within the ACs over a longer period than provided by the heat-shock to prevent PC expansion, as the Nkx2.5-GFP is only thought to last ~8 hr (<xref ref-type="bibr" rid="bib35">George et al., 2015</xref>), a long requirement would seem unlikely as <italic>nkx2.5</italic> mutants can also be rescued to adulthood following a single heat-shock at the 20 somite stage. Therefore, we postulate that Nr2f1a must also concurrently affect the AC expression of other TFs within the core PC regulatory network that promote PC differentiation, which warrants further investigation. Furthermore, it is interesting that the putative <italic>Tg(–55nkx2.5:EGFP</italic>) enhancer begins expression at later stages (~72 hpf), correlating with the PC marker expansion and implying the enhancer may be activated to reinforce <italic>nkx2.5</italic> expression at this border. Additionally, Nr2f1a appears to be expressed equivalently throughout the cardiomyocytes of the zebrafish atrium (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>; <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3</xref>) and we did not observe overlap of VC and PC markers within the <italic>nr2f1a</italic> mutant atria at the stages examined, suggesting that Nr2f1a at least functionally, if not directly, must interact with other signaling pathways and factors to confer the regional effects within these AC populations. Altogether, our current data support that Nr2f1a must intersect and functionally interact with multiple gene regulatory networks to mediate its regional requirements preventing the progressive acquisition of VC and PC identity in different AC subpopulations. The nature of these factors and signaling will be investigated in the future.</p><p>In considering the implications of our data, it is interesting that in humans, congenital malformations, including AVSDs, are associated with increased incidence of arrhythmias (<xref ref-type="bibr" rid="bib106">Williams and Perry, 2018</xref>). Moreover, the arrhythmias can arise from complications secondary to the structural defects or pleiotropic requirements in the development of the myocardium and the conduction system (<xref ref-type="bibr" rid="bib15">Bruneau et al., 1999</xref>; <xref ref-type="bibr" rid="bib31">Ellesøe et al., 2016</xref>; <xref ref-type="bibr" rid="bib106">Williams and Perry, 2018</xref>). A prime example of the latter is mutations in <italic>NKX2.5</italic>, which are associated with numerous CHDs, including atrial and ventricular septal defects, and conduction defects, consistent with its requirements in working cardiomyocyte and PC differentiation shown in experimental models (<xref ref-type="bibr" rid="bib8">Benson et al., 1999</xref>; <xref ref-type="bibr" rid="bib31">Ellesøe et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Elliott et al., 2003</xref>; <xref ref-type="bibr" rid="bib46">Jhaveri et al., 2018</xref>; <xref ref-type="bibr" rid="bib66">McElhinney et al., 2003</xref>; <xref ref-type="bibr" rid="bib86">Schott et al., 1998</xref>; <xref ref-type="bibr" rid="bib109">Xie et al., 2013</xref>; <xref ref-type="bibr" rid="bib112">Yu et al., 2014</xref>). Similar to <italic>NKX2.5</italic>, <italic>NR2F2</italic> mutations in humans have now been associated with myriad CHDs, including atrial septal defects and AVSDs (<xref ref-type="bibr" rid="bib1">Al Turki et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Nakamura et al., 2011</xref>; <xref ref-type="bibr" rid="bib77">Poot et al., 2007</xref>; <xref ref-type="bibr" rid="bib79">Qiao et al., 2018</xref>; <xref ref-type="bibr" rid="bib95">Upadia et al., 2018</xref>). While it is presently unclear if there are also accompanying arrhythmias or conduction defects in these patients, given our results, we speculate that further evaluation of patients with <italic>NR2F2</italic> mutations will show that they have or are at higher risk to develop arrhythmias.</p><p>In conclusion, mutations in genes, such as <italic>NR2F2</italic>, that are required for the maintenance of cardiomyocyte identity have been associated with multiple types of CHDs in humans (<xref ref-type="bibr" rid="bib1">Al Turki et al., 2014</xref>; <xref ref-type="bibr" rid="bib7">Benjamin et al., 2018</xref>; <xref ref-type="bibr" rid="bib8">Benson et al., 1999</xref>; <xref ref-type="bibr" rid="bib21">Cheng et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">Hoffman and Kaplan, 2002</xref>; <xref ref-type="bibr" rid="bib60">Loffredo, 2000</xref>; <xref ref-type="bibr" rid="bib71">Nakamura et al., 2011</xref>; <xref ref-type="bibr" rid="bib86">Schott et al., 1998</xref>; <xref ref-type="bibr" rid="bib96">van der Linde et al., 2011</xref>). Hence, elucidating the transcriptional mechanisms that maintain cardiomyocyte identity and regulate cardiomyocyte plasticity may provide insights into the etiology of CHDs, as well as help refine stem cell-derived tissue engineering and regenerative strategies. Our results have delineated novel requirements for Nr2f TFs in maintaining AC identity in vertebrates, which may help provide a framework for our understanding of the molecular etiology of concurrent structural malformations and conduction defects in patients.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Zebrafish lines used</title><p>Adult zebrafish were raised and maintained under standard laboratory conditions (<xref ref-type="bibr" rid="bib104">Westerfield, 2000</xref>). Transgenic lines used: <italic>Tg(–5.1myl7:DsRed2-NLS)<sup>f2</sup></italic> (<xref ref-type="bibr" rid="bib63">Mably et al., 2003</xref>), <italic>SqET33-mi59B</italic> (<xref ref-type="bibr" rid="bib76">Poon et al., 2016</xref>), <italic>TgBAC(–36nkx2.5:ZsYellow)<sup>fb7</sup></italic> (<xref ref-type="bibr" rid="bib115">Zhou et al., 2011</xref>), <italic>Tg(myh6:EGFP)<sup>s958</sup></italic> (<xref ref-type="bibr" rid="bib114">Zhang et al., 2013</xref>), <italic>Tg(hsp70l:nkx2.5-EGFP)<sup>fcu1</sup></italic> (<xref ref-type="bibr" rid="bib35">George et al., 2015</xref>), <italic>Tg(myl7:EGFP)<sup>f1</sup></italic> (<xref ref-type="bibr" rid="bib44">Huang et al., 2003</xref>), <italic>Tg(myl7:NLS-KikGR</italic>) (<xref ref-type="bibr" rid="bib54">Lazic and Scott, 2011</xref>). Three <italic>nr2f1a</italic> mutant alleles were used: <italic>nr2f1a<sup>el512</sup> and nr2f1a<sup>ci1009</sup></italic>, which were reported previously (<xref ref-type="bibr" rid="bib30">Duong et al., 2018</xref>), and <italic>nr2f1a<sup>ci1017</sup></italic>, which was identified from an ENU screen. Additional details of this allele will be reported elsewhere (manuscript in preparation). The <italic>nr2f1a<sup>ci1017</sup></italic> allele was used for RNA-seq and ATAC-seq. The <italic>nr2f1a<sup>el512</sup> and nr2f1a<sup>ci1009</sup></italic> alleles were used for the photoconversion assay. All other experiments were completed using the <italic>nr2f1a<sup>ci1009</sup></italic> allele. WT and <italic>nr2f1a<sup>+/-</sup></italic>embryos were overtly indistinguishable, including with respect to their hearts. Therefore, unless otherwise indicated, WT in figures in which embryos were genotyped refers to either WT or <italic>nr2f1a<sup>+/-</sup></italic>embryos. For all experiments, embryos were grown in 0.003% 1-phenyl-2-thiourea to prevent pigmentation.</p></sec><sec id="s4-2"><title>Generation of transgenic <italic>Tg(-55nkx2.5:EGFP</italic>) enhancer line</title><p>The putative <italic>nkx2.5</italic> enhancer transgenic line was generated using standard Tol2/Gateway methods (<xref ref-type="bibr" rid="bib52">Kwan et al., 2007</xref>). The enhancer region at ~55 kb upstream of <italic>nkx2.5</italic> was amplified with PCR of genomic DNA and cloned into the pDONR221 middle entry vector. Subsequently, it was transferred into the <italic>E1b-GFP-Tol2</italic> Gateway destination vector (Addgene plasmid #37846, <xref ref-type="bibr" rid="bib9">Birnbaum et al., 2012</xref>). To generate transgenic lines, one cell embryos were co-injected with 25 pg of the <italic>–55nkx2.5:EGFP</italic> plasmid and 25 pg Tol2 mRNA (<xref ref-type="bibr" rid="bib52">Kwan et al., 2007</xref>). Injected embryos were raised to adulthood and transgenic founders were identified via outcrossing to WT fish. Multiple founders with overtly equivalent GFP expression within the atrium were identified. The line that was used in this study has been designated <italic>Tg(–55nkx2.5:EGFP)<sup>ci1015</sup></italic>.</p></sec><sec id="s4-3"><title>Generation of <italic>–55nkx2.5</italic> enhancer crispants</title><p>To generate <italic>–55nkx2.5</italic> enhancer crispants (CRISPR/Cas9-injected embryos), crRNAs flanking the endogenous enhancer sequence were designed using IDT’s custom gRNA design tool (<ext-link ext-link-type="uri" xlink:href="https://www.idtdna.com/">https://www.idtdna.com/</ext-link>). crRNA:tracrRNA duplexes were prepared as described previously (<xref ref-type="bibr" rid="bib43">Hoshijima et al., 2019</xref>). Briefly, equal volumes of 100 μM target-specific crRNA and common tracrRNA were mixed together and annealed by heating to 95°C for 5 min, then cooled at 0.1 °C/s to 25°C, followed by rapid cooling to 4°C in a PCR machine to make a 50 μM solution of the crRNA:tracrRNA duplex, referred to as the duplex guide RNA (dgRNA). An equal volume of duplex buffer (IDT) was then added to further dilute the dgRNA to 25 μM. To generate 5 μM dgRNA;Cas9 complexes, we combined: 1 μL of each 25 μM dgRNA, 0.4 μL 61 μM Cas9 stock (Alt-R S.p. Cas9 Nuclease V3, IDT), 1.6 μL H<sub>2</sub>O, and 1 μL phenol red. Prior to injection, the solution was incubated at 37°C for 5 min and then placed at room temperature. We injected 1 nL of the 5 μM dgRNA:Cas9 complex into one-cell stage embryos. Efficiency of dgRNA:Cas9 complexes was assessed using PCR on individual embryos.</p></sec><sec id="s4-4"><title>IHC and cell quantification</title><p>IHC was performed as previously described (<xref ref-type="bibr" rid="bib101">Waxman et al., 2008</xref>). Embryos were fixed in 1% formaldehyde in PBS for 1 hr at room temperature and then washed 1× in PBS, 2× in 0.1% saponin/1× PBS followed by blocking in saponin blocking solution (0.1% saponin, 10% sheep serum, 1× PBS, 2 mg/mL BSA) for 1 hr. Primary antibodies were diluted in saponin blocking solution and applied to embryos overnight at 4°C. Embryos were washed with 0.1% saponin/1× PBS multiple times before being incubated with secondary antibodies diluted in saponin blocking solution for 2 hr at room temperature. Embryos were washed multiple times with 0.1% saponin/1× PBS before imaging. Antibody information is provided in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p><p>IHC for quantification of cardiomyocytes in the AVC required the use of two rabbit primary antibodies (anti-DsRed and anti-Vmhc; <xref ref-type="bibr" rid="bib89">Song et al., 2019</xref>). To accommodate this, after blocking, embryos were first incubated with anti-Amhc (anti-Myh6/S46, mouse IgG1) and anti-DsRed (rabbit) overnight at 4°C. Secondary antibodies (anti-mouse IgG1-Dylight 405 and anti-rabbit-TRITC) were then applied for 2 hr at room temperature. After washing multiple times with 0.1% saponin/1× PBS, embryos were again incubated in saponin blocking solution for 1 hr. Anti-Vmhc (rabbit) was then diluted in saponin blocking solution and applied to embryos overnight at 4°C. Embryos were then washed multiple times with 0.1% saponin/1× PBS. Anti-rabbit-Alexa-488 was diluted in saponin blocking solution and embryos were incubated in secondary antibody for 1 hr at room temperature, followed by multiple washes with 0.1% saponin/1× PBS.</p><p>IHC for activated Caspase 3 was performed as previously described (<xref ref-type="bibr" rid="bib82">Rydeen and Waxman, 2016</xref>). Embryos were fixed in 4% paraformaldehyde overnight at 4°C then dehydrated in a methanol series and left in 100% methanol overnight at –20°C. Embryos were then rehydrated in PBST (PBS +0.1% Tween-20), permeabilized for 20 min using PDT (PBST + 1% DMSO) supplemented with 0.3% Triton-X, and then incubated in blocking solution (1× PBS, 10% sheep serum, 0.1% Tween-20) for 1 hr. Primary antibodies were diluted in blocking solution and applied to embryos overnight at 4°C. Embryos were then washed 3× for 20 min with PDT and blocked again in blocking solution for 30 min. Secondary antibodies were diluted in blocking solution and applied to embryos for 2 hr at room temperature. Following secondary antibody incubation, embryos were washed multiple times with PDT.</p><p>Following IHC, embryos were imaged on a Nikon A1R inverted confocal microscope. Nikon’s Denoise-AI was employed on images taken using an HD resonance scanner. Cardiomyocytes were counted using Photoshop and ImageJ. For quantification of PCs, DsRed2-NLS<sup>+</sup>/Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes were counted as PCs, while the DsRed2-NLS<sup>+</sup>/Amhc<sup>+</sup>/<italic>fgf13a:</italic>EGFP<sup>-</sup> cardiomyocytes were counted as atrium. For AVC counting, DsRed2-NLS<sup>+</sup>/Amhc<sup>+</sup>/Vmhc<sup>-</sup> cardiomyocytes were counted as atrium, DsRed2-NLS<sup>+</sup>/Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes were counted as AVC, and DsRed2-NLS<sup>+</sup>/Amhc<sup>-</sup>/Vmhc<sup>+</sup> cardiomyocytes were counted as ventricle.</p></sec><sec id="s4-5"><title>EdU assay for cell proliferation</title><p>EdU labeling was performed using a Click-iT EdU Alexa Fluor Imaging Kit (Molecular Probes) according to the manufacturer’s instructions. At 48 or 72 hpf, embryos carrying the <italic>Tg(myl7:DsRed2-NLS</italic>) transgene were placed in glass vials (30 embryos per vial) and incubated with 10 mM EdU for 30 min on ice. EdU was then washed out and embryos were returned to Petri dishes and incubated at 28.5°C until 72 or 96 hpf, respectively. Embryos were then fixed in 1% formaldehyde in PBS and IHC was performed using saponin protocol listed above. After IHC, embryos were post-fixed in 2% formaldehyde in PBS for 1 hr at room temperature followed by washes with 1× PBS. The Click-iT reaction was then performed according to the manufacturer’s protocol. Embryos were imaged on a Nikon A1R inverted confocal, as described above. In each chamber, the number of EdU<sup>+</sup>/DsRed2-NLS<sup>+</sup> cardiomyocytes were counted and normalized to the total number of DsRed2-NLS<sup>+</sup> cardiomyocytes to determine the proliferation index.</p></sec><sec id="s4-6"><title>Cardiomyocyte temporal differentiation assay</title><p>Embryos from a cross of adult <italic>nr2f1a<sup>+/-</sup>; Tg(myl7:NLS-KikGR</italic>) zebrafish and <italic>nr2f1a<sup>+/-</sup>; Et(fgf13a:EGFP</italic>) zebrafish were sorted for both the <italic>Et(fgf13a:EGFP</italic>) and <italic>Tg(myl7:NLS-KikGR</italic>) transgenes. As the <italic>Et(fgf13a:EGFP</italic>) is expressed in the PCs and the <italic>Tg(myl7:NLS-KikGR</italic>) is expressed in all cardiomyocytes, we were able to distinguish between these two transgenes before photoconversion of the NLS-KikGR. At 72 hpf, embryos carrying both transgenes were anesthetized in 0.16 mg/mL tricaine and exposed to UV light using a DAPI filter on Zeiss M2BioV12 Stereo microscope for 30 min to photoconvert the NLS-KikGR. At 96 hpf, photoconverted embryos were fixed in 1% formaldehyde in PBS for 1 hr at room temperature, then washed 1× in PBS followed by 2× in 0.1% saponin/1× PBS. Embryos were imaged the same day they were fixed using a Nikon A1R inverted confocal microscope with an HD resonance scanner. Nikon’s Denoise-AI was employed on acquired images.</p></sec><sec id="s4-7"><title>Heart rate analysis</title><p>To analyze heart rate, embryos were anesthetized in 0.16 mg/mL tricaine and mounted in 1% low-melt agarose. Hearts were imaged on a Nikon Ti-2 SpectraX Widefield microscope with an Andor Xyla 4.2 megapixel, 16-bit sCMOS monochromatic camera at 200 frames per second (fps) in a controlled temperature chamber (28.5°C). Analysis performed in Nikon Elements software.</p></sec><sec id="s4-8"><title>Heat-shock experiments</title><p>Embryos resulting from a cross of adult <italic>nr2f1a<sup>+/-</sup>; Et(fgf13a:EGFP); Tg(myl7:DsRed2-NLS</italic>); and <italic>nr2f1a<sup>+/</sup>; Tg(hsp70l:nkx2.5-EGFP</italic>) zebrafish were first sorted for the <italic>Et(fgf13a:EGFP</italic>) transgene, as it is also expressed at low levels in the epidermis and in the olfactory pits (<xref ref-type="bibr" rid="bib76">Poon et al., 2016</xref>). At 20 or 40 hpf, 10 <italic>Et(fgf13a:EGFP)<sup>+</sup></italic> embryos per tube were placed into 0.5 mL PCR tubes with 200 µL embryo water and heat-shocked for 30 min by raising the temperature to 37°C using a thermocycler. Embryos were then returned to Petri dishes and placed in a 28.5°C incubator. 3 to 4 hr after the heat-shock, when the Nkx2.5-EGFP becomes visible, embryos were sorted based on the presence of Nkx2.5-EGFP, which could be distinguished over the fluorescence from the <italic>Et(fgf13a:EGFP</italic>) transgene as the Nkx2.5-EGFP signal is much stronger than that of the <italic>Et(fgf13a:EGFP</italic>). Nkx2.5-EGFP is not visible by 10 hr post heat-shock (<xref ref-type="bibr" rid="bib35">George et al., 2015</xref>) and, as such, does not interfere with quantification of <italic>fgf13a:</italic>EGFP<sup>+</sup> cardiomyocytes. Embryos were then returned to the 28.5°C incubator and allowed to develop until the desired timepoints when they were harvested, processed for IHC, imaged with confocal microscopy, and the cardiomyocytes counted as described above. Embryos without the <italic>Tg(hsp70l:nkx2.5-EGFP</italic>) transgene that were heat-shocked served as controls. All embryos were genotyped for the <italic>nr2f1a</italic> mutant allele as well as the <italic>Tg(hsp70l:nkx2.5-EGFP</italic>) transgene following analysis, to ensure embryos were sorted correctly after the heat-shock.</p></sec><sec id="s4-9"><title>Fluorescence-activated cell sorting</title><p>EGFP<sup>+</sup> cardiomyocytes from WT and <italic>nr2f1a</italic> mutant with the <italic>Tg(amhc:EGFP</italic>), <italic>Tg(myl7:EGFP</italic>), or <italic>Tg(amhc:EGFP); Tg(myl7:DsRed2-NLS</italic>) transgenes were isolated using FACS at 48 or 96 hpf, as indicated. Briefly, embryos were dissociated as described previously (<xref ref-type="bibr" rid="bib40">Holowiecki et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Samsa et al., 2016</xref>; <xref ref-type="bibr" rid="bib90">Stachura and Traver, 2011</xref>) with the following modifications. WT and <italic>nr2f1a</italic> mutant embryos were harvested, rinsed in Hank’s Balanced Salt Solution with Ca<sup>2+</sup> and Mg<sup>2+</sup> and transferred to Eppendorf tubes in 500 µL of FACS media (0.9× PBS, 2% fetal bovine serum). 60 µL of Liberase (Roche) was added and a pipette was used to triturate the embryos. Embryos were then incubated at 32.5°C for 15 min before being triturated again. This process was repeated until the embryos were completely dissociated. Following dissociation, the cell suspensions were centrifuged at 1300 rpm (100 × <italic>g</italic>) for 5 min at 4°C. The supernatant was discarded, and the pellets were resuspended in a total volume of 400 µL. Samples were then filtered through a 40 µm strainer and collected into a FACS tube. FACS was performed by the CCHMC Research Flow Cytometry Core using a 70 µm nozzle and cells were collected into Eppendorf tubes for downstream applications.</p></sec><sec id="s4-10"><title>Real-time qPCR</title><p>2229 WT and 704 <italic>nr2f1a</italic> mutant <italic>Tg(myl7:EGFP)<sup>+</sup></italic> were captured using flow-sorting at 96 hpf. PolyA RNA was collected from the cardiomyocytes using the Single Cell RNA Purification Kit (Norgen Biotek) and then amplified using the SeqPlex RNA Amplification Kit (Sigma-Aldrich), which generates double-stranded cDNA. RT-qPCR was performed using SYBR Green Mix in a Bio-Rad CFX-96 PCR machine. Expression levels were standardized to β-actin and analyzed using the 2<sup>−ΔΔCT</sup> Livak method. Primer sequences are provided in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p></sec><sec id="s4-11"><title>RNA-seq and ATAC-seq analysis</title><p>For RNA-seq, 7797 WT and 4118 <italic>nr2f1a</italic> mutant <italic>Tg(amhc:EGFP)<sup>+</sup></italic> were captured from flow-sorting of ~200 WT and <italic>nr2f1a</italic> mutant embryos at 48 hpf. RNA was collected using the Single Cell RNA Purification Kit (Norgen Biotek). PolyA RNA was then amplified using the MessageAmpII aRNA Amplification Kit (Thermo Fisher) and submitted to the CCHMC Sequencing core for quality control and library generation. Single-end sequencing was performed. RNA-seq data were submitted to the CCHMC Bioinformatics (BMI) core for analysis. To assess the need for trimming of adapter sequences and bad quality segments, the RNA-seq reads in FASTQ format were first subjected to quality control using FastQC v0.11.5, Trim Galore! V0.4.2, and Cutadapt v1.9.1 (<xref ref-type="bibr" rid="bib2">Andrews, 2010</xref>; <xref ref-type="bibr" rid="bib51">Krueger, 2012</xref>; <xref ref-type="bibr" rid="bib65">Martin, 2011</xref>). The trimmed reads were aligned to the reference zebrafish genome version GRCz10/danRer10 with the program STAR v2.5.2 (<xref ref-type="bibr" rid="bib28">Dobin et al., 2013</xref>). Aligned reads were stripped of duplicate reads using Picard v1.89 (<xref ref-type="bibr" rid="bib14">Broad Institute, 2018</xref>). Gene-level expression was assessed by counting features for each gene, as defined in the NCBI’s RefSeq database (<xref ref-type="bibr" rid="bib55">Li et al., 2009</xref>). Read counting was done with the program feature Counts v1.5.3 from the Rsubread package (<xref ref-type="bibr" rid="bib58">Liao et al., 2019</xref>). Raw counts were normalized as transcripts per million. Differential gene expressions between conditions were assessed with the R v3.4.4 package DESeq2 v1.18.1 (<xref ref-type="bibr" rid="bib61">Love et al., 2014</xref>).</p><p>For ATAC-seq, 8230 WT and 4338 <italic>nr2f1a</italic> mutant <italic>Tg(amhc:EGFP)<sup>+</sup>; Tg(myl7:DsRed2-NLS)<sup>+</sup></italic> were captured from flow-sorting of ~200 WT and <italic>nr2f1a</italic> mutant embryos at 48 hpf. ATAC-seq libraries were generated from the cells using the Nextera Kit (Illumina), as previously reported (<xref ref-type="bibr" rid="bib18">Buenrostro et al., 2015</xref>). Libraries were submitted to the CCHMC Sequencing core for paired-end sequencing. ATAC-seq data were then submitted to the CCHMC BMI Core for analysis. Reads in FASTQ format were subjected to quality control, as above. The trimmed reads were aligned to the zebrafish genome (GRCz10/danRer10) using STAR v2.5.2 with splice awareness turned off. Aligned reads were stripped of duplicate reads using Picard v1.89. Peaks were called using MACS v2.1.2 using the broad peaks mode (<xref ref-type="bibr" rid="bib113">Zhang et al., 2008</xref>). Peaks with q-value &lt;0.01 were selected for further analysis. Common peaks among all samples were obtained by merging called peaks at 50% overlap using BEDtools v2.27.0 (<xref ref-type="bibr" rid="bib80">Quinlan and Hall, 2010</xref>). The common peaks, originally in BED format, were converted to a Gene Transfer Format to enable fast counting of reads under the peaks with the program feature Counts v1.5.3 (Rsubread package) (<xref ref-type="bibr" rid="bib58">Liao et al., 2019</xref>). Differential open chromatin relative to control samples was assessed with the R package DESeq2 v1.18.1 (<xref ref-type="bibr" rid="bib61">Love et al., 2014</xref>). Each differentially open chromatin region was annotated with closest differentially expressed gene from the RNA-seq. Differentially open chromatin regions are selected for motif enrichment analysis using HOMER v4.10 (<xref ref-type="bibr" rid="bib37">Heinz et al., 2010</xref>) and known zebrafish motifs from CIS-BP v1.92 (<xref ref-type="bibr" rid="bib103">Weirauch et al., 2014</xref>) are used to detect motif occurrences.</p><p>RNA-seq and ATAC-seq data used are deposited in GEO - accession number GSE194054.</p></sec><sec id="s4-12"><title>Electrophysiological analysis of hearts</title><p>Optical mapping of action potential duration and conduction velocities were performed similar to what was previously reported (<xref ref-type="bibr" rid="bib24">Colombo et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Mosimann et al., 2015</xref>; <xref ref-type="bibr" rid="bib74">Panáková et al., 2010</xref>). Briefly, hearts from zebrafish embryos were isolated at 48, 72, and 96 hpf and stained with the transmembrane potential-sensitive dye FluoVolt (Invitrogen) for 20 min. To measure action potential duration, fluorescence intensities were recorded with a high-speed CCD camera (Redshirt Imaging) with 14-bit resolution at 2000 fps. Action potentials were temporally (800 Hz low-pass cutoff) and spatially (3×3 pixel average) filtered to enhance signal-to-noise ratios. Action potential duration at 20% repolarization (APD20) was defined as the absolute time difference between the decay phase and the upstroke phase of the local action potential at 20% repolarization and was measured at the midpoint of the atria. Conduction velocity vectors across the hearts were derived using an established algorithm (<xref ref-type="bibr" rid="bib6">Bayly et al., 1998</xref>) with custom scripts in MATLAB (Version R2018B, Mathworks) and estimated from the local action potentials (<xref ref-type="bibr" rid="bib74">Panáková et al., 2010</xref>). All electrophysiological measurements were averaged across the relevant anatomical segments for each heart. Embryos were genotyped following analysis.</p></sec><sec id="s4-13"><title>Statistical analysis</title><p>Comparisons between groups were analyzed using Student’s t-test and one- and two-way ANOVAs with multiple comparisons as appropriate. Fisher’s exact test was used to determine if two proportions were statistically distinct. Statistical analysis used for the different analyses is indicated in the figure legends. Statistical analysis was performed using GraphPad Prism. A p-value of &lt;0.05 was considered statistically significant for all analysis. Error bars indicate s.e.m.</p></sec><sec id="s4-14"><title>Materials availability</title><p>Materials created that were used in this study are available from the authors without restrictions.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All zebrafish husbandry and experiments were performed in accordance with protocols approved by the Cincinnati Children's Hospital Medical Center Institutional Animal Care and Use Committee (IACUC). Protocol # 2020-0091.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>(xlsx) Sheets with integrated and primary RNA-seq and assay for transpose-accessible chromatin sequencing (ATAC-seq) data with differential gene expression, changes in called peaks, and putative Nr2f binding sites.</title></caption><media xlink:href="elife-77408-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Antibody information.</title></caption><media xlink:href="elife-77408-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Primer information.</title></caption><media xlink:href="elife-77408-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-77408-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing data have been deposited in GEO - accession number GSE194054.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>KE</given-names></name><name><surname>Ravisankar</surname><given-names>P</given-names></name><name><surname>Beerens</surname><given-names>MM</given-names></name><name><surname>MacRae</surname><given-names>CA</given-names></name><name><surname>Waxman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Nr2f1a maintains atrial nkx2.5 expression to repress pacemaker identity within venous atrial cardiomyocytes of zebrafish</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE194054">GSE194054</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank members of the Waxman lab for fruitful discussions and the CCHMC veterinary staff for care of the zebrafish. This work was supported by funding from the National Institutes of Health: [R01 HL137766, R01 HL141186, and R01 HL154522 to JSW], [F31 HL152600 to KEM], and [R24 OD017870 and the Leducq Foundation to CAM].</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Turki</surname><given-names>S</given-names></name><name><surname>Manickaraj</surname><given-names>AK</given-names></name><name><surname>Mercer</surname><given-names>CL</given-names></name><name><surname>Gerety</surname><given-names>SS</given-names></name><name><surname>Hitz</surname><given-names>MP</given-names></name><name><surname>Lindsay</surname><given-names>S</given-names></name><name><surname>D’Alessandro</surname><given-names>LCA</given-names></name><name><surname>Swaminathan</surname><given-names>GJ</given-names></name><name><surname>Bentham</surname><given-names>J</given-names></name><name><surname>Arndt</surname><given-names>AK</given-names></name><name><surname>Louw</surname><given-names>J</given-names></name><name><surname>Low</surname><given-names>J</given-names></name><name><surname>Breckpot</surname><given-names>J</given-names></name><name><surname>Gewillig</surname><given-names>M</given-names></name><name><surname>Thienpont</surname><given-names>B</given-names></name><name><surname>Abdul-Khaliq</surname><given-names>H</given-names></name><name><surname>Harnack</surname><given-names>C</given-names></name><name><surname>Hoff</surname><given-names>K</given-names></name><name><surname>Kramer</surname><given-names>HH</given-names></name><name><surname>Schubert</surname><given-names>S</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Toka</surname><given-names>O</given-names></name><name><surname>Cosgrove</surname><given-names>C</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Lucassen</surname><given-names>AM</given-names></name><name><surname>O’Kelly</surname><given-names>IM</given-names></name><name><surname>Salmon</surname><given-names>AP</given-names></name><name><surname>Bu’lock</surname><given-names>FA</given-names></name><name><surname>Granados-Riveron</surname><given-names>J</given-names></name><name><surname>Setchfield</surname><given-names>K</given-names></name><name><surname>Thornborough</surname><given-names>C</given-names></name><name><surname>Brook</surname><given-names>JD</given-names></name><name><surname>Mulder</surname><given-names>B</given-names></name><name><surname>Klaassen</surname><given-names>S</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Devriendt</surname><given-names>K</given-names></name><name><surname>Fitzpatrick</surname><given-names>DF</given-names></name><name><surname>Wilson</surname><given-names>DI</given-names></name><name><surname>Mital</surname><given-names>S</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><collab>UK10K Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Rare variants in NR2F2 cause congenital heart defects in humans</article-title><source>American Journal of Human Genetics</source><volume>94</volume><fpage>574</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2014.03.007</pub-id><pub-id pub-id-type="pmid">24702954</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FastQC: A quality control tool for high throughput sequence data</article-title><ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc">http://www.bioinformatics.babraham.ac.uk/projects/fastqc</ext-link><date-in-citation iso-8601-date="2019-03-19">March 19, 2019</date-in-citation></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrenberg</surname><given-names>AB</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Baier</surname><given-names>H</given-names></name><name><surname>Huisken</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Optogenetic control of cardiac function</article-title><source>Science</source><volume>330</volume><fpage>971</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1126/science.1195929</pub-id><pub-id pub-id-type="pmid">21071670</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>ZZ</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Cepko</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Regulation of chamber-specific gene expression in the developing heart by irx4</article-title><source>Science</source><volume>283</volume><fpage>1161</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1126/science.283.5405.1161</pub-id><pub-id pub-id-type="pmid">10024241</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>AS</given-names></name><name><surname>Merk</surname><given-names>S</given-names></name><name><surname>Arnoldi</surname><given-names>E</given-names></name><name><surname>Zwermann</surname><given-names>L</given-names></name><name><surname>Kloos</surname><given-names>P</given-names></name><name><surname>Gebauer</surname><given-names>M</given-names></name><name><surname>Steinmeyer</surname><given-names>K</given-names></name><name><surname>Bleich</surname><given-names>M</given-names></name><name><surname>Kääb</surname><given-names>S</given-names></name><name><surname>Pfeufer</surname><given-names>A</given-names></name><name><surname>Uberfuhr</surname><given-names>P</given-names></name><name><surname>Dugas</surname><given-names>M</given-names></name><name><surname>Steinbeck</surname><given-names>G</given-names></name><name><surname>Nabauer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Functional profiling of human atrial and ventricular gene expression</article-title><source>Pflugers Archiv</source><volume>450</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1007/s00424-005-1404-8</pub-id><pub-id pub-id-type="pmid">15877233</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayly</surname><given-names>PV</given-names></name><name><surname>KenKnight</surname><given-names>BH</given-names></name><name><surname>Rogers</surname><given-names>JM</given-names></name><name><surname>Hillsley</surname><given-names>RE</given-names></name><name><surname>Ideker</surname><given-names>RE</given-names></name><name><surname>Smith</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Estimation of conduction velocity vector fields from epicardial mapping data</article-title><source>IEEE Transactions on Bio-Medical Engineering</source><volume>45</volume><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1109/10.668746</pub-id><pub-id pub-id-type="pmid">9581054</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Virani</surname><given-names>SS</given-names></name><name><surname>Callaway</surname><given-names>CW</given-names></name><name><surname>Chamberlain</surname><given-names>AM</given-names></name><name><surname>Chang</surname><given-names>AR</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Chiuve</surname><given-names>SE</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>Delling</surname><given-names>FN</given-names></name><name><surname>Deo</surname><given-names>R</given-names></name><name><surname>de Ferranti</surname><given-names>SD</given-names></name><name><surname>Ferguson</surname><given-names>JF</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Gillespie</surname><given-names>C</given-names></name><name><surname>Isasi</surname><given-names>CR</given-names></name><name><surname>Jiménez</surname><given-names>MC</given-names></name><name><surname>Jordan</surname><given-names>LC</given-names></name><name><surname>Judd</surname><given-names>SE</given-names></name><name><surname>Lackland</surname><given-names>D</given-names></name><name><surname>Lichtman</surname><given-names>JH</given-names></name><name><surname>Lisabeth</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Longenecker</surname><given-names>CT</given-names></name><name><surname>Lutsey</surname><given-names>PL</given-names></name><name><surname>Mackey</surname><given-names>JS</given-names></name><name><surname>Matchar</surname><given-names>DB</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Mussolino</surname><given-names>ME</given-names></name><name><surname>Nasir</surname><given-names>K</given-names></name><name><surname>O’Flaherty</surname><given-names>M</given-names></name><name><surname>Palaniappan</surname><given-names>LP</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>DK</given-names></name><name><surname>Reeves</surname><given-names>MJ</given-names></name><name><surname>Ritchey</surname><given-names>MD</given-names></name><name><surname>Rodriguez</surname><given-names>CJ</given-names></name><name><surname>Roth</surname><given-names>GA</given-names></name><name><surname>Rosamond</surname><given-names>WD</given-names></name><name><surname>Sampson</surname><given-names>UKA</given-names></name><name><surname>Satou</surname><given-names>GM</given-names></name><name><surname>Shah</surname><given-names>SH</given-names></name><name><surname>Spartano</surname><given-names>NL</given-names></name><name><surname>Tirschwell</surname><given-names>DL</given-names></name><name><surname>Tsao</surname><given-names>CW</given-names></name><name><surname>Voeks</surname><given-names>JH</given-names></name><name><surname>Willey</surname><given-names>JZ</given-names></name><name><surname>Wilkins</surname><given-names>JT</given-names></name><name><surname>Wu</surname><given-names>JH</given-names></name><name><surname>Alger</surname><given-names>HM</given-names></name><name><surname>Wong</surname><given-names>SS</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name><collab>American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Heart disease and stroke statistics-2018 update: a report from the American heart association</article-title><source>Circulation</source><volume>137</volume><fpage>e67</fpage><lpage>e492</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000558</pub-id><pub-id pub-id-type="pmid">29386200</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>DW</given-names></name><name><surname>Silberbach</surname><given-names>GM</given-names></name><name><surname>Kavanaugh-McHugh</surname><given-names>A</given-names></name><name><surname>Cottrill</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Riggs</surname><given-names>S</given-names></name><name><surname>Smalls</surname><given-names>O</given-names></name><name><surname>Johnson</surname><given-names>MC</given-names></name><name><surname>Watson</surname><given-names>MS</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Plowden</surname><given-names>J</given-names></name><name><surname>Kugler</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mutations in the cardiac transcription factor Nkx2.5 affect diverse cardiac developmental pathways</article-title><source>The Journal of Clinical Investigation</source><volume>104</volume><fpage>1567</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1172/JCI8154</pub-id><pub-id pub-id-type="pmid">10587520</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaum</surname><given-names>RY</given-names></name><name><surname>Clowney</surname><given-names>EJ</given-names></name><name><surname>Agamy</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yamanaka</surname><given-names>T</given-names></name><name><surname>Pappalardo</surname><given-names>Z</given-names></name><name><surname>Clarke</surname><given-names>SL</given-names></name><name><surname>Wenger</surname><given-names>AM</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Gurrieri</surname><given-names>F</given-names></name><name><surname>Everman</surname><given-names>DB</given-names></name><name><surname>Schwartz</surname><given-names>CE</given-names></name><name><surname>Birk</surname><given-names>OS</given-names></name><name><surname>Bejerano</surname><given-names>G</given-names></name><name><surname>Lomvardas</surname><given-names>S</given-names></name><name><surname>Ahituv</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Coding exons function as tissue-specific enhancers of nearby genes</article-title><source>Genome Research</source><volume>22</volume><fpage>1059</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1101/gr.133546.111</pub-id><pub-id pub-id-type="pmid">22442009</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaschke</surname><given-names>RJ</given-names></name><name><surname>Hahurij</surname><given-names>ND</given-names></name><name><surname>Kuijper</surname><given-names>S</given-names></name><name><surname>Just</surname><given-names>S</given-names></name><name><surname>Wisse</surname><given-names>LJ</given-names></name><name><surname>Deissler</surname><given-names>K</given-names></name><name><surname>Maxelon</surname><given-names>T</given-names></name><name><surname>Anastassiadis</surname><given-names>K</given-names></name><name><surname>Spitzer</surname><given-names>J</given-names></name><name><surname>Hardt</surname><given-names>SE</given-names></name><name><surname>Schöler</surname><given-names>H</given-names></name><name><surname>Feitsma</surname><given-names>H</given-names></name><name><surname>Rottbauer</surname><given-names>W</given-names></name><name><surname>Blum</surname><given-names>M</given-names></name><name><surname>Meijlink</surname><given-names>F</given-names></name><name><surname>Rappold</surname><given-names>G</given-names></name><name><surname>Gittenberger-de Groot</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Targeted mutation reveals essential functions of the homeodomain transcription factor Shox2 in sinoatrial and pacemaking development</article-title><source>Circulation</source><volume>115</volume><fpage>1830</fpage><lpage>1838</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.637819</pub-id><pub-id pub-id-type="pmid">17372176</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blow</surname><given-names>MJ</given-names></name><name><surname>McCulley</surname><given-names>DJ</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Akiyama</surname><given-names>JA</given-names></name><name><surname>Holt</surname><given-names>A</given-names></name><name><surname>Plajzer-Frick</surname><given-names>I</given-names></name><name><surname>Shoukry</surname><given-names>M</given-names></name><name><surname>Wright</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Afzal</surname><given-names>V</given-names></name><name><surname>Bristow</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Rubin</surname><given-names>EM</given-names></name><name><surname>Visel</surname><given-names>A</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Chip-Seq identification of weakly conserved heart enhancers</article-title><source>Nature Genetics</source><volume>42</volume><fpage>806</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1038/ng.650</pub-id><pub-id pub-id-type="pmid">20729851</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bootman</surname><given-names>MD</given-names></name><name><surname>Higazi</surname><given-names>DR</given-names></name><name><surname>Coombes</surname><given-names>S</given-names></name><name><surname>Roderick</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Calcium signalling during excitation-contraction coupling in mammalian atrial myocytes</article-title><source>Journal of Cell Science</source><volume>119</volume><fpage>3915</fpage><lpage>3925</lpage><pub-id pub-id-type="doi">10.1242/jcs.03223</pub-id><pub-id pub-id-type="pmid">16988026</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandenburg</surname><given-names>S</given-names></name><name><surname>Kohl</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>GSB</given-names></name><name><surname>Gusev</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>E</given-names></name><name><surname>Rog-Zielinska</surname><given-names>EA</given-names></name><name><surname>Hebisch</surname><given-names>E</given-names></name><name><surname>Dura</surname><given-names>M</given-names></name><name><surname>Didié</surname><given-names>M</given-names></name><name><surname>Gotthardt</surname><given-names>M</given-names></name><name><surname>Nikolaev</surname><given-names>VO</given-names></name><name><surname>Hasenfuss</surname><given-names>G</given-names></name><name><surname>Kohl</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>CW</given-names></name><name><surname>Lederer</surname><given-names>WJ</given-names></name><name><surname>Lehnart</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Axial tubule junctions control rapid calcium signaling in atria</article-title><source>The Journal of Clinical Investigation</source><volume>126</volume><fpage>3999</fpage><lpage>4015</lpage><pub-id pub-id-type="doi">10.1172/JCI88241</pub-id><pub-id pub-id-type="pmid">27643434</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Broad Institute</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Picard</article-title><ext-link ext-link-type="uri" xlink:href="http://broadinstitute.github.io/picard/">http://broadinstitute.github.io/picard/</ext-link><date-in-citation iso-8601-date="2019-03-19">March 19, 2019</date-in-citation></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Logan</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>N</given-names></name><name><surname>Levi</surname><given-names>T</given-names></name><name><surname>Tabin</surname><given-names>CJ</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Chamber-Specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome</article-title><source>Developmental Biology</source><volume>211</volume><fpage>100</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1006/dbio.1999.9298</pub-id><pub-id pub-id-type="pmid">10373308</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Bao</surname><given-names>ZZ</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Schott</surname><given-names>JJ</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name><name><surname>Cepko</surname><given-names>CL</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cardiac expression of the ventricle-specific homeobox gene irx4 is modulated by Nkx2-5 and dHAND</article-title><source>Developmental Biology</source><volume>217</volume><fpage>266</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1006/dbio.1999.9548</pub-id><pub-id pub-id-type="pmid">10625552</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Bao</surname><given-names>ZZ</given-names></name><name><surname>Fatkin</surname><given-names>D</given-names></name><name><surname>Xavier-Neto</surname><given-names>J</given-names></name><name><surname>Georgakopoulos</surname><given-names>D</given-names></name><name><surname>Maguire</surname><given-names>CT</given-names></name><name><surname>Berul</surname><given-names>CI</given-names></name><name><surname>Kass</surname><given-names>DA</given-names></name><name><surname>Kuroski-de Bold</surname><given-names>ML</given-names></name><name><surname>de Bold</surname><given-names>AJ</given-names></name><name><surname>Conner</surname><given-names>DA</given-names></name><name><surname>Rosenthal</surname><given-names>N</given-names></name><name><surname>Cepko</surname><given-names>CL</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cardiomyopathy in irx4-deficient mice is preceded by abnormal ventricular gene expression</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>1730</fpage><lpage>1736</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.5.1730-1736.2001</pub-id><pub-id pub-id-type="pmid">11238910</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buenrostro</surname><given-names>JD</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Atac-Seq: A method for assaying chromatin accessibility genome-wide</article-title><source>Current Protocols in Molecular Biology</source><volume>109</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1002/0471142727.mb2129s109</pub-id><pub-id pub-id-type="pmid">25559105</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkhard</surname><given-names>S</given-names></name><name><surname>van Eif</surname><given-names>V</given-names></name><name><surname>Garric</surname><given-names>L</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>On the evolution of the cardiac pacemaker</article-title><source>Journal of Cardiovascular Development and Disease</source><volume>4</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.3390/jcdd4020004</pub-id><pub-id pub-id-type="pmid">29367536</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkhard</surname><given-names>SB</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Spatially resolved RNA-sequencing of the embryonic heart identifies a role for Wnt/β-catenin signaling in autonomic control of heart rate</article-title><source>eLife</source><volume>7</volume><elocation-id>e31515</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.31515</pub-id><pub-id pub-id-type="pmid">29400650</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Two novel mutations of the IRX4 gene in patients with congenital heart disease</article-title><source>Human Genetics</source><volume>130</volume><fpage>657</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1007/s00439-011-0996-7</pub-id><pub-id pub-id-type="pmid">21544582</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christoffels</surname><given-names>VM</given-names></name><name><surname>Smits</surname><given-names>GJ</given-names></name><name><surname>Kispert</surname><given-names>A</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Development of the pacemaker tissues of the heart</article-title><source>Circulation Research</source><volume>106</volume><fpage>240</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.205419</pub-id><pub-id pub-id-type="pmid">20133910</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Churko</surname><given-names>JM</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><name><surname>Treutlein</surname><given-names>B</given-names></name><name><surname>Venkatasubramanian</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Wessells</surname><given-names>QN</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Mantalas</surname><given-names>G</given-names></name><name><surname>Neff</surname><given-names>N</given-names></name><name><surname>Jabart</surname><given-names>E</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Nolan</surname><given-names>GP</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Defining human cardiac transcription factor hierarchies using integrated single-cell heterogeneity analysis</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4906</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07333-4</pub-id><pub-id pub-id-type="pmid">30464173</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>S</given-names></name><name><surname>de Sena-Tomás</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>V</given-names></name><name><surname>Werdich</surname><given-names>AA</given-names></name><name><surname>Kapur</surname><given-names>S</given-names></name><name><surname>MacRae</surname><given-names>CA</given-names></name><name><surname>Targoff</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nkx genes establish second heart field cardiomyocyte progenitors at the arterial pole and pattern the venous pole through ISL1 repression</article-title><source>Development</source><volume>145</volume><elocation-id>dev161497</elocation-id><pub-id pub-id-type="doi">10.1242/dev.161497</pub-id><pub-id pub-id-type="pmid">29361575</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Pater</surname><given-names>E</given-names></name><name><surname>Clijsters</surname><given-names>L</given-names></name><name><surname>Marques</surname><given-names>SR</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Garavito-Aguilar</surname><given-names>ZV</given-names></name><name><surname>Yelon</surname><given-names>D</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Distinct phases of cardiomyocyte differentiation regulate growth of the zebrafish heart</article-title><source>Development</source><volume>136</volume><fpage>1633</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1242/dev.030924</pub-id><pub-id pub-id-type="pmid">19395641</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Pater</surname><given-names>E</given-names></name><name><surname>Ciampricotti</surname><given-names>M</given-names></name><name><surname>Priller</surname><given-names>F</given-names></name><name><surname>Veerkamp</surname><given-names>J</given-names></name><name><surname>Strate</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Lagendijk</surname><given-names>AK</given-names></name><name><surname>Schilling</surname><given-names>TF</given-names></name><name><surname>Herzog</surname><given-names>W</given-names></name><name><surname>Abdelilah-Seyfried</surname><given-names>S</given-names></name><name><surname>Hammerschmidt</surname><given-names>M</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Bmp signaling exerts opposite effects on cardiac differentiation</article-title><source>Circulation Research</source><volume>110</volume><fpage>578</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.261172</pub-id><pub-id pub-id-type="pmid">22247485</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devalla</surname><given-names>HD</given-names></name><name><surname>Schwach</surname><given-names>V</given-names></name><name><surname>Ford</surname><given-names>JW</given-names></name><name><surname>Milnes</surname><given-names>JT</given-names></name><name><surname>El-Haou</surname><given-names>S</given-names></name><name><surname>Jackson</surname><given-names>C</given-names></name><name><surname>Gkatzis</surname><given-names>K</given-names></name><name><surname>Elliott</surname><given-names>DA</given-names></name><name><surname>Chuva de Sousa Lopes</surname><given-names>SM</given-names></name><name><surname>Mummery</surname><given-names>CL</given-names></name><name><surname>Verkerk</surname><given-names>AO</given-names></name><name><surname>Passier</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Atrial-Like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology</article-title><source>EMBO Molecular Medicine</source><volume>7</volume><fpage>394</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.15252/emmm.201404757</pub-id><pub-id pub-id-type="pmid">25700171</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Star: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dohn</surname><given-names>TE</given-names></name><name><surname>Ravisankar</surname><given-names>P</given-names></name><name><surname>Tirera</surname><given-names>FT</given-names></name><name><surname>Martin</surname><given-names>KE</given-names></name><name><surname>Gafranek</surname><given-names>JT</given-names></name><name><surname>Duong</surname><given-names>TB</given-names></name><name><surname>VanDyke</surname><given-names>TL</given-names></name><name><surname>Touvron</surname><given-names>M</given-names></name><name><surname>Barske</surname><given-names>LA</given-names></name><name><surname>Crump</surname><given-names>JG</given-names></name><name><surname>Waxman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Nr2f-dependent allocation of ventricular cardiomyocyte and pharyngeal muscle progenitors</article-title><source>PLOS Genetics</source><volume>15</volume><elocation-id>e1007962</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007962</pub-id><pub-id pub-id-type="pmid">30721228</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duong</surname><given-names>TB</given-names></name><name><surname>Ravisankar</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>YC</given-names></name><name><surname>Gafranek</surname><given-names>JT</given-names></name><name><surname>Rydeen</surname><given-names>AB</given-names></name><name><surname>Dohn</surname><given-names>TE</given-names></name><name><surname>Barske</surname><given-names>LA</given-names></name><name><surname>Crump</surname><given-names>JG</given-names></name><name><surname>Waxman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nr2f1a balances atrial chamber and atrioventricular canal size via BMP signaling-independent and -dependent mechanisms</article-title><source>Developmental Biology</source><volume>434</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2017.11.010</pub-id><pub-id pub-id-type="pmid">29157563</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellesøe</surname><given-names>SG</given-names></name><name><surname>Johansen</surname><given-names>MM</given-names></name><name><surname>Bjerre</surname><given-names>JV</given-names></name><name><surname>Hjortdal</surname><given-names>VE</given-names></name><name><surname>Brunak</surname><given-names>S</given-names></name><name><surname>Larsen</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Familial atrial septal defect and sudden cardiac death: identification of a novel Nkx2-5 mutation and a review of the literature</article-title><source>Congenital Heart Disease</source><volume>11</volume><fpage>283</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1111/chd.12317</pub-id><pub-id pub-id-type="pmid">26679770</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>DA</given-names></name><name><surname>Kirk</surname><given-names>EP</given-names></name><name><surname>Yeoh</surname><given-names>T</given-names></name><name><surname>Chandar</surname><given-names>S</given-names></name><name><surname>McKenzie</surname><given-names>F</given-names></name><name><surname>Taylor</surname><given-names>P</given-names></name><name><surname>Grossfeld</surname><given-names>P</given-names></name><name><surname>Fatkin</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>O</given-names></name><name><surname>Hayes</surname><given-names>P</given-names></name><name><surname>Feneley</surname><given-names>M</given-names></name><name><surname>Harvey</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cardiac homeobox gene Nkx2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome</article-title><source>Journal of the American College of Cardiology</source><volume>41</volume><fpage>2072</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(03)00420-0</pub-id><pub-id pub-id-type="pmid">12798584</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espinoza-Lewis</surname><given-names>RA</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Shox2 is essential for the differentiation of cardiac pacemaker cells by repressing Nkx2-5</article-title><source>Developmental Biology</source><volume>327</volume><fpage>376</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2008.12.028</pub-id><pub-id pub-id-type="pmid">19166829</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espinoza-Lewis</surname><given-names>RA</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Jiao</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>YP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ectopic expression of Nkx2.5 suppresses the formation of the sinoatrial node in mice</article-title><source>Developmental Biology</source><volume>356</volume><fpage>359</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2011.05.663</pub-id><pub-id pub-id-type="pmid">21640717</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>V</given-names></name><name><surname>Colombo</surname><given-names>S</given-names></name><name><surname>Targoff</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An early requirement for Nkx2.5 ensures the first and second heart field ventricular identity and cardiac function into adulthood</article-title><source>Developmental Biology</source><volume>400</volume><fpage>10</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2014.12.019</pub-id><pub-id pub-id-type="pmid">25536398</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>DF</given-names></name><name><surname>Li</surname><given-names>RG</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>HY</given-names></name><name><surname>Hou</surname><given-names>XM</given-names></name><name><surname>Qu</surname><given-names>XK</given-names></name><name><surname>Xu</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>JQ</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name><name><surname>Qiu</surname><given-names>XB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tbx5 loss-of-function mutation contributes to atrial fibrillation and atypical Holt-Oram syndrome</article-title><source>Molecular Medicine Reports</source><volume>13</volume><fpage>4349</fpage><lpage>4356</lpage><pub-id pub-id-type="doi">10.3892/mmr.2016.5043</pub-id><pub-id pub-id-type="pmid">27035640</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname><given-names>S</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Spann</surname><given-names>N</given-names></name><name><surname>Bertolino</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Laslo</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>JX</given-names></name><name><surname>Murre</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title><source>Molecular Cell</source><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id><pub-id pub-id-type="pmid">20513432</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>JIE</given-names></name><name><surname>Kaplan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The incidence of congenital heart disease</article-title><source>Journal of the American College of Cardiology</source><volume>39</volume><fpage>1890</fpage><lpage>1900</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(02)01886-7</pub-id><pub-id pub-id-type="pmid">12084585</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>IM</given-names></name><name><surname>Glaser</surname><given-names>A</given-names></name><name><surname>Bacon</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Gretz</surname><given-names>N</given-names></name><name><surname>Steinbeisser</surname><given-names>H</given-names></name><name><surname>Rottbauer</surname><given-names>W</given-names></name><name><surname>Just</surname><given-names>S</given-names></name><name><surname>Rappold</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Islet1 is a direct transcriptional target of the homeodomain transcription factor Shox2 and rescues the shox2-mediated bradycardia</article-title><source>Basic Research in Cardiology</source><volume>108</volume><elocation-id>339</elocation-id><pub-id pub-id-type="doi">10.1007/s00395-013-0339-z</pub-id><pub-id pub-id-type="pmid">23455426</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holowiecki</surname><given-names>A</given-names></name><name><surname>Linstrum</surname><given-names>K</given-names></name><name><surname>Ravisankar</surname><given-names>P</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Waxman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pbx4 limits heart size and fosters arch artery formation by partitioning second heart field progenitors and restricting proliferation</article-title><source>Development</source><volume>147</volume><elocation-id>dev185652</elocation-id><pub-id pub-id-type="doi">10.1242/dev.185652</pub-id><pub-id pub-id-type="pmid">32094112</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honjo</surname><given-names>H</given-names></name><name><surname>Boyett</surname><given-names>MR</given-names></name><name><surname>Kodama</surname><given-names>I</given-names></name><name><surname>Toyama</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Correlation between electrical activity and the size of rabbit sino-atrial node cells</article-title><source>The Journal of Physiology</source><volume>496 ( Pt 3)</volume><fpage>795</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1996.sp021728</pub-id><pub-id pub-id-type="pmid">8930845</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>Engel</surname><given-names>A</given-names></name><name><surname>Brons</surname><given-names>JF</given-names></name><name><surname>Verkerk</surname><given-names>AO</given-names></name><name><surname>de Lange</surname><given-names>FJ</given-names></name><name><surname>Wong</surname><given-names>LYE</given-names></name><name><surname>Bakker</surname><given-names>ML</given-names></name><name><surname>Clout</surname><given-names>DE</given-names></name><name><surname>Wakker</surname><given-names>V</given-names></name><name><surname>Barnett</surname><given-names>P</given-names></name><name><surname>Ravesloot</surname><given-names>JH</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Verheijck</surname><given-names>EE</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>1098</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1101/gad.416007</pub-id><pub-id pub-id-type="pmid">17473172</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshijima</surname><given-names>K</given-names></name><name><surname>Jurynec</surname><given-names>MJ</given-names></name><name><surname>Klatt Shaw</surname><given-names>D</given-names></name><name><surname>Jacobi</surname><given-names>AM</given-names></name><name><surname>Behlke</surname><given-names>MA</given-names></name><name><surname>Grunwald</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Highly efficient methods for generating deletion mutations and F0 embryos that lack gene function in zebrafish</article-title><source>Developmental Cell</source><volume>51</volume><elocation-id>645-657.e4</elocation-id><pub-id pub-id-type="doi">10.1016/j.devcel.2019.10.004</pub-id><pub-id pub-id-type="pmid">31708433</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>CJ</given-names></name><name><surname>Tu</surname><given-names>CT</given-names></name><name><surname>Hsiao</surname><given-names>CD</given-names></name><name><surname>Hsieh</surname><given-names>FJ</given-names></name><name><surname>Tsai</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Germ-Line transmission of a myocardium-specific GFP transgene reveals critical regulatory elements in the cardiac myosin light chain 2 promoter of zebrafish</article-title><source>Developmental Dynamics</source><volume>228</volume><fpage>30</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/dvdy.10356</pub-id><pub-id pub-id-type="pmid">12950077</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ionta</surname><given-names>V</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Rafie</surname><given-names>R</given-names></name><name><surname>Giacomello</surname><given-names>A</given-names></name><name><surname>Marbán</surname><given-names>E</given-names></name><name><surname>Cho</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Shox2 overexpression favors differentiation of embryonic stem cells into cardiac pacemaker cells, improving biological pacing ability</article-title><source>Stem Cell Reports</source><volume>4</volume><fpage>129</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2014.11.004</pub-id><pub-id pub-id-type="pmid">25533636</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jhaveri</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>PF</given-names></name><name><surname>Saarel</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expanding the electrical phenotype of Nkx2-5 mutations: Ventricular tachycardia, atrial fibrillation, and complete heart block within one family</article-title><source>HeartRhythm Case Reports</source><volume>4</volume><fpage>530</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1016/j.hrcr.2018.08.001</pub-id><pub-id pub-id-type="pmid">30479953</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joyner</surname><given-names>RW</given-names></name><name><surname>van Capelle</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Propagation through electrically coupled cells. How a small SA node drives a large atrium</article-title><source>Biophysical Journal</source><volume>50</volume><fpage>1157</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(86)83559-7</pub-id><pub-id pub-id-type="pmid">3801575</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>A</given-names></name><name><surname>Flack</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1907">1907</year><article-title>The form and nature of the muscular connections between the primary divisions of the vertebrate heart</article-title><source>Journal of Anatomy and Physiology</source><volume>41</volume><fpage>172</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">17232727</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenyon</surname><given-names>EJ</given-names></name><name><surname>McEwen</surname><given-names>GK</given-names></name><name><surname>Callaway</surname><given-names>H</given-names></name><name><surname>Elgar</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Functional analysis of conserved non-coding regions around the short stature Hox gene (SHOX) in whole zebrafish embryos</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e21498</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0021498</pub-id><pub-id pub-id-type="pmid">21731768</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koibuchi</surname><given-names>N</given-names></name><name><surname>Chin</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chf1/Hey2 plays a pivotal role in left ventricular maturation through suppression of ectopic atrial gene expression</article-title><source>Circulation Research</source><volume>100</volume><fpage>850</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000261693.13269.bf</pub-id><pub-id pub-id-type="pmid">17332425</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Trim Galore: a wrapper tool around Cutadapt and FastQC to consistently apply quality and adapter trimming to FastQ files, with some extra functionality for MspI-digested RRBS-type (Reduced Representation Bisufite-Seq) libraries</article-title><ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/trim_galore">https://www.bioinformatics.babraham.ac.uk/projects/trim_galore</ext-link><date-in-citation iso-8601-date="2019-03-19">March 19, 2019</date-in-citation></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname><given-names>KM</given-names></name><name><surname>Fujimoto</surname><given-names>E</given-names></name><name><surname>Grabher</surname><given-names>C</given-names></name><name><surname>Mangum</surname><given-names>BD</given-names></name><name><surname>Hardy</surname><given-names>ME</given-names></name><name><surname>Campbell</surname><given-names>DS</given-names></name><name><surname>Parant</surname><given-names>JM</given-names></name><name><surname>Yost</surname><given-names>HJ</given-names></name><name><surname>Kanki</surname><given-names>JP</given-names></name><name><surname>Chien</surname><given-names>Cb</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs</article-title><source>Developmental Dynamics</source><volume>236</volume><fpage>3088</fpage><lpage>3099</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21343</pub-id><pub-id pub-id-type="pmid">17937395</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakatta</surname><given-names>EG</given-names></name><name><surname>Maltsev</surname><given-names>VA</given-names></name><name><surname>Vinogradova</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A coupled system of intracellular Ca2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart’s pacemaker</article-title><source>Circulation Research</source><volume>106</volume><fpage>659</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.206078</pub-id><pub-id pub-id-type="pmid">20203315</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazic</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>IC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mef2cb regulates late myocardial cell addition from a second heart field-like population of progenitors in zebrafish</article-title><source>Developmental Biology</source><volume>354</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2011.03.028</pub-id><pub-id pub-id-type="pmid">21466801</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Wysoker</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>N</given-names></name><name><surname>Marth</surname><given-names>G</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><year iso-8601-date="2009">2009</year><article-title>The sequence alignment/map format and samtools</article-title><source>Bioinformatics</source><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Sim</surname><given-names>S</given-names></name><name><surname>Priest</surname><given-names>JR</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Quertermous</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name><name><surname>Wu</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Transcriptomic profiling maps anatomically patterned subpopulations among single embryonic cardiac cells</article-title><source>Developmental Cell</source><volume>39</volume><fpage>491</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2016.10.014</pub-id><pub-id pub-id-type="pmid">27840109</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Cattaneo</surname><given-names>P</given-names></name><name><surname>Zhuang</surname><given-names>S</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Spann</surname><given-names>NJ</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Bu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>HSV</given-names></name><name><surname>Zhuang</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Geng</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Banerjee</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Zambon</surname><given-names>AC</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Evans</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Transcription factor ISL1 is essential for pacemaker development and function</article-title><source>The Journal of Clinical Investigation</source><volume>125</volume><fpage>3256</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.1172/JCI68257</pub-id><pub-id pub-id-type="pmid">26193633</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads</article-title><source>Nucleic Acids Research</source><volume>47</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkz114</pub-id><pub-id pub-id-type="pmid">30783653</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Espinoza-Lewis</surname><given-names>RA</given-names></name><name><surname>Jiao</surname><given-names>Z</given-names></name><name><surname>Sheu</surname><given-names>I</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>YP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Functional redundancy between human SHOX and mouse Shox2 genes in the regulation of sinoatrial node formation and pacemaking function</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>17029</fpage><lpage>17038</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.234252</pub-id><pub-id pub-id-type="pmid">21454626</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loffredo</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Epidemiology of cardiovascular malformations: prevalence and risk factors</article-title><source>American Journal of Medical Genetics</source><volume>97</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1002/1096-8628(200024)97:4&lt;319::aid-ajmg1283&gt;3.0.co;2-e</pub-id><pub-id pub-id-type="pmid">11376444</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-Seq data with deseq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>JF</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Mahida</surname><given-names>SN</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>ML</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Zheng</surname><given-names>GY</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>MJ</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>QS</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Li</surname><given-names>YG</given-names></name><name><surname>Tian</surname><given-names>XL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tbx5 mutations contribute to early-onset atrial fibrillation in Chinese and Caucasians</article-title><source>Cardiovascular Research</source><volume>109</volume><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw003</pub-id><pub-id pub-id-type="pmid">26762269</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mably</surname><given-names>JD</given-names></name><name><surname>Mohideen</surname><given-names>M</given-names></name><name><surname>Burns</surname><given-names>CG</given-names></name><name><surname>Chen</surname><given-names>JN</given-names></name><name><surname>Fishman</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Heart of glass regulates the concentric growth of the heart in zebrafish</article-title><source>Current Biology</source><volume>13</volume><fpage>2138</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2003.11.055</pub-id><pub-id pub-id-type="pmid">14680629</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangoni</surname><given-names>ME</given-names></name><name><surname>Nargeot</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genesis and regulation of the heart automaticity</article-title><source>Physiological Reviews</source><volume>88</volume><fpage>919</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1152/physrev.00018.2007</pub-id><pub-id pub-id-type="pmid">18626064</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>EMBnet.Journal</source><volume>17</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.14806/ej.17.1.200</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McElhinney</surname><given-names>DB</given-names></name><name><surname>Geiger</surname><given-names>E</given-names></name><name><surname>Blinder</surname><given-names>J</given-names></name><name><surname>Benson</surname><given-names>DW</given-names></name><name><surname>Goldmuntz</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Nkx2.5 mutations in patients with congenital heart disease</article-title><source>Journal of the American College of Cardiology</source><volume>42</volume><fpage>1650</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2003.05.004</pub-id><pub-id pub-id-type="pmid">14607454</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesirca</surname><given-names>P</given-names></name><name><surname>Torrente</surname><given-names>AG</given-names></name><name><surname>Mangoni</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Functional role of voltage gated Ca (2+) channels in heart automaticity</article-title><source>Frontiers in Physiology</source><volume>6</volume><elocation-id>19</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2015.00019</pub-id><pub-id pub-id-type="pmid">25698974</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mommersteeg</surname><given-names>MTM</given-names></name><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>Prall</surname><given-names>OWJ</given-names></name><name><surname>de Gier-de Vries</surname><given-names>C</given-names></name><name><surname>Wiese</surname><given-names>C</given-names></name><name><surname>Clout</surname><given-names>DEW</given-names></name><name><surname>Papaioannou</surname><given-names>VE</given-names></name><name><surname>Brown</surname><given-names>NA</given-names></name><name><surname>Harvey</surname><given-names>RP</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Molecular pathway for the localized formation of the sinoatrial node</article-title><source>Circulation Research</source><volume>100</volume><fpage>354</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000258019.74591.b3</pub-id><pub-id pub-id-type="pmid">17234970</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cardiac chamber formation: Development, genes, and evolution</article-title><source>Physiological Reviews</source><volume>83</volume><fpage>1223</fpage><lpage>1267</lpage><pub-id pub-id-type="doi">10.1152/physrev.00006.2003</pub-id><pub-id pub-id-type="pmid">14506305</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosimann</surname><given-names>C</given-names></name><name><surname>Panáková</surname><given-names>D</given-names></name><name><surname>Werdich</surname><given-names>AA</given-names></name><name><surname>Musso</surname><given-names>G</given-names></name><name><surname>Burger</surname><given-names>A</given-names></name><name><surname>Lawson</surname><given-names>KL</given-names></name><name><surname>Carr</surname><given-names>LA</given-names></name><name><surname>Nevis</surname><given-names>KR</given-names></name><name><surname>Sabeh</surname><given-names>MK</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Davidson</surname><given-names>AJ</given-names></name><name><surname>DiBiase</surname><given-names>A</given-names></name><name><surname>Burns</surname><given-names>CE</given-names></name><name><surname>Burns</surname><given-names>CG</given-names></name><name><surname>MacRae</surname><given-names>CA</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chamber identity programs drive early functional partitioning of the heart</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>8146</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms9146</pub-id><pub-id pub-id-type="pmid">26306682</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>E</given-names></name><name><surname>Makita</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Nagaya</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>M</given-names></name><name><surname>Manabe</surname><given-names>H</given-names></name><name><surname>Taketazu</surname><given-names>G</given-names></name><name><surname>Kajino</surname><given-names>H</given-names></name><name><surname>Fujieda</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>5.78 MB terminal deletion of chromosome 15q in a Girl, evaluation of NR2F2 as candidate gene for congenital heart defects</article-title><source>European Journal of Medical Genetics</source><volume>54</volume><fpage>354</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2010.12.004</pub-id><pub-id pub-id-type="pmid">21172461</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Yanez</surname><given-names>DA</given-names></name><name><surname>Touma</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Jaroszewicz</surname><given-names>A</given-names></name><name><surname>Jordan</surname><given-names>MC</given-names></name><name><surname>Pellegrini</surname><given-names>M</given-names></name><name><surname>Roos</surname><given-names>KP</given-names></name><name><surname>Nakano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nkx2-5 suppresses the proliferation of atrial myocytes and conduction system</article-title><source>Circulation Research</source><volume>114</volume><fpage>1103</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303219</pub-id><pub-id pub-id-type="pmid">24563458</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>SY</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Tsang</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Differential gene expressions in atrial and ventricular myocytes: insights into the road of applying embryonic stem cell-derived cardiomyocytes for future therapies</article-title><source>American Journal of Physiology. Cell Physiology</source><volume>299</volume><fpage>C1234</fpage><lpage>C1249</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00402.2009</pub-id><pub-id pub-id-type="pmid">20844252</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panáková</surname><given-names>D</given-names></name><name><surname>Werdich</surname><given-names>AA</given-names></name><name><surname>Macrae</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Wnt11 patterns a myocardial electrical gradient through regulation of the L-type Ca (2+) channel</article-title><source>Nature</source><volume>466</volume><fpage>874</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1038/nature09249</pub-id><pub-id pub-id-type="pmid">20657579</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>FA</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Tsai</surname><given-names>MJ</given-names></name><name><surname>Tsai</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>1037</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1101/gad.13.8.1037</pub-id><pub-id pub-id-type="pmid">10215630</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>KL</given-names></name><name><surname>Liebling</surname><given-names>M</given-names></name><name><surname>Kondrychyn</surname><given-names>I</given-names></name><name><surname>Brand</surname><given-names>T</given-names></name><name><surname>Korzh</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Development of the cardiac conduction system in zebrafish</article-title><source>Gene Expression Patterns</source><volume>21</volume><fpage>89</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.gep.2016.08.003</pub-id><pub-id pub-id-type="pmid">27593944</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poot</surname><given-names>M</given-names></name><name><surname>Eleveld</surname><given-names>MJ</given-names></name><name><surname>van ’t Slot</surname><given-names>R</given-names></name><name><surname>van Genderen</surname><given-names>MM</given-names></name><name><surname>Verrijn Stuart</surname><given-names>AA</given-names></name><name><surname>Hochstenbach</surname><given-names>R</given-names></name><name><surname>Beemer</surname><given-names>FA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Proportional growth failure and oculocutaneous albinism in a girl with a 6.87 MB deletion of region 15q26.2→qter</article-title><source>European Journal of Medical Genetics</source><volume>50</volume><fpage>432</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2007.08.003</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>XXI</given-names></name><name><surname>Sidhwani</surname><given-names>P</given-names></name><name><surname>Marques</surname><given-names>SR</given-names></name><name><surname>George</surname><given-names>V</given-names></name><name><surname>Targoff</surname><given-names>KL</given-names></name><name><surname>Chi</surname><given-names>NC</given-names></name><name><surname>Yelon</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fgf signaling enforces cardiac chamber identity in the developing ventricle</article-title><source>Development</source><volume>144</volume><fpage>1328</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1242/dev.143719</pub-id><pub-id pub-id-type="pmid">28232600</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>XH</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>XY</given-names></name><name><surname>Xu</surname><given-names>YJ</given-names></name><name><surname>Huang</surname><given-names>RT</given-names></name><name><surname>Xue</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Qu</surname><given-names>XK</given-names></name><name><surname>Li</surname><given-names>RG</given-names></name><name><surname>Qiu</surname><given-names>XB</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A novel NR2F2 loss-of-function mutation predisposes to congenital heart defect</article-title><source>European Journal of Medical Genetics</source><volume>61</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2017.12.003</pub-id><pub-id pub-id-type="pmid">29222010</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>I</given-names></name><name><surname>Kawakami</surname><given-names>Y</given-names></name><name><surname>Büscher</surname><given-names>D</given-names></name><name><surname>Raya</surname><given-names>A</given-names></name><name><surname>Rodríguez-León</surname><given-names>J</given-names></name><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Rodríguez Esteban</surname><given-names>C</given-names></name><name><surname>Izpisúa Belmonte</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Tbx2 and TBX3 regulate the dynamics of cell proliferation during heart remodeling</article-title><source>PLOS ONE</source><volume>2</volume><elocation-id>e398</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0000398</pub-id><pub-id pub-id-type="pmid">17460765</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydeen</surname><given-names>AB</given-names></name><name><surname>Waxman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cyp26 enzymes facilitate second heart field progenitor addition and maintenance of ventricular integrity</article-title><source>PLOS Biology</source><volume>14</volume><elocation-id>e2000504</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.2000504</pub-id><pub-id pub-id-type="pmid">27893754</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Tsuchida</surname><given-names>M</given-names></name><name><surname>Lampe</surname><given-names>PD</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cardiomyocyte FGF signaling is required for Cx43 phosphorylation and cardiac gap junction maintenance</article-title><source>Experimental Cell Research</source><volume>319</volume><fpage>2152</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2013.05.022</pub-id><pub-id pub-id-type="pmid">23742896</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samsa</surname><given-names>LA</given-names></name><name><surname>Fleming</surname><given-names>N</given-names></name><name><surname>Magness</surname><given-names>S</given-names></name><name><surname>Qian</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Isolation and characterization of single cells from zebrafish embryos</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>53877</elocation-id><pub-id pub-id-type="doi">10.3791/53877</pub-id><pub-id pub-id-type="pmid">27022828</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>R</given-names></name><name><surname>Kamei</surname><given-names>H</given-names></name><name><surname>Hakuno</surname><given-names>F</given-names></name><name><surname>Takahashi</surname><given-names>SI</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>In vivo loss of function study reveals the short stature homeobox-containing (SHOX) gene plays indispensable roles in early embryonic growth and bone formation in zebrafish</article-title><source>Developmental Dynamics</source><volume>244</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1002/dvdy.24239</pub-id><pub-id pub-id-type="pmid">25483930</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schott</surname><given-names>JJ</given-names></name><name><surname>Benson</surname><given-names>DW</given-names></name><name><surname>Basson</surname><given-names>CT</given-names></name><name><surname>Pease</surname><given-names>W</given-names></name><name><surname>Silberbach</surname><given-names>GM</given-names></name><name><surname>Moak</surname><given-names>JP</given-names></name><name><surname>Maron</surname><given-names>BJ</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Congenital heart disease caused by mutations in the transcription factor Nkx2-5</article-title><source>Science</source><volume>281</volume><fpage>108</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1126/science.281.5373.108</pub-id><pub-id pub-id-type="pmid">9651244</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schram</surname><given-names>G</given-names></name><name><surname>Pourrier</surname><given-names>M</given-names></name><name><surname>Melnyk</surname><given-names>P</given-names></name><name><surname>Nattel</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function</article-title><source>Circulation Research</source><volume>90</volume><fpage>939</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1161/01.res.0000018627.89528.6f</pub-id><pub-id pub-id-type="pmid">12016259</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyrnias</surname><given-names>I</given-names></name><name><surname>Mair</surname><given-names>W</given-names></name><name><surname>Harzheim</surname><given-names>D</given-names></name><name><surname>Walker</surname><given-names>SA</given-names></name><name><surname>Roderick</surname><given-names>HL</given-names></name><name><surname>Bootman</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Comparison of the T-tubule system in adult rat ventricular and atrial myocytes, and its role in excitation-contraction coupling and inotropic stimulation</article-title><source>Cell Calcium</source><volume>47</volume><fpage>210</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2009.10.001</pub-id><pub-id pub-id-type="pmid">20106523</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>YC</given-names></name><name><surname>Dohn</surname><given-names>TE</given-names></name><name><surname>Rydeen</surname><given-names>AB</given-names></name><name><surname>Nechiporuk</surname><given-names>AV</given-names></name><name><surname>Waxman</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HDAC1-mediated repression of the retinoic acid-responsive gene ripply3 promotes second heart field development</article-title><source>PLOS Genetics</source><volume>15</volume><elocation-id>e1008165</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1008165</pub-id><pub-id pub-id-type="pmid">31091225</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stachura</surname><given-names>DL</given-names></name><name><surname>Traver</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cellular dissection of zebrafish hematopoiesis</article-title><source>Methods in Cell Biology</source><volume>101</volume><fpage>75</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-387036-0.00004-9</pub-id><pub-id pub-id-type="pmid">21550440</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Najafi</surname><given-names>N</given-names></name><name><surname>Cass</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Islet 1 is expressed in distinct cardiovascular lineages, including pacemaker and coronary vascular cells</article-title><source>Developmental Biology</source><volume>304</volume><fpage>286</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2006.12.048</pub-id><pub-id pub-id-type="pmid">17258700</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabibiazar</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>RA</given-names></name><name><surname>Liao</surname><given-names>A</given-names></name><name><surname>Quertermous</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transcriptional profiling of the heart reveals chamber-specific gene expression patterns</article-title><source>Circulation Research</source><volume>93</volume><fpage>1193</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000103171.42654.DD</pub-id><pub-id pub-id-type="pmid">14576202</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Targoff</surname><given-names>KL</given-names></name><name><surname>Colombo</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>V</given-names></name><name><surname>Schell</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Solnica-Krezel</surname><given-names>L</given-names></name><name><surname>Yelon</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nkx genes are essential for maintenance of ventricular identity</article-title><source>Development</source><volume>140</volume><fpage>4203</fpage><lpage>4213</lpage><pub-id pub-id-type="doi">10.1242/dev.095562</pub-id><pub-id pub-id-type="pmid">24026123</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tessadori</surname><given-names>F</given-names></name><name><surname>van Weerd</surname><given-names>JH</given-names></name><name><surname>Burkhard</surname><given-names>SB</given-names></name><name><surname>Verkerk</surname><given-names>AO</given-names></name><name><surname>de Pater</surname><given-names>E</given-names></name><name><surname>Boukens</surname><given-names>BJ</given-names></name><name><surname>Vink</surname><given-names>A</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name><name><surname>Bakkers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification and functional characterization of cardiac pacemaker cells in zebrafish</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e47644</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047644</pub-id><pub-id pub-id-type="pmid">23077655</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadia</surname><given-names>J</given-names></name><name><surname>Gonzales</surname><given-names>PR</given-names></name><name><surname>Robin</surname><given-names>NH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Novel de novo pathogenic variant in the NR2F2 gene in a boy with congenital heart defect and dysmorphic features</article-title><source>American Journal of Medical Genetics. Part A</source><volume>176</volume><fpage>1423</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.38700</pub-id><pub-id pub-id-type="pmid">29663647</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Linde</surname><given-names>D</given-names></name><name><surname>Konings</surname><given-names>EEM</given-names></name><name><surname>Slager</surname><given-names>MA</given-names></name><name><surname>Witsenburg</surname><given-names>M</given-names></name><name><surname>Helbing</surname><given-names>WA</given-names></name><name><surname>Takkenberg</surname><given-names>JJM</given-names></name><name><surname>Roos-Hesselink</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Birth prevalence of congenital heart disease worldwide</article-title><source>Journal of the American College of Cardiology</source><volume>58</volume><fpage>2241</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2011.08.025</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Weerd</surname><given-names>JH</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The formation and function of the cardiac conduction system</article-title><source>Development</source><volume>143</volume><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1242/dev.124883</pub-id><pub-id pub-id-type="pmid">26786210</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Hennessey</surname><given-names>JA</given-names></name><name><surname>Kirkton</surname><given-names>RD</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Graham</surname><given-names>V</given-names></name><name><surname>Puranam</surname><given-names>RS</given-names></name><name><surname>Rosenberg</surname><given-names>PB</given-names></name><name><surname>Bursac</surname><given-names>N</given-names></name><name><surname>Pitt</surname><given-names>GS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fibroblast growth factor homologous factor 13 regulates Na+ channels and conduction velocity in murine hearts</article-title><source>Circulation Research</source><volume>109</volume><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.247957</pub-id><pub-id pub-id-type="pmid">21817159</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>EQ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Pitt</surname><given-names>GS</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Conditional knockout of fgf13 in murine hearts increases arrhythmia susceptibility and reveals novel ion channel modulatory roles</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>104</volume><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2017.01.009</pub-id><pub-id pub-id-type="pmid">28119060</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>EI</given-names></name><name><surname>Honjo</surname><given-names>H</given-names></name><name><surname>Anno</surname><given-names>T</given-names></name><name><surname>Boyett</surname><given-names>MR</given-names></name><name><surname>Kodama</surname><given-names>I</given-names></name><name><surname>Toyama</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Modulation of pacemaker activity of sinoatrial node cells by electrical load imposed by an atrial cell model</article-title><source>The American Journal of Physiology</source><volume>269</volume><fpage>H1735</fpage><lpage>H1742</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.1995.269.5.H1735</pub-id><pub-id pub-id-type="pmid">7503272</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waxman</surname><given-names>JS</given-names></name><name><surname>Keegan</surname><given-names>BR</given-names></name><name><surname>Roberts</surname><given-names>RW</given-names></name><name><surname>Poss</surname><given-names>KD</given-names></name><name><surname>Yelon</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Hoxb5b acts downstream of retinoic acid signaling in the forelimb field to restrict heart field potential in zebrafish</article-title><source>Developmental Cell</source><volume>15</volume><fpage>923</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2008.09.009</pub-id><pub-id pub-id-type="pmid">19081079</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>F</given-names></name><name><surname>Mehrkens</surname><given-names>D</given-names></name><name><surname>Friedrich</surname><given-names>FW</given-names></name><name><surname>Stubbendorff</surname><given-names>M</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Müller</surname><given-names>JC</given-names></name><name><surname>Schrepfer</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>SM</given-names></name><name><surname>Carrier</surname><given-names>L</given-names></name><name><surname>Eschenhagen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Localization of islet-1-positive cells in the healthy and infarcted adult murine heart</article-title><source>Circulation Research</source><volume>110</volume><fpage>1303</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.259630</pub-id><pub-id pub-id-type="pmid">22427341</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weirauch</surname><given-names>MT</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Albu</surname><given-names>M</given-names></name><name><surname>Cote</surname><given-names>AG</given-names></name><name><surname>Montenegro-Montero</surname><given-names>A</given-names></name><name><surname>Drewe</surname><given-names>P</given-names></name><name><surname>Najafabadi</surname><given-names>HS</given-names></name><name><surname>Lambert</surname><given-names>SA</given-names></name><name><surname>Mann</surname><given-names>I</given-names></name><name><surname>Cook</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Goity</surname><given-names>A</given-names></name><name><surname>van Bakel</surname><given-names>H</given-names></name><name><surname>Lozano</surname><given-names>JC</given-names></name><name><surname>Galli</surname><given-names>M</given-names></name><name><surname>Lewsey</surname><given-names>MG</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Mukherjee</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Reece-Hoyes</surname><given-names>JS</given-names></name><name><surname>Govindarajan</surname><given-names>S</given-names></name><name><surname>Shaulsky</surname><given-names>G</given-names></name><name><surname>Walhout</surname><given-names>AJM</given-names></name><name><surname>Bouget</surname><given-names>FY</given-names></name><name><surname>Ratsch</surname><given-names>G</given-names></name><name><surname>Larrondo</surname><given-names>LF</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name><name><surname>Hughes</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Determination and inference of eukaryotic transcription factor sequence specificity</article-title><source>Cell</source><volume>158</volume><fpage>1431</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.009</pub-id><pub-id pub-id-type="pmid">25215497</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Westerfield</surname><given-names>M.</given-names></name></person-group><year iso-8601-date="2000">2000</year><source>The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish Danio rerio</source><publisher-name>University of Oregon Press</publisher-name></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiese</surname><given-names>C</given-names></name><name><surname>Grieskamp</surname><given-names>T</given-names></name><name><surname>Airik</surname><given-names>R</given-names></name><name><surname>Mommersteeg</surname><given-names>MTM</given-names></name><name><surname>Gardiwal</surname><given-names>A</given-names></name><name><surname>de Gier-de Vries</surname><given-names>C</given-names></name><name><surname>Schuster-Gossler</surname><given-names>K</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name><name><surname>Kispert</surname><given-names>A</given-names></name><name><surname>Christoffels</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and TBX3</article-title><source>Circulation Research</source><volume>104</volume><fpage>388</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.187062</pub-id><pub-id pub-id-type="pmid">19096026</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>MR</given-names></name><name><surname>Perry</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Arrhythmias and conduction disorders associated with atrial septal defects</article-title><source>Journal of Thoracic Disease</source><volume>10</volume><fpage>S2940</fpage><lpage>S2944</lpage><pub-id pub-id-type="doi">10.21037/jtd.2018.08.27</pub-id><pub-id pub-id-type="pmid">30305954</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witzel</surname><given-names>HR</given-names></name><name><surname>Cheedipudi</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Dobreva</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Isl2b regulates anterior second heart field development in zebrafish</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>41043</elocation-id><pub-id pub-id-type="doi">10.1038/srep41043</pub-id><pub-id pub-id-type="pmid">28106108</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>CM</given-names></name><name><surname>Lanz</surname><given-names>RB</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Respress</surname><given-names>JL</given-names></name><name><surname>Ather</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Tsai</surname><given-names>SJ</given-names></name><name><surname>Wehrens</surname><given-names>XHT</given-names></name><name><surname>Tsai</surname><given-names>MJ</given-names></name><name><surname>Tsai</surname><given-names>SY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Atrial identity is determined by a COUP-TFII regulatory network</article-title><source>Developmental Cell</source><volume>25</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2013.04.017</pub-id><pub-id pub-id-type="pmid">23725765</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>WH</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>RG</given-names></name><name><surname>Qu</surname><given-names>XK</given-names></name><name><surname>Fang</surname><given-names>WY</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Prevalence and spectrum of Nkx2.5 mutations associated with idiopathic atrial fibrillation</article-title><source>Clinics</source><volume>68</volume><fpage>777</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.6061/clinics/2013(06)09</pub-id><pub-id pub-id-type="pmid">23778487</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xin</surname><given-names>M</given-names></name><name><surname>Small</surname><given-names>EM</given-names></name><name><surname>van Rooij</surname><given-names>E</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><name><surname>Srivastava</surname><given-names>D</given-names></name><name><surname>Nakagawa</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Essential roles of the bHLH transcription factor hrt2 in repression of atrial gene expression and maintenance of postnatal cardiac function</article-title><source>PNAS</source><volume>104</volume><fpage>7975</fpage><lpage>7980</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702447104</pub-id><pub-id pub-id-type="pmid">17468400</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sinden</surname><given-names>DS</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Pitt</surname><given-names>GS</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FGF13 modulates the gating properties of the cardiac sodium channel Nav1.5 in an isoform-specific manner</article-title><source>Channels</source><volume>10</volume><fpage>410</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1080/19336950.2016.1190055</pub-id><pub-id pub-id-type="pmid">27246624</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>JH</given-names></name><name><surname>Song</surname><given-names>HM</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>WJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>RG</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>WF</given-names></name><name><surname>Qiu</surname><given-names>XB</given-names></name><name><surname>Jiang</surname><given-names>JQ</given-names></name><name><surname>Qu</surname><given-names>XK</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>WY</given-names></name><name><surname>Jiang</surname><given-names>JF</given-names></name><name><surname>Yang</surname><given-names>YQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutational spectrum of the Nkx2-5 gene in patients with lone atrial fibrillation</article-title><source>International Journal of Medical Sciences</source><volume>11</volume><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.7150/ijms.8407</pub-id><pub-id pub-id-type="pmid">24782644</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>DS</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Myers</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Model-Based analysis of ChIP-Seq (MACS)</article-title><source>Genome Biology</source><volume>9</volume><elocation-id>R137</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2008-9-9-r137</pub-id><pub-id pub-id-type="pmid">18798982</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Ouyang</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Ocorr</surname><given-names>K</given-names></name><name><surname>Kang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Yelon</surname><given-names>D</given-names></name><name><surname>Chi</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>In vivo cardiac reprogramming contributes to zebrafish heart regeneration</article-title><source>Nature</source><volume>498</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1038/nature12322</pub-id><pub-id pub-id-type="pmid">23783515</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Cashman</surname><given-names>TJ</given-names></name><name><surname>Nevis</surname><given-names>KR</given-names></name><name><surname>Obregon</surname><given-names>P</given-names></name><name><surname>Carney</surname><given-names>SA</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>A</given-names></name><name><surname>Mosimann</surname><given-names>C</given-names></name><name><surname>Sondalle</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>RE</given-names></name><name><surname>Heideman</surname><given-names>W</given-names></name><name><surname>Burns</surname><given-names>CE</given-names></name><name><surname>Burns</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Latent TGF-β binding protein 3 identifies a second heart field in zebrafish</article-title><source>Nature</source><volume>474</volume><fpage>645</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/nature10094</pub-id><pub-id pub-id-type="pmid">21623370</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77408.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meilhac</surname><given-names>Sigolène M</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Imagine-Institut Pasteur</institution></institution-wrap><country>France</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.02.24.481762" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.24.481762"/></front-stub><body><p>Addressing the role of NR2F transcription factors in the fish heart, this important work provides novel insight into atrial chamber patterning. Solid evidence supports the identification of a new mechanism of pacemaker cell restriction, involving nkx2.5 maintenance in the atrium by nr2f1a. Whether nr2f1 also restricts ventricular fate as shown in the mouse model will require more investigation. This manuscript will be of interest to developmental biologists and pediatric cardiologists.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77408.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Meilhac</surname><given-names>Sigolène M</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Imagine-Institut Pasteur</institution></institution-wrap><country>France</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Meilhac</surname><given-names>Sigolène M</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0495fxg12</institution-id><institution>Imagine-Institut Pasteur</institution></institution-wrap><country>France</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Christoffels</surname><given-names>Vincent M</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05grdyy37</institution-id><institution>Amsterdam University Medical Centers</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.24.481762">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.02.24.481762v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Nr2f1a maintains atrial nkx2.5 expression to repress pacemaker identity within venous atrial cardiomyocytes&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Sigolène M Meilhac as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Edward Morrisey as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Vincent M. Christoffels (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>As you will see, reviewers refer to a strong paper addressing patterning of the atrial chamber and a striking new mechanism of pacemaker cell restriction, but they also indicate that further work would be necessary for publication. In particular, three major issues have been raised.</p><p>1) The claim of transdifferentiation is currently not supported by the data. The definition of AC/VC/PC requires clarification, as well as that of the boundary between chambers. The same definition should be used throughout the paper. The tracking of a limited number of markers (fgf13a:GFP transgene for example) to ascribe cell lineage or inconsistencies between markers (cells that take on ventricular gene expression in mutants have more of an atrial electrophysiological character) raise concerns about the conclusion of transdifferentiation. Inconsistencies between figures (1D versus 1J-J, 2F versus 4F, 1B and 2K, 1J-L versus S1 and 2G-I) should be resolved. An in-depth analysis of the ATAC-seq and RNA-seq data in wild-type and mutant atrial cells and comparison with epigenetic state data from other models would provide better insights into lineage changes. In addition, cell tracking is required to conclude transdifferentiation.</p><p>2) Alternative mechanisms through which pacemaker cells are expanded should be addressed experimentally: cell death, cell proliferation, or progenitor recruitment.</p><p>3) The identification of nkx2.5 as a target of nr2f1a to repress pacemaker cells needs strengthening. Please explain how nrf2f1a is envisioned to act as a suppressor of pacemaker phenotype (atrial-specific activator of nkx2-5) as the gene is expressed in pacemaker cells and in the posterior second heart field progenitors the atria and sinus venosus (including pacemaker cells) derive from. Maintenance of nkx2.5 expression by nr2f1a at the venous pole is incongruent with the atrial to ventricular shifts observed. More details on nr2f1a expression and co-expression with nkx2.5 and pacemaker markers would be useful. The authors assume the identified enhancer regulates nkx2-5, but do not provide evidence for this. Overexpression of nkx2.5 not completely suppresses but delays the appearance of pacemaker cells. Examination of nkx2.5 rescue should be extended at a functional level (cardiac function and electrophysiology).</p><p>Detailed comments of the reviewers are below. Please take into account all comments and provide more explanations on the methods as detailed by the reviewers. If you are not able to address experimentally some reviewer comments within the revision period, please discuss the limitations or alternative hypotheses in the manuscript.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>– Please provide a clear indication of the biological system under investigation in the title.</p><p>– Abbreviations complicate reading.</p><p>– How fluorescence of Nkx2.5-EGFP is distinguished over the Et(fgf13a:EGFP) transgene?</p><p>– Was cell counting done in 3D or in 2D in a projection image? Can a partial cell count in 2D explain variations between Fig2G+H and 1J? Please clarify the method section.</p><p>– Please complete the criteria of differential expression in the RNA-seq (p-value or adjusted p-value ? cut-off ?).</p><p>– &quot;ectopic expression&quot; (line 139) is not correct since amhc positive cells normally do express ventricular and pacemaker markers.</p><p>– Two mutant lines are described in the method section. Which line is used for each experiment? How have they been validated for the loss of nr2f1a expression?</p><p>– How are vmhc and AVC markers in the transcriptomic dataset?</p><p>– Provide single-channel images for Figure 1C-H, 2A-F to clarify marker overlap.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Figure 1: the overlap in Amhc and Vmhc should be more clearly shown. As there appears to be a significant overlap by 48 hpf (1D), what do these markers show at earlier time points? Finally, the image shown in 1D does not appear to be congruent with the data in 1J-L – based on the image, I would expect to see more vmhc + CMs in the mutant atrium at 48 hpf.</p><p>2. Line 168: The cell death and proliferation data are important to argue it is a fate conversion vs loss/expansion of populations that is occurring. It should be shown, or some form of fate tracing (photoconversion, etc.) should be used if statements like those in lines 174/5 are to be made.</p><p>3. Figure 4: The extent of fgf13a:GFP + cells in the atrium in nr2f1a mutants at 96hpf appears to differ markedly in Figures 2 (most of the cells are +) vs 4 (appears to be a lower proportion of the atrium as shown). How are chamber boundaries being defined in these analyses?</p><p>4. Figure 5: Somewhat confusing – how are new PCs made from 48 to 96hpf if Nkx2.5 is still present? ACs are still lost in &quot;rescued&quot; hearts – presumably, these now make VCs? Importantly, does the nkx2.5 transgene rescue/normalize heart rate or conduction? It is important to distinguish an effect on the fgf13a transgene (which is convincing) versus a more important effect on PC and AC fate and FUNCTION is reflected in these results.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1) Please provide more details in figure 1 regarding the RNAseq analysis. Why did the authors use a cut-off of &gt;2 fold difference rather than significance? Could they provide an MA plot or so to show distributions of FC and p values of all transcripts detected? How many transcripts were differentially expressed? What kind of biological processes were changed?</p><p>2) In figure 1B the behavior of pacemaker markers is inconsistent. Please provide data or references showing the expression of these markers in fish pacemaker cells (e.g. I did not find these data for tbx3a etc.). Furthermore, central pacemaker markers like isl1a (Isl1 homologue) and shox2a (Shox2 homologue) are downregulated in mutants? That is unexpected, and also inconsistent with the data given in figure 2K.</p><p>3) Arterial pole of the atrium is confusing, as arterial pole usually refers to the actual arterial pole of the heart (distal/downstream portion of the ventricle).</p><p>4) Please explain how the authors envision nrf2f1a/Nrf2f2 acts as a suppressor of pacemaker phenotype (atrial-specific activator of nkx2-5) as the gene is expressed in pacemaker cells and in the posterior second heart field progenitors the atria and sinus venosus (including pacemaker cells) derive from.</p><p>5) The cell numbers seem inconsistent between the different figures. In suppl Figure 1, there are about 75 amhc+ cells in wt, and 20 or so in mutants. In figure 1, there are close to 100 amhc+ cells in wt, and about 50 in mutants? In figure 2 there are 60 amhc+ cells in wt, and 40, 20 and 10 amhc+ cells in mutants at subsequent stages. If one adds the amhc+ and fgf13a-gfp+ cells, the numbers are 40, 30, 20, respectively (figure 2c). Which numbers are correct? Is the number of amhc+ cells very low in mutants from stage 48 hpf onwards, without changing, or is there a decrease during development?</p><p>A more general issue related to the cell number issues, the data can be explained by transdifferentiation of atrial cells into pacemaker cells, as the authors seem to favor, or by reduced addition of cardiomyocytes fated to become atrial, while the normal atrial-pacemaker demarcation programs are still active, or by reduced atrial differentiation. The latter 2 options are consistent with the data of suppl Figure 1. The authors should resolve this, and provide additional support for the trans-differentiation hypothesis. Thus, does a fraction of cells expressing pacemaker markers derive from atrial marker expressing cells in mutants, or is there an increased population of &quot;de novo&quot; pacemaker cells (not previously atrial marker positive) in the venous pole and a decreased population of atrial cells because of defective recruitment from progenitors or defective atrial differentiation.</p><p>6) Line 201: &quot;Thus, we would predict…&quot; Why would the heart rate be predicted to decrease? More pacemaker cells in mutants may also result in increased automaticity and increased spontaneous depolarizations.</p><p>7) The relation between hyperpolarization, increased repolarization times and increased numbers of pacemaker cells in mutants is not clear to me. Pacemaker cells have increased, not decreased resting membrane potentials, decreased Vmax (due to lower sodium channel activity), and unstable resting membrane potentials. The authors could analyse the electrophysiological properties of the pacemaker cells in wt and mutants (fgf13a-gfp label is perfect for that purpose), and also investigate the transcriptomes for differential expression of particular ion handling proteins known to be involved in the action potential morphology, membrane potential and intercellular conduction.</p><p>8) Line 217 &quot;…slower conduction…&quot; and line 219 &quot;… more conduction system-like…&quot; If anything, the conduction system shows very high conduction velocities. Perhaps refer to pacemaker properties. The remark regarding Vmax here is not clear. Vmax is low in pacemaker cells compared to atrial cells.</p><p>9) Line 242, transdifferentiation. See comment 4.</p><p>10) The authors assume the identified enhancer regulates nkx2-5, but do not provide evidence for this. The enhancer could be removed from the genome, for example. Did the authors analyse the topologically associated domain of nkx2-5 to see whether the enhancer is part of it? Is any interaction data available?</p><p>Please provide more detailed data regarding the ATAC-seq experiment. How many accessible sites, how many differential accessible sites, examples of known atrial accessible sites, UCSC browser views of a few examples to get an impression regarding data quality and signal-to-noise ratios. What is the correlation between RNAseq identified target genes and differential accessibility?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77408.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>As you will see, reviewers refer to a strong paper addressing patterning of the atrial chamber and a striking new mechanism of pacemaker cell restriction, but they also indicate that further work would be necessary for publication. In particular, three major issues have been raised.</p><p>(1.A) The claim of transdifferentiation is currently not supported by the data.</p></disp-quote><p>This first comment is essentially the same as Essential Revision comment #2. Please see the response to Essential Revision comment #2 below for how we specifically addressed issues of transdifferentiation vs progenitor recruitment.</p><disp-quote content-type="editor-comment"><p>(1.B) The definition of AC/VC/PC requires clarification, as well as that of the boundary between chambers. The same definition should be used throughout the paper.</p></disp-quote><p>Thank you for this suggestion to help clarify our references to the specific cardiomyocyte populations. In the revised manuscript, we have now changed the references to cardiomyocyte populations examined, such as Amhc<sup>+</sup>/Vmhc<sup>-</sup>, so that they are defined primarily by their expression of the differentiation and transgenic markers used for the specific analysis. We then state our interpretations with respect to what that means regarding the atrial, atrioventricular canal, ventricular, and pacemaker cardiomyocyte populations. The boundaries between chambers and cardiomyocyte populations were determined by the expression of the indicated markers. The references to the cardiomyocyte populations with the designated markers have been changed throughout the text and figure legends, the main figures, and the figure supplements.</p><disp-quote content-type="editor-comment"><p>(1.C) The tracking of a limited number of markers (fgf13a:GFP transgene for example) to ascribe cell lineage or inconsistencies between markers (cells that take on ventricular gene expression in mutants have more of an atrial electrophysiological character) raise concerns about the conclusion of transdifferentiation.</p></disp-quote><p>a. We acknowledge that unfortunately there are a limited number of specific markers to use for some of the cardiomyocyte populations, in particular the pacemaker cardiomyocytes within the zebrafish hearts. This is something we have struggled with in our experiments. We did not use some established markers in that analysis, such as Bmp4, because they are expressed in the atrioventricular canal and pacemaker cells at the venous pole. This created some ambiguity to effects seen at later stages in the mutants due to the expression in both regions of the heart and the smaller atria. With other markers that should be expressed more specifically in the pacemaker cardiomyocytes, such as <italic>shox</italic> and <italic>shox2</italic>, there were technical issues in that the probes for both standard and HCR in situ hybridization, while marking the population, were not consistent or robust enough for us to perform quantitative analysis. Therefore, we primarily relied on immunohistochemistry for Isl1 and the <italic>fgf13a:EGFP</italic> reporter, because we found they were the most robust markers for the pacemaker cardiomyocytes currently available for analysis in the zebrafish hearts.</p><p>b. Regarding the electrophysiological characteristics (lines 248-280 of the revised manuscript), for the analysis of the action potentials we focused on regions that are closer to the middle of the morphological atrium where cardiomyocytes would express Amhc<sup>+</sup> and <italic>fgf13a</italic>:EGFP<sup>+</sup> and not express ventricular markers within the enlarged atrioventricular canal of <italic>nr2f1a</italic> mutant hearts based on our immunohistochemical analysis. Our data does show that this atrial region has electrophysiological properties more consistent with the central conduction system and not the WT atrial cardiomyocytes. The atrioventricular canal region also has altered conduction properties, as there is less slowing of conduction in the <italic>nr2f1a</italic> mutant atrioventricular canals. The lack of slowing of conduction at the atrioventricular canal of <italic>nr2f1a</italic> mutants is consistent with these cardiomyocytes taking on ventricular-like conduction properties and the gene expression changes we observe. Despite the improper conduction properties, as we showed previously larger endocardial cushions are still formed (Duong et al., 2018), supporting that the Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes still must have atrioventricular cardiomyocyte properties that promote valve formation. Please also see responses to Reviewer #3’s comments 6, 7, and 8.</p><disp-quote content-type="editor-comment"><p>(1.D) Inconsistencies between figures (1D versus 1J-J, 2F versus 4F, 1B and 2K, 1J-L versus S1 and 2G-I) should be resolved.</p></disp-quote><p>Thank you for point these out. We have tried to address each of the inconsistencies for the listed figures.</p><p>a. With respect to Figures 1D vs 1J-J, it appears the origin of this comment is Reviewer #2’s comment 1, “<italic>Finally, the image shown in 1D does not appear to be congruent with the data in 1J-L – based on the image, I would expect to see more vmhc + CMs in the mutant atrium at 48 hpf</italic>.” In considering this comment, it is not clear to us what Reviewer #2 found inconsistent about this data. Our data show there is an increase in total Vmhc<sup>+</sup> cardiomyocytes in the <italic>nr2f1a</italic> mutant hearts compared to WT sibling hearts. However, the increase in total Vmhc<sup>+</sup> cardiomyocytes comes from the combined Amhc<sup>-</sup>/Vmhc<sup>+</sup> and Amhc<sup>+</sup>/Vmhc<sup>+</sup> cardiomyocytes populations, which are marking ventricular and atrioventricular canal cardiomyocytes respectively. There is not an increase in the Vmhc+-only (Amhc<sup>-</sup>/Vmhc<sup>+</sup>) ventricular cardiomyocytes in the <italic>nr2f1a</italic> mutants relative to the WT control embryos. This is illustrated in Figure 1 —figure supplement 2 of the revised manuscript (Supplemental Figure 1 of the original manuscript), which shows there is not a statistically significant difference in the number of Vmhc<sup>+</sup>-only (Amhc<sup>-</sup>/Vmhc<sup>+</sup>) cardiomyocytes from these conditions from 48-96 hpf. To address this comment and better convey the expansion of Vmhc expression within the <italic>nr2f1a</italic> mutant hearts, we have provided the individual image channels in a revised Figure 1 —figure supplement 1 and also show the proportions of Vmhc<sup>+</sup> cardiomyocyte populations in the hearts in Figure 1 —figure supplement 2D.</p><p>b. With respect to Figures 2F vs 4F, it appears this comment originated from Reviewer #2’s comment 3, “<italic>The extent of fgf13a:GFP + cells in the atrium in nr2f1a mutants at 96hpf appears to differ markedly in Figures 2 (most of the cells are +) vs 4 (appears to be a lower proportion of the atrium as shown). How are chamber boundaries being defined in these analyses?</italic>” We respectfully disagree that there is a significant difference in what is being shown between the effects in these images. In both Figure 2F and Figure 4F, the <italic>fgf13a:EGFP</italic> expression extends approximately half way across smaller atrium of the <italic>nr2f1a</italic> mutant hearts and overlaps significantly with Amhc<sup>+</sup> cardiomyocytes. There can be variation in both the morphology of the hearts and the expansion of the <italic>fgf13a:EGFP</italic> expression in the <italic>nr2f1a</italic> mutants, with the representative heart in Figure 2F being more distended than Figure 4F. However, we are not basing the analysis and interpretations on cardiac or chamber morphology. We are basing the interpretation on the overlap of Amhc and <italic>fgf13a</italic>:EGFP expression. Importantly, our quantification of cardiomyocytes shows in Figure 2H that despite their morphology the <italic>nr2f1a</italic> mutant hearts have consistently more Amhc<sup>+</sup>/<italic>fgf13a</italic>:EGFP<sup>+</sup> cardiomyocytes than sibling control embryos by 96 hpf. To address this comment and clarify our presentation of this data, we have revised Figure 4 to include the individual panels so that they are also showing Amhc expression within the hearts, which allows for better visualization of Amhc and <italic>fgf13a</italic>:EGFP expression within the atrium compared to the merged image in Figure 4F.</p><p>c. With respect to Figures 1B vs 2K, the RNA-seq in Figure 1B was performed on sorted <italic>amhc</italic>:EGFP<sup>+</sup> cardiomyocytes at 48hpf. While Figure 2K was RT-qPCR for the respective genes from <italic>myl7:EGFP<sup>+</sup></italic> (pan-cardiac) cardiomyocytes flow sorted at 96hpf. We performed the experiments this way as they are complementary analyses and provide insights into changes observed at the earlier stages of analysis that generated the hypotheses and those found to change at later stages of heart development following our temporal analysis. The sorting using a pan-cardiac marker was chosen because the smaller <italic>amhc:EGFP</italic><sup>+</sup> population observed at 96 hpf was technically difficult to sort and so we could better analyze changes in ventricular markers within the whole hearts. Figure 2K shows that by 96 hpf, the hearts overall have increased expression of selected ventricular and pacemakers markers, consistent with what we observe with the IHC shown in Figures 1 and 2.</p><p>d. With respect to Figures 1J-L vs S1, we do not understand what exactly could be inconsistent with these graphs. As we indicated in the Figure S1 legend of the original manuscript, the data shown in Figure S1 (Figure 1 —figure supplement 2 of the revised manuscript) is the same data shown in Figures 1J-L. These are not separate experiments. We separated out the individual cardiomyocytes populations in Figure 1 —figure supplement 2 to make it easier for the reader to observe the effects on the individual cardiomyocyte populations, as the stacked graphs may be difficult to easily observe some of the differences.</p><p>e. With respect to Figure 1J-L vs 2G-I, thank you for pointing this out. We understand why there many have been some confusion. There can be some slight experiment-to-experiment variability in the number of cardiomyocytes quantified within the hearts, which can be affected by a variety of factors, including the embryos, the IHC, and the microscope used. Importantly, despite slight differences in cardiomyocyte numbers for these different experiments, the trends on the cardiomyocyte populations quantified in the graphs between the original Figure 1J-L and Figure 2G-I were the same and did not affect the interpretation that there were decreased Amhc<sup>+</sup> cardiomyocytes and increased Vmhc<sup>+</sup> (ventricular) and <italic>fgf13a</italic>:EGFP<sup>+</sup> (pacemaker) cardiomyocytes in the <italic>nr2f1a</italic> mutant hearts. However, to alleviate any confusion, we have replaced the graphs in Figure 2G-I with an experimental replicate showing the same trends, but the cardiomyocytes counts were more similar to those of Figure 1J-L. Again, the trends are the same from all the biological replicates and do not affect the interpretation regarding the changes in cardiomyocyte populations.</p><disp-quote content-type="editor-comment"><p>(1.E) An in-depth analysis of the ATAC-seq and RNA-seq data in wild-type and mutant atrial cells and comparison with epigenetic state data from other models would provide better insights into lineage changes.</p></disp-quote><p>We appreciate this comment and suggestion. Certainly, gaining a greater understanding of the level of conservation for the roles of Nr2fs within cardiomyocytes shown in this study is a goal that we have. However, it is not clear to us from the comment how these proposed comparisons should be done. For these types of comparisons, ATAC-seq and RNA-seq would need to be available from pretty similar cell types and collected in a similar manner, as chromatin state and expression can be very dynamic depending on factors such as developmental stage and cell type. Therefore, it is not clear to us that there is an available dataset we could use for this comparison to look at conserved changes in chromatin or gene expression, and even if there was, that it would immediately provide additional insight into the lineage changes. Another problem is that many cardiac enhancers are not highly conserved in the heart compared to other tissues (Blow et al., 2010). While the putative <italic>nkx2.5</italic> enhancer may not be highly conserved at the sequence level, we cannot rule out that is functionally conserved. However, this additional analysis would take significantly more time to perform. We have modified the text to specifically mention the lack of conservation of the putative <italic>nkx2.5</italic> enhancer element within the heart and that this may not be unusual, in the revised manuscript (lines 335-337).</p><disp-quote content-type="editor-comment"><p>(1.F) In addition, cell tracking is required to conclude transdifferentiation.</p></disp-quote><p>This comment addresses the same issue as Essential Revision comment 2. We have included additional experimental data in the revised manuscript to support that cardiomyocytes are transdifferentiating in the <italic>nr2f1a</italic> mutant hearts. Please see our response to Essential Revisions comment 2 below.</p><disp-quote content-type="editor-comment"><p>2) Alternative mechanisms through which pacemaker cells are expanded should be addressed experimentally: cell death, cell proliferation, or progenitor recruitment.</p></disp-quote><p>A major concern from the reviewers was that they felt we had not ruled out the possibility that the additional pacemaker cardiomyocytes in the <italic>nr2f1a</italic> mutant hearts could be added from another source, such as through progenitor recruitment and newly-differentiated pacemaker cardiomyocytes at the venous pole, and were not from the transdifferentiation of atrial (Amhc<sup>+</sup>) cardiomyocytes. We did mention in the original manuscript that we did not see effects on cardiomyocyte proliferation or death within the hearts of <italic>nr2f1a</italic> mutants. However, we did not show this data as it was negative. Furthermore, our data in Figure 1L show that the <italic>nr2f1a</italic> mutant hearts effectively do not grow from 48 to 96 hpf. Therefore, it is unlikely the expansion of pacemaker cardiomyocyte gene expression within the <italic>nr2f1a</italic> mutant hearts could be explained by being from newly-added cardiomyocytes. To explain the pacemaker expansion being from newly-differentiating pacemaker cardiomyocytes with a static number of total cardiomyocytes, one would have to posit there is a treadmilling effect with atrial cardiomyocytes dying at a significant rate and being replaced by newly-differentiating pacemaker cardiomyocytes. To specifically address the issue of progenitor recruitment/newly-differentiating cardiomyocytes vs transdifferentiation, in the revised manuscript we have included the data examining cell death with active Caspase 3 and cell proliferation using both pHH3 and EdU. We also performed analysis of the temporal addition of newly-differentiating cardiomyocytes within the <italic>nr2f1a</italic> mutant hearts with the previous reported Tg(<italic>myl7:NLS-KikGR)</italic> transgene. Altogether, these data support that the Amhc<sup>+</sup> cardiomyocytes in the venous pole of the atrium are acquiring pacemaker gene expression. The text of the revised manuscript now refers to these experiments and the new supplemental figures (lines 189-198 and 229-247, and Figure 1 —figure supplement 3, Figure 1 —figure supplement 4, and Figure 2 —figure supplement 3).</p><disp-quote content-type="editor-comment"><p>(3.A) The identification of nkx2.5 as a target of nr2f1a to repress pacemaker cells needs strengthening. Please explain how nrf2f1a is envisioned to act as a suppressor of pacemaker phenotype (atrial-specific activator of nkx2-5) as the gene is expressed in pacemaker cells and in the posterior second heart field progenitors the atria and sinus venosus (including pacemaker cells) derive from.</p></disp-quote><p>We agree that we do not yet understand how Nr2f1a mechanistically promotes/maintains Nkx2.5 expression in venous atrial cardiomyocytes and represses pacemaker identity in atrial cardiomyocytes. Since Nr2f1a is expressed throughout atrial cardiomyocytes (Figure 6 —figure supplement 3), including pacemaker cardiomyocytes, we hypothesize that Nr2f1a must interact with other factors and signaling to provide these regional effects. The identification of these factors and signaling extends beyond this manuscript. We specifically discuss and state this hypothesis in the Discussion of the revised manuscript (lines 436-443).</p><disp-quote content-type="editor-comment"><p>(3.B) Maintenance of nkx2.5 expression by nr2f1a at the venous pole is incongruent with the atrial to ventricular shifts observed. More details on nr2f1a expression and co-expression with nkx2.5 and pacemaker markers would be useful.</p></disp-quote><p>a. Unfortunately, it is not clear to us how maintenance of <italic>nkx2.5</italic> expression is incongruent with the atrial to ventricular shifts. In <italic>nkx2.5</italic> zebrafish mutants, the hearts fail to maintain ventricular identity and transition to atrial and pacemaker cardiomyocyte identity (Colombo et al., 2018). As Nkx2.5 expression is not lost in the atrioventricular canal of the <italic>nr2f1a</italic> mutants, but the more venous atrial cardiomyocytes, we would not predict that the ability to promote or maintain ventricular identity would be affected in the <italic>nr2f1a</italic> mutant hearts.</p><p>b. To address the comment about co-expression of Nr2f1a and Nkx2.5, we have added immunohistochemistry of Nr2f1a and Nkx2.5 with pacemaker markers. However, they cannot be examined together as the antibodies were both generated in rabbits. The data of the co-expression are mentioned in the Results and Discussion and supplemental figures of the revised manuscript (lines 287-291 and 436-443 Figure 4 —figure supplement 4 and Figure 6 —figure supplement 3).</p><disp-quote content-type="editor-comment"><p>(3.C) The authors assume the identified enhancer regulates nkx2-5, but do not provide evidence for this.</p></disp-quote><p>In the revised manuscript, we have examined the function of the putative <italic>nkx2.5</italic> enhancer using CRISPR/Cas9 to delete it. We find that deletion of the putative <italic>nkx2.5</italic> enhancer in embryos leads to a loss of Nkx2.5<sup>+</sup> cardiomyocytes and an expansion of the <italic>fgf13a:</italic>EGFP reporter in atrial cardiomyocytes. This new experiment has been described in the Results (lines 348-364) and included in a revised Figure 6 and new Figure 6 —figure supplement 2 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(3.D) Overexpression of nkx2.5 not completely suppresses but delays the appearance of pacemaker cells. Examination of nkx2.5 rescue should be extended at a functional level (cardiac function and electrophysiology).</p></disp-quote><p>We assessed heart rate following induction of Nkx2.5 at the 20 somite stage in <italic>nr2f1a</italic> mutants at 96 hpf. Despite the strong effects on the <italic>fgf13</italic>:EGFP reporter in <italic>nr2f1a</italic> mutants, this does not restore heart rate at that stage. One reason for the failure to rescue heart rate could be that at this stage the pacemaker cardiomyocytes have already started to expand. Furthermore, this result is consistent with the hypothesis that additional factors besides Nkx2.5 are needed to fully rescue atrial cardiomyocyte and restrict pacemaker cardiomyocyte identities within the venous pole of the atrium. This data is now mentioned in the Results (lines 314-319) and included in a new Figure 5 —figure supplement 1 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(3.E) Detailed comments of the reviewers are below. Please take into account all comments and provide more explanations on the methods as detailed by the reviewers. If you are not able to address experimentally some reviewer comments within the revision period, please discuss the limitations or alternative hypotheses in the manuscript.</p></disp-quote><p>We have responded to all the comments and comments not addressed in the Essential Revisions below. We have expanded the Methods as requested by the reviewers, and we have included the Methods used for new experiments added to the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>– Please provide a clear indication of the biological system under investigation in the title.</p></disp-quote><p>We have revised the title to indicate that the studies use zebrafish.</p><disp-quote content-type="editor-comment"><p>– Abbreviations complicate reading.</p></disp-quote><p>We have tried to limit the use of abbreviations for the cardiomyocyte populations in the revised manuscript. This was in large part achieved through changing how the populations of cardiomyocytes are referenced. When we did use abbreviations, we made sure they are clearly defined.</p><disp-quote content-type="editor-comment"><p>– How fluorescence of Nkx2.5-EGFP is distinguished over the Et(fgf13a:EGFP) transgene?</p></disp-quote><p>As we indicated in the Methods of the original manuscript, prior to the heat-shock, we first sorted embryos for those that were transgenic for the <italic>fgf13a</italic>:EGFP expression based on its expression in the epidermis. Following the heat-shock, transgenic and non-transgenic <italic>hsp70l:nkx2.5-EGFP</italic> embryos were sorted based on induced Nkx2.5-EGFP expression, which shortly after the heat-shock is significantly brighter than the transgenic <italic>fgf13a</italic>:EGFP expression. In the revised manuscript, we have tried to clarify how we distinguished the expression of these transgenes with a statement in the Results (lines 301-303) and in the Methods (lines 584-588). In the initial manuscript, we unintentionally omitted that the genotypes of all embryos were subsequently confirmed with PCR genotyping following imaging for the presence or absence of the <italic>hsp70l:nkx2.5-EGFP</italic> transgene. This is now also included in the revised Methods (lines 591-593).</p><disp-quote content-type="editor-comment"><p>– Was cell counting done in 3D or in 2D in a projection image? Can a partial cell count in 2D explain variations between Fig2G+H and 1J? Please clarify the method section.</p></disp-quote><p>The cardiomyocytes were counted using MaxIP projections from confocal images of the whole hearts. We do not think partial counts could explain variation between these figures. It is more likely some experiment-to-experiment variation that can occur. Please see our response to Essential Revisions comment 1D for additional details of how we addressed this issue in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>– Please complete the criteria of differential expression in the RNA-seq (p-value or adjusted p-value ? cut-off ?).</p></disp-quote><p>This data should have been included in Supplementary file 1. There is now a sheet with all the RNA-seq data included in a revised Supplementary file 1.</p><disp-quote content-type="editor-comment"><p>– &quot;ectopic expression&quot; (line 139) is not correct since amhc positive cells normally do express ventricular and pacemaker markers.</p></disp-quote><p>Thank you. We have modified this sentence (line 150 of the revised manuscript).</p><disp-quote content-type="editor-comment"><p>– Two mutant lines are described in the method section. Which line is used for each experiment? How have they been validated for the loss of nr2f1a expression?</p></disp-quote><p>The <italic>nr2f1a<sup>el512</sup></italic> and <italic>nr2f1a<sup>ci1009</sup></italic> mutant alleles lines were reported previously (Duong et al., 2018). The <italic>nr2f1a<sup>ci1017</sup> allele</italic> was verified phenotypically, through complementation tests with the previous lines, and Western blots for Nr2f1a. As indicated in the text, additional details of the allele are in another manuscript that will be published shortly. As the <italic>nr2f1a</italic> mutant cardiac phenotype was published previously, it was not necessary to belabor the point of the additional alleles. The <italic>nr2f1a<sup>ci1017</sup></italic> allele was used for the RNA and ATAC-seq experiments. The <italic>nr2f1a<sup>el512</sup></italic> and the <italic>nr2f1a<sup>ci1009</sup></italic> alleles were used for the temporal differentiation assay with the <italic>myl7:KikGR</italic>. All the rest of the experiments in the manuscript were performed with the <italic>nr2f1a<sup>ci1009</sup></italic> allele<italic>.</italic> There was no experimental rationale for using these lines for different experiments, other than they had the necessary transgenes to perform desired experiments crossed into them.</p><disp-quote content-type="editor-comment"><p>– How are vmhc and AVC markers in the transcriptomic dataset?</p></disp-quote><p><italic>Vmhc</italic> (<italic>myh7</italic>) for some reason was not found in the RNA-seq data sets from sorted <italic>amhc</italic>:EGFP<sup>+</sup> cardiomyocytes. However, other markers of ventricular identity were, as we indicated. We know from previous analysis (Duong et al., 2018) and RT-qPCR shown in Figure 2K that <italic>vmhc</italic> expression is increased in the whole hearts. Despite the trends we observe, it could reflect that a limited number of these cardiomyocytes were captured due to lower <italic>amhc</italic> expression in these cardiomyocytes from <italic>nr2f1a</italic> mutant hearts and the expression didn’t meet the defined cut-offs. Furthermore, it is difficult to distinguish some of the atrioventricular canal markers from pacemaker markers at this stage. Again, as we reported previously, when examining the heart atrioventricular canal markers are also expanded (Duong et al., 2018).</p><disp-quote content-type="editor-comment"><p>– Provide single-channel images for Figure 1C-H, 2A-F to clarify marker overlap.</p></disp-quote><p>Single-channel images have been provided for Figures 1 and 2 in Figure 1 —figure supplement 1 and Figure 2 —figure supplement 1 of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Figure 1: the overlap in Amhc and Vmhc should be more clearly shown. As there appears to be a significant overlap by 48 hpf (1D), what do these markers show at earlier time points? Finally, the image shown in 1D does not appear to be congruent with the data in 1J-L – based on the image, I would expect to see more vmhc + CMs in the mutant atrium at 48 hpf.</p></disp-quote><p>a. We have provided images of hearts at an earlier time points (30 hpf). These show that there is actually significant overlap of Vmhc and Amhc at these earlier stages in the heart tube, which to our knowledge has not really been reported previously at the shown stage. Importantly, we did not find a difference in the overlap of Vmhc and Amhc between WT and <italic>nr2f1a</italic> mutant hearts at this stage. This suggests that Nr2f1a is required to refine the number of Vmhc and Amhc cardiomyocytes in the atrioventricular canal, consistent with our previous report (Duong et al. 2018). This new data and related interpretations are now described in the Results and Discussion of the revised manuscript (lines 160-162 and 385-390) and in new panels included in Figure 1- supplement 1.</p><p>b. We have tried to address the issue of inconsistency between Figure 1D and 1J-L in the response to Essential Revisions comment 1D.</p><disp-quote content-type="editor-comment"><p>2. Line 168: The cell death and proliferation data are important to argue it is a fate conversion vs loss/expansion of populations that is occurring. It should be shown, or some form of fate tracing (photoconversion, etc.) should be used if statements like those in lines 174/5 are to be made.</p></disp-quote><p>Thanks you. We have provided the cardiomyocyte death and proliferation analysis, and additional lineage tracing/temporal differentiation assay to examine newly-differentiating cells in the <italic>nr2f1a</italic> mutant hearts to address the issue of fate conversion/transdifferentiation. Please see our response to Essential Revision comment 2 for additional details of how we addressed this issue.</p><disp-quote content-type="editor-comment"><p>3. Figure 4: The extent of fgf13a:GFP + cells in the atrium in nr2f1a mutants at 96hpf appears to differ markedly in Figures 2 (most of the cells are +) vs 4 (appears to be a lower proportion of the atrium as shown). How are chamber boundaries being defined in these analyses?</p></disp-quote><p>Please see our response to Essential Revision comment 1D for how we addressed this issue.</p><disp-quote content-type="editor-comment"><p>4. Figure 5: Somewhat confusing – how are new PCs made from 48 to 96hpf if Nkx2.5 is still present? ACs are still lost in &quot;rescued&quot; hearts – presumably, these now make VCs? Importantly, does the nkx2.5 transgene rescue/normalize heart rate or conduction? It is important to distinguish an effect on the fgf13a transgene (which is convincing) versus a more important effect on PC and AC fate and FUNCTION is reflected in these results.</p></disp-quote><p>a. It is difficult to address this issue because it is not clear to us from this comment what exactly Reviewer #2 finds confusing. Normally, Nkx2.5 is expressed in virtually all cardiomyocytes within the zebrafish heart except for pacemaker cardiomyocytes at the venous pole of the heart. This is now shown in Figure 4 —figure supplement 1 of the revised manuscript. In the <italic>nr2f1a</italic> mutants, Nkx2.5 is not completely lost throughout the heart. It just recedes from the venous pole of the heart, which corresponds with the new marker expression for the pacemaker cardiomyocytes (Figure 4). As Nkx2.5 is still expressed throughout the heart in the mutants, we would not expect to observe difference in the effect on ventricular cardiomyocytes.</p><p>b. In the “rescued” hearts where Nkx2.5-EGFP is induced, it is not clear that Nkx2.5-EGFP is still visible at the later stages following the heat-shock. The previous characterization of the <italic>hsp70l:nkx2.5-EGFP</italic> line showed that Nkx2.5-EGFP was no longer detectable by 10 hrs after the heat shock (George et al., 2015). While inducing Nkx2.5-EGFP at the 20 somite stage is sufficient to rescue <italic>nkx2.5</italic> mutant embryos to adulthood (George et al., 2015), it does not mean it is perpetually expressed following the heat shock at the stages examined in the analysis. Moreover, we do not see the Nkx2.5-EGFP at 48 through 96 hpf following the heat-shock at 20 somites. Similar to the <italic>nkx2.5</italic> mutant rescue, we see maximal repression of the pacemaker reporter (<italic>fgf13a:EGFP</italic>) when induced at the 20 somite stage. These results suggest that even though we observe the regression of Nkx2.5 at later stages in the mutants, Nkx2.5 and Nr2f1a complexes must be required earlier to establish these boundaries. We include this in the Discussion of the revised manuscript (lines 421-425 and 429).</p><p>c. We did assess rescue of heart rate following Nkx2.5-EGFP induction as requested. Please see our response to Essential Revisions comment 3.D.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>1) Please provide more details in figure 1 regarding the RNAseq analysis. Why did the authors use a cut-off of &gt;2 fold difference rather than significance? Could they provide an MA plot or so to show distributions of FC and p values of all transcripts detected? How many transcripts were differentially expressed? What kind of biological processes were changed?</p></disp-quote><p>We did not present the RNA-seq data this way as we did not think it provided additional information that was necessary. It served as the basis for additional in vivo investigation of a hypothesis in the embryos. All of the RNA-seq data are now included in a sheet in Supplement File 1. They were unintentionally omitted from the excel sheet originally submitted. The expression can be represented in different ways. We felt the differences were best illustrated using fold difference changes that were found in this data set.</p><disp-quote content-type="editor-comment"><p>2) In figure 1B the behavior of pacemaker markers is inconsistent. Please provide data or references showing the expression of these markers in fish pacemaker cells (e.g. I did not find these data for tbx3a etc.). Furthermore, central pacemaker markers like isl1a (Isl1 homologue) and shox2a (Shox2 homologue) are downregulated in mutants? That is unexpected, and also inconsistent with the data given in figure 2K.</p></disp-quote><p>a. Please see our response to Essential Revision comment 1D.</p><p>b. References to the expression of the pacemaker marker genes in the zebrafish have been added to the revised manuscript (lines 147,148, 207-209).</p><disp-quote content-type="editor-comment"><p>3) Arterial pole of the atrium is confusing, as arterial pole usually refers to the actual arterial pole of the heart (distal/downstream portion of the ventricle).</p></disp-quote><p>We welcome suggestions for what would be the best way to refer to this anatomical position in the context of our study as we would like to be as clear as possible. Given the changes in heart morphology and markers within the different regions of the <italic>nr2f1a</italic> mutant hearts, it was not clear how to best refer to this portion of the atrium, which is not often specifically referred to as most studies have not had reason to refer to these different regions within the zebrafish atrium. Therefore, it seemed clearest to us to use arterial and venous as relative anatomical position markers with respect to the direction of blood flow in the heart, as is done with respect to the whole hearts in fish and mammals, and contrast these positions with our references to the pacemaker cardiomyocytes at the venous pole of the heart/atrium. In the Abstract and Introduction of the revised manuscript, we have also defined arterial and venous as the outflow and inflow portion of the atrium to help clarify this point (lines 27, 29, 110, and 114).</p><disp-quote content-type="editor-comment"><p>4) Please explain how the authors envision nrf2f1a/Nrf2f2 acts as a suppressor of pacemaker phenotype (atrial-specific activator of nkx2-5) as the gene is expressed in pacemaker cells and in the posterior second heart field progenitors the atria and sinus venosus (including pacemaker cells) derive from.</p></disp-quote><p>Please see our responses to Essential Revisions comments 3.A and 3.B, Reviewer #1’s major comment 3.</p><disp-quote content-type="editor-comment"><p>5) The cell numbers seem inconsistent between the different figures. In suppl Figure 1, there are about 75 amhc+ cells in wt, and 20 or so in mutants. In figure 1, there are close to 100 amhc+ cells in wt, and about 50 in mutants? In figure 2 there are 60 amhc+ cells in wt, and 40, 20 and 10 amhc+ cells in mutants at subsequent stages. If one adds the amhc+ and fgf13a-gfp+ cells, the numbers are 40, 30, 20, respectively (figure 2c). Which numbers are correct? Is the number of amhc+ cells very low in mutants from stage 48 hpf onwards, without changing, or is there a decrease during development?</p><p>A more general issue related to the cell number issues, the data can be explained by transdifferentiation of atrial cells into pacemaker cells, as the authors seem to favor, or by reduced addition of cardiomyocytes fated to become atrial, while the normal atrial-pacemaker demarcation programs are still active, or by reduced atrial differentiation. The latter 2 options are consistent with the data of suppl Figure 1. The authors should resolve this, and provide additional support for the trans-differentiation hypothesis. Thus, does a fraction of cells expressing pacemaker markers derive from atrial marker expressing cells in mutants, or is there an increased population of &quot;de novo&quot; pacemaker cells (not previously atrial marker positive) in the venous pole and a decreased population of atrial cells because of defective recruitment from progenitors or defective atrial differentiation.</p></disp-quote><p>a. Please see our response to Essential Revisions comment 1.D for how we addressed concerns of the inconsistencies.</p><p>b. Please see our response to Essential Revisions comment 2 for how we experimentally addressed concerns of transdifferentiation vs. new addition of cardiomyocytes.</p><disp-quote content-type="editor-comment"><p>6) Line 201: &quot;Thus, we would predict…&quot; Why would the heart rate be predicted to decrease? More pacemaker cells in mutants may also result in increased automaticity and increased spontaneous depolarizations.</p></disp-quote><p>Thank you for the comment. The reviewer is correct. One might readily imagine ways in which increased numbers of pacemaker cells could lead to any number of heart rate outcomes depending on their cell autonomous features, their capacitance, and other biophysical properties as well as particular patterns of intercellular coupling. In our description of the anticipated heart rate findings, we neglected to fully outline our rationale. Given the typical intrinsic automaticity of a coupled cellular mass is a function of the total electrical capacitance of that mass, we simply hypothesized that the intrinsic heart rate might be slower as the mass of coupled pacemaker cells increased. Clearly, this assumes that cellular characteristics and coupling are unchanged, but as these properties were also measured directly in the work described we did not elaborate on these elements at this stage. We have revised the text to be more explicit on this point (lines 252-255).</p><disp-quote content-type="editor-comment"><p>7) The relation between hyperpolarization, increased repolarization times and increased numbers of pacemaker cells in mutants is not clear to me. Pacemaker cells have increased, not decreased resting membrane potentials, decreased Vmax (due to lower sodium channel activity), and unstable resting membrane potentials. The authors could analyse the electrophysiological properties of the pacemaker cells in wt and mutants (fgf13a-gfp label is perfect for that purpose), and also investigate the transcriptomes for differential expression of particular ion handling proteins known to be involved in the action potential morphology, membrane potential and intercellular conduction.</p></disp-quote><p>We apologize if the relationship between the various cellular parameters, myocardial physiology, and cell identity markers was not clear. Our intent was to convey that the atria in the <italic>nr2f1a</italic> mutants exhibit intermediate electrophysiologic characteristics consistent with cardiomyocytes of the central conduction system, although we cannot readily classify them as pacemaker, atrial, or ventricular cardiomyocytes. While we cannot perform the analysis in the <italic>fgf13a:EGFP</italic> transgenic fish, we did analyze the electrophysiology in different regions of the atria that would be consistent with them having <italic>fgf13a</italic>:EGFP<sup>+</sup> and <italic>fgf13a:</italic>EGFP<italic><sup>-</sup></italic> cardiomyocytes in our studies and did not identify discrete physiological boundaries. This intermediate state which we identified in the <italic>nr2f1a<sup>-/-</sup></italic> atria exhibits atrial Vmax and ventricular repolarization with hyperpolarization of the resting membrane potential and no significant changes in phase 4 depolarization. These features and the slowed conduction observed suggest cellular electrophysiology and cell-cell interactions most consistent with the central conduction system. This is of importance for several reasons not least the known gradients of function between atrial cardiomyocyte and central conduction system observed from mid-atrium distally in humans. We have clarified the relevant text in the Introduction, Results, and Discussion (lines 118, 252-255, 266, 267, 272, 273, 408).</p><disp-quote content-type="editor-comment"><p>8) Line 217 &quot;…slower conduction…&quot; and line 219 &quot;… more conduction system-like…&quot; If anything, the conduction system shows very high conduction velocities. Perhaps refer to pacemaker properties. The remark regarding Vmax here is not clear. Vmax is low in pacemaker cells compared to atrial cells.</p></disp-quote><p>We apologize that we did not make it clear that we were referring not to the ventricular (His-Purkinje) conduction system but rather to the central conduction system whose biology we believe these experiments are helping to elucidate. We have clarified the relevant text of the revised manuscript (lines 118, 252-255, 266, 267, 272, 273, 408).</p><disp-quote content-type="editor-comment"><p>9) Line 242, transdifferentiation. See comment 4.</p></disp-quote><p>Please see our response to Essential Revisions comment 2 for how we experimentally addressed concerns of transdifferentiation vs. new addition of cardiomyocytes.</p><disp-quote content-type="editor-comment"><p>10) The authors assume the identified enhancer regulates nkx2-5, but do not provide evidence for this. The enhancer could be removed from the genome, for example. Did the authors analyse the topologically associated domain of nkx2-5 to see whether the enhancer is part of it? Is any interaction data available?</p><p>Please provide more detailed data regarding the ATAC-seq experiment. How many accessible sites, how many differential accessible sites, examples of known atrial accessible sites, UCSC browser views of a few examples to get an impression regarding data quality and signal-to-noise ratios. What is the correlation between RNAseq identified target genes and differential accessibility?</p></disp-quote><p>a. Thank you for the suggestion. We have provided experimental analysis of the putative <italic>nkx2.5</italic> enhancer. Please see response to Essential Revisions comment 3.C.</p><p>b. While it would be ideal and we would have loved to analyze the topologically association of chromatin in these zebrafish cardiomyocytes, presently it is not possible to perform the techniques, such as HI-C, to analyze chromatin conformation in these cells. Therefore, we cannot presently directly address this comment experimentally.</p><p>c. The ATAC-seq data and their relationship to changes in gene expression from the RNA-seq are summarized in a sheet in Supplementary file 1. Examples of UCSC browser views for select genes have now been added to a new Figure 6 —figure supplement 1 of the revised manuscript as requested to show the quality of the data. Additionally, Bigwig files were submitted to GEO.</p></body></sub-article></article>